



Australian Government

**Department of Health
and Aged Care**



Medical Research Future Fund

Financial assistance to support the
Australian Medical Research and
Innovation Priorities 2020-2022

May 2023

Table of Contents

List of Tables	iii
Introduction	1
Background	2
Purpose of this report	2
Australian Medical Research Advisory Board	2
Australian Medical Research and Innovation Strategy and Priorities	2
10-year investment plan for the MRFF	5
MRFF policy, performance, and assurance	6
New policies	6
MRFF Consumer Reference Panel	6
MRFF Grant Variation Policy	6
MRFF Eligible Organisations at NHMRC	6
Departmental staff engagement in MRFF applications and grants	6
Commonwealth Commercialisation Clauses in MRFF grant agreement.....	7
Performance and evaluation	7
Completed evaluation activities	7
MRFF Grant Opportunity Gender Data Report.....	7
Assurance	8
ANAO audit and our response to the findings	8
Project progress and final reports.....	8
Medical Research Future Fund – since inception	9
Financial assistance from the MRFF Special Account	10
Funding	12
Highlights from the MRFF initiatives	13
A snapshot of publications of research funded by MRFF	19
Medical Research Future Fund 2020-2022	21
Funding	21
Missions	21
Analysis of MRFF funding	22
Gender analysis	37
Consistency of financial assistance with the 2020–2022 Priorities	49
Processes for determining grants of financial assistance	53
Determination of MRFF initiatives	53
Determination of grants of financial assistance	53
MRFF Grant Assessment Committees	55
A snapshot of Grant Assessment Committees	56

Other financial assistance provided by the Australian Government for medical research and innovation	58
Other financial assistance provided by the Australian Government for research and development	59
Appendix A Initiatives under the 2020–2022 Priorities	60
Appendix B MRFF Disbursements since inception by theme and initiative.	62
Appendix C MRFF grants since inception by theme and initiative.	63
Appendix D MRFF grant opportunities since inception by theme and initiative.	64
Appendix E MRFF grants with payments commencing between 7 November 2020 and 5 November 2022	65
Appendix F MRFF funding with payments commencing between 7 November 2020 and 5 November 2022	105
Appendix G Funded rates of MRFF grant opportunities opened between 7 November 2020 and 5 November 2022	106
Appendix H Methodology used in this report	109
Grant opportunities and grants awarded	109
Funded rates and gender of Chief Investigators	109
Grant Assessment Committees	109

List of Tables

Table 1 Australian Medical Research and Innovation Priorities 2020–2022.....	3
Table 2 - Funding for MRFF initiatives, since 2016–17, as at 30 November 2022	10
Table 3 MRFF themes: grants, grant opportunities and funding between 7 November 2020 and 5 November 2022	23
Table 4 MRFF initiatives: grants, grant opportunities and funding between 7 November 2020 and 5 November 2022	24
Table 5 Location of lead researcher for grants with payments commencing between 7 November 2020 and 5 November 2022	25
Table 6 Organisation of lead researcher for grants with payments commencing between 7 November 2020 and 5 November 2022	26
Table 7 Broad research area of grants, grant opportunities and funding between 7 November 2020 and 5 November 2022	27
Table 8 Top 20 Field of research of grants, grant opportunities and funding between 7 November 2020 and 5 November 2022	28
Table 9 Funded rate by MRFF theme	31
Table 10 Funded rate by MRFF initiative	32
Table 11 Funded rate by broad research area.....	33
Table 12 Funded rate by the top 20 field of research	34
Table 13 Funded rate by age of Chief Investigators.....	35

Table 14	Funded rate by age of Chief Investigator A (lead applicant).....	36
Table 15	Chief investigators applying for MRFF grant opportunities	37
Table 16	Funded rates by Chief Investigators and by lead applicant (Chief Investigator A). 38	
Table 17	Funded rates by Chief Investigators by MRFF theme	39
Table 18	Chief investigators A applying for MRFF grant opportunities by MRFF theme	40
Table 19	Funded rates by Chief Investigators by MRFF initiative	41
Table 20	Chief investigators A applying for MRFF grant opportunities by MRFF initiative...	42
Table 21	Funded rates by Chief Investigators by broad research area	44
Table 22	Chief Investigator A applying for MRFF grant opportunities by broad research area 45	
Table 23	Funded rates by Chief Investigator by top 20 fields of research	46
Table 24	Funded rates by Chief Investigators by location	48
Table 25	MRFF initiatives and open grant opportunities during 2020-2022 Priorities (7 November 2020 and 5 November 2022).....	49
Table 26	Australian Government financial support for medical research and innovation, 2020–21 and 2021–22.....	58
Table 27	Australian Government financial support for key research and development initiatives, 2020–21 and 2021–22	59
Table A	MRFF initiatives under the 2020–2022 Priorities.....	60
Table B	MRFF Disbursements since inception by theme and initiative	62
Table C	MRFF grants since inception by theme and initiative	63
Table D	MRFF Grant opportunities opened since inception by theme and initiative	64
Table E	- MRFF grant recipients with payments commencing between 7 November 2020 and 5 November 2022 inclusive.....	65
Table F	Total funding by MRFF initiative, with payments commencing between 7 November 2020 and 5 November 2022	105
Table G	Funded rates of MRFF grant opportunities	106

Introduction

The Health and Medical Research Office (HMRO) within the Department of Health and Aged Care (the Department) is responsible for the management of the Medical Research Future Fund (MRFF). The HMRO is committed to transparency of information within the operational framework of the Department's policy and legislative requirements, including obligations under the *Privacy Act 1988*.

The Australian Government established the MRFF under the *Medical Research Future Fund Act 2015* (MRFF Act) to provide grants of financial assistance to support health and medical research, improve health outcomes, quality of life and health system sustainability. MRFF funding is primarily disbursed through expert-reviewed competitive processes to ensure the integrity of the research design, quality and safety for patients, and best return on Australian Government investment.

This report presents information required under the MRFF Act. The report also provides updates on the operation of the MRFF and analysis of the grants provided by the MRFF.

Further information is at the [MRFF website](#).

Background

Purpose of this report

The *Medical Research Future Fund Act 2015* (MRFF Act) requires the Health Minister to report to Parliament on the financial assistance provided for medical research and medical innovation from the MRFF Special Account during the time the most recent Australian Medical Research and Innovation Priorities were in force.

Accordingly, this report presents the financial assistance provided from the MRFF Special Account for the period when the *Australian Medical Research and Innovation Priorities 2020–2022* (2020–2022 Priorities) were in force; from 7 November 2020 to 5 November 2022.

As required under the MRFF Act, this report:

- describes how the financial assistance provided was consistent with the 2020–2022 Priorities
- describes the processes for determining the grants of financial assistance
- includes information about any other financial assistance provided by the Australian Government for medical research and medical innovation.

The report also provides other information about the MRFF, including details of grant opportunities, grants awarded, and statistics such as funding rates, some of which dates from the inception of the MRFF.

Australian Medical Research Advisory Board

The second Australian Medical Research Advisory Board (AMRAB) for the MRFF was announced on 17 September 2021 for the period 2021–2026. Professor Ian Frazer AC continued as the Chair, and Professor Caroline Homer AO was announced as the inaugural Deputy Chair.

The following members continued to serve on the second AMRAB: Mr Yasser El-Ansary; Professor Doug Hilton AO; and Professor Anne Kelso AO.

The following members were newly appointed to the second AMRAB: Professor Tom Calma AO; Professor Denise Doolan; and Ms Imelda Lynch.

Australian Medical Research and Innovation Strategy and Priorities

The MRFF Act establishes the independent AMRAB to determine the:

- Australian Medical Research and Innovation Strategy (the Strategy) every 5 years
- Australian Medical Research and Innovation Priorities (the Priorities) every 2 years.

The MRFF Act requires the Health Minister to consider the Priorities when making decisions about the financial assistance provided from the MRFF Special Account.

AMRAB developed the first *Australian Medical Research and Innovation Strategy 2016–2021* (2016–2021 Strategy) in 2016 after extensive public consultation.

While the 2020–2022 Priorities were in force, AMRAB developed the second *Australian Medical Research and Innovation Strategy 2021–2026* (2021–2026 Strategy) in 2021 after extensive public consultation.¹

The 2021–2026 Strategy intends to:

Transform health and medical research using priority-driven investments that promote collaborative research, research innovation, research translation and impact to improve lives, whilst contributing to health system sustainability, nurturing the next generation of researchers and building the Australian economy.

Table 1 lists the 2020–2022 Priorities. As required by the MRFF Act, the Priorities must be consistent with the Strategy that is in force.

Both the MRFF Strategy and Priorities are informed by national consultation, as required under the MRFF Act. The 2020–2022 Priorities were consistent with both the 2016–2021 Strategy and the 2021–2026 Strategy.

Table 1
Australian Medical Research and Innovation Priorities 2020–2022

Platform	Priority	Description
Strategic and international horizons	One Health — Antimicrobial Resistance	There are no borders between human and animal health when it comes to antimicrobial resistance (AMR). Research into stewardship practices, diagnostic and treatment tools, preventative measures, and new or novel antimicrobials and vaccines that spans this divide is critical.
	Global Health and Health Security	Global health challenges including health emergencies and pandemic preparedness, the impact of climate and environmental change on health, and the development and implementation of low technology preventative, diagnostic and treatment solutions are best addressed through international research collaboration.
	Aboriginal and Torres Strait Islander Health	Indigenous leadership and Indigenous-led priority setting to drive health-related research to improve the health of Aboriginal and Torres Strait Islander Australians and to close the gap on health mortality and morbidity.
	Ageing and Aged Care	Research into the diseases of ageing and the means to prolong quality of life, including tackling cognitive decline and dementia, and compressing the period of intense morbidity in later years through biomedical discovery and health service innovation in residential and home care.
Data and infrastructure	Digital Health Intelligence	Data science, informatics, advanced clinical decision making tools, wearables and artificial intelligence research and other emerging innovative technologies are the key to realising the benefits of healthcare digitalisation.

¹ Australian Medical Research Advisory Board (2021). *Australian Medical Research and Innovation Strategy 2021–2026*, AMRAB, Canberra.

Health services and systems	Comparative Effectiveness Research	Support systematic evaluation and demonstration of the comparative value of health interventions to better inform the decisions policy makers, clinicians and consumers make in healthcare.
	Primary Care Research	Address the capacity and production gap in primary care research with an emphasis on multi-disciplinary, adaptive research methodologies, innovative models of care and clinician capability support.
Capacity and collaboration	Clinical Researcher Capacity	Continue to support and enhance Australian clinical researcher capacity with a focus on next generation fellowships that target multidisciplinary engagement, fields of emerging scientific effort that have healthcare application potential and primary care. Overarching responsibility to increase capacity and capability sits within individual MRFF programs.
	Consumer-Driven Research	Conduct research that is driven by crowdsourcing consumer priorities and purposefully connecting researchers to consumers with the intent of enhancing evidence translation into every day clinical practice.
Trials and translation	Drug Repurposing	Partner with industry to foster an enduring partnership to systematically identify drugs with repurposed therapeutic potential for investigative research.
	Public Health Interventions	Targeted research to test innovative public health approaches to addressing modifiable risk factors that are at the heart of the rise of chronic and complex disease prevalence and persistence in Australia. Equity of access to healthcare will benefit with a focus on the increased role of remote care interventions through mobile, telehealth and digital health.
Commercialisation	Translational Research Infrastructure	Address gaps in early biomedical and medical technology product development by supporting access to expertise and infrastructure in partnership with industry that seeks to accelerate rapid pre-clinical work and evaluation and build sustainability in the sector.
Source: Australian Medical Research Advisory Board (2021). <i>Australian Medical Research and Innovation Priorities 2020–2022</i> , AMRAB, Canberra.		

10-year investment plan for the MRFF

In March 2022, the Australian Government announced a second \$6.3 billion, [10-year Investment Plan](#) for the MRFF that directs MRFF funding through 4 themes:

- **Patients**, which aims to bring benefits to patients, including supporting life-changing clinical trials, funding innovative treatments and advanced health care and medical technologies
- **Researchers**, which aims to support Australian researchers, including to help build their skills and capacity, support their research in priority areas and assist them to develop and bring new research discoveries to the market
- **Research missions** are large programs of work that bring together key researchers, health professionals, stakeholders, industry partners and patients to tackle big health challenges
- **Research translation**, which aims to translate research outcomes into practice by building the evidence base to support the adoption of best practice care into health care delivery.

There are 21 initiatives under these themes, funded across 10 years (starting in 2022-23) to support lifesaving research, create jobs, strengthen the local industry base for commercialising research and innovation, and further grow Australia's reputation as a world leader in medical research.

This second 10-year Investment Plan builds on the first 10-year investment plan announced as part of the 2019-20 Budget.

The first and second 10-year investment plans were in place while the 2020–2022 Priorities were in force.

The 10-year Investment Plan is a mechanism for implementing the Strategy and the related Priorities and will continue to evolve to address emerging health challenges and respond to the evolution of these guiding documents. The Strategy, the Priorities and the 10-year Investment Plan provide transparency and predictability to researchers and industry about the strategic objectives and scale of MRFF disbursements.

MRFF policy, performance, and assurance

The Department is committed to continuous improvement of MRFF policies and procedures to ensure they are fit for purpose, generate improvements in health care and outcomes, and support researchers in doing their work.

New policies

MRFF Consumer Reference Panel

The MRFF Consumer Reference Panel (CRP), established in April 2022, advises the HMRO Chief Executive Officer on strategies for strengthening consumer involvement in the implementation of the MRFF.

The CRP is helping the HMRO to:

- fund research that has the best opportunity for improving the health and wellbeing of individuals and their families and carers
- improve consumer confidence in and engagement with the MRFF, by providing consumers a more formal and clear communication channel into the MRFF.

Information regarding the CRP, including members and terms of reference, can be found on the Department's [website](#).

MRFF Grant Variation Policy

The [MRFF Grant Variation Policy](#), published in May 2022, provides advice to MRFF recipients who may need to request a variation to their grant agreement, such as to extend the end date of the grant or change personnel.

MRFF Eligible Organisations at NHMRC

MRFF grants can only be made to organisations that meet criteria defined in the MRFF Act. Since 18 August 2021, organisations meeting the requirements set out in the MRFF Act can apply to become an [MRFF Eligible Organisation](#) in order to apply for MRFF funding through the National Health and Medical Research Council (NHMRC). This new process expanded the type of organisations that were eligible to apply for and receive MRFF funding administered by the NHMRC. As of October 2022, the NHMRC had certified and approved 177 MRFF Eligible Organisations.

Organisations that meet requirements set out in the MRFF Act continue to be able to apply for MRFF funding through the Business Grants Hub (BGH).

Departmental staff engagement in MRFF applications and grants

To reinforce the Department's commitment to the highest standards of probity, professionalism, integrity and ethical conduct, a [policy statement](#) for departmental staff participating in activities funded by the MRFF was published on 18 March 2022.

Commonwealth Commercialisation Clauses in MRFF grant agreement

While the Australian Government does not make any claim to the ownership of intellectual property resulting from MRFF-funded research activities, the Department has developed Commonwealth Commercialisation Clauses that seek to ensure that the Australian community can benefit from the outcomes of research funded through the MRFF.

This is achieved through the inclusion of specific arrangements in some MRFF grant agreements that provide the Australian Government with an early opportunity to purchase commercialised products resulting from MRFF-funded activities, on market terms.

Performance and evaluation

Completed evaluation activities

The [MRFF Monitoring, evaluation and learning strategy](#) provides an overarching framework for assessing the performance of the MRFF. It also aims to establish a learning system to support continued improvements within the MRFF.

To date, 3 MRFF evaluation activities have been completed:

- *Evaluation of the Rapid Applied Research Translation Initiative* (2020) – the final report can be found on the Department's [website](#)
- *Medical Research Commercialisation Landscape Report* (2020) – the final report can be found on the Department's [website](#)
- *Million Minds Mental Health Research Mission Review* (2021-22) – the final report can be found on the Department's [website](#).

The Department continues the evaluation program set out in the MRFF Monitoring, evaluation and learning strategy, with two further evaluations due to be completed in 2023:

- Evaluation of the Clinical Trials Activity initiative
- Review of the Australian Brain Cancer Mission.

MRFF Grant Opportunity Gender Data Report

This report provides an overview of gender data for applicants and grantees for competitive MRFF grant opportunities. Personal data for 60 competitive grant opportunities up to 30 June 2021 was obtained from MRFF applications submitted through the NHMRC and BGH. 56 of the analysed grant opportunities were administered by the NHMRC, and 4 by BGH. The assessment included data for Chief Investigators (CIs), or equivalent.

Overall, while more men applied for MRFF grants than women, funded rates were relatively comparable. There were differences by field of research (in application numbers and funded rates) and at career stages.

The report, including analysis and data tables, can be found on the Department's [website](#).

Assurance

ANAO audit and our response to the findings

In September 2021, the Auditor General tabled a report titled [Department of Health's Management of Financial Assistance under the Medical Research Future Fund](#).

The Australian National Audit Office (ANAO) found:

- Health's management of the MRFF is largely effective
- clear governance and coordinating structures have been established and the roles and responsibilities of Health and its implementation partners are defined
- Health's management of MRFF grants is largely compliant with legislative and policy requirements
- Health does not have adequate performance measures for MRFF.

The Auditor General made 3 recommendations:

- Department of Health identify, assess and manage risks at the theme or initiative level of the 10-year Investment Plan
- Department of Health reports grants in the same way that grant opportunities are classified in the grant opportunity guidelines and reported on GrantConnect
- Department of Health develops adequate performance measures for the Medical Research Future Fund for inclusion in its portfolio budget statements and annual performance statements.

The Department has addressed all 3 recommendations and is continuing to implement continuous improvements to MRFF policies and processes in response to other findings in the report.²

Project progress and final reports

MRFF grantees are required to submit regular project reports describing the progress and outcomes of their research via the relevant administering grants hub (BGH or the NHMRC).

Routine monitoring provides assurance that projects are meeting their intended objectives during MRFF funding and after it ends, allows oversight of issues and risks as they arise, and provides information to support improvements in grant design (e.g., understanding key features of successful projects).

Further information about project reporting can be found on the Department's [website](#), and the website of the relevant grants hub.

² Medical Research Future Fund – Outcomes of Performance Audit by the Australian National Audit Office (ANAO) at <https://www.health.gov.au/resources/publications/medical-research-future-fund-outcomes-of-performance-audit-by-the-australian-national-audit-office-anao>

Medical Research Future Fund – since inception

The establishment of the MRFF was announced in the 2014-15 Budget. The MRFF Act received the Royal Assent from the Governor-General on 26 August 2015. The first disbursements from the MRFF Special Account began during the 2016-17 financial year. Since the inception of the MRFF, the financial assistance provided, and the number of grants, has increased year on year.

Financial year	MRFF budget (\$ million)	MRFF disbursements (\$ million)	Grant Opportunities	Grants
2015-16	10.0			
2016-17	60.9	18.0	6	4
2017-18	143.3	30.1	18	71
2018-19	222.4	206.4	35	122
2019-20	392.7	375.5	53	242
2020-21	597.9	597.9	36	227
2021-22	627.5	627.4	38	238
2022-23	650.0	67.4	8	3
Total	2,704.7	1,922.6	194	907

For the above table, **MRFF disbursements** values, **Grant Opportunities** data and **Grants data** for 2022-23 are for a partial Financial Year (FY), noting this report was prepared prior to the end of the 2022-23 FY. MRFF budget values for 2022-23 are for the full 2022-23 FY.

MRFF budget values are taken from Health Portfolio Budget Statements in the relevant financial year (more information at the Department's [website](#)). **MRFF disbursements** values represent payments made to all active grants in the relevant FY (i.e., new grants as well as grants commenced in previous FYs – see Table 2, below). **Grant Opportunities data** represents all grant opportunities that had opened for applications as at 31 December 2022. **Grants data** represents newly awarded and announced grants for the relevant FY. Detailed data by MRFF theme and initiative is available at Appendices B-D.

Financial assistance from the MRFF Special Account

Table 2 presents the funding profiles of all MRFF initiatives since 2016–17, as at 30 November 2022. See Appendix A for a description of each of these initiatives.

Table 2 - Funding for MRFF initiatives, since 2016–17, as at 30 November 2022

Theme	Initiative	Actuals (\$ million)						Budget (\$ million)				10 year total	Total (\$ million)	
		16 17	17 18	18 19	19 20	20 21	21 22	22 23	23 24	24 25	25 26		Out years (26 27 to 31 32)	Total
Patients	Emerging Priorities and Consumer-Driven Research	7.0		63.4	54.0	84.5	84.4	69.5	63.5	60.0	60.0	546.2	360.0	906.2
	Clinical Trials Activity	1.0	4.8	47.4	68.1	63.7	59.3	75.0	75.0	75.0	75.0	544.3	450.0	994.3
	Global Health		2.5	1.8	3.4	2.7	3.0	3.0	3.0	3.0	3.0	25.3	18.0	43.3
Researchers	Frontier Health and Medical Research				20.1	53.6	61.5	70.0	70.0	70.0	70.0	415.2	420.0	835.2
	Researcher Exchange and Development within Industry				8.0	10.0	10.0	4.0				32.0		32.0
	Clinician Researchers		1.8	4.9	19.8	20.4	22.2	20.0	20.0	20.0	20.0	149.0	120.0	269.0
	Early to Mid-Career Researchers							13.4	26.8	35.2	40.0	115.4	268.8	384.2
Research Missions	Australian Brain Cancer Mission		1.0	4.7	7.4	5.0	3.6	5.0	5.0	5.0	5.0	41.8	5.0	46.8
	Million Minds Mental Health Research Mission			6.2	7.0	12.0	15.0	25.0	15.0	20.0	10.0	110.1	15.0	125.1
	Genomics Health Futures Mission			8.8	37.5	87.4	69.9	54.9	50.0	50.0	50.0	408.6	91.2	499.8
	Dementia, Ageing and Aged Care Mission			10.0	13.1	17.0	17.2	17.5	17.5	17.5	17.5	127.3	52.5	179.8
	Indigenous Health Research Fund			15.0	22.5	18.8	11.4	12.5	12.5	12.5	12.5	117.7	37.5	155.2

	Stem Cell Therapies Mission			6.0	17.6	18.0	18.0	18.0	18.0	18.0	113.6	36.0	149.6	
	Cardiovascular Health Mission			22.1	23.8	23.6	24.0	25.0	20.0	20.0	158.6	60.0	218.6	
	Traumatic Brain Injury Mission			5.0	4.0	3.9	5.0	5.0	5.0	5.0	32.9	15.0	47.9	
	For allocation to Research Missions pending evaluation											590.8	590.8	
Research Translation	Preventive and Public Health Research	10.0	11.2	35.2	63.9	31.5	71.2	81.7	68.6	60.5	433.7	314.5	748.2	
	Primary Health Care Research			6.7	7.1	4.1	10.0	10.0	10.0	10.0	57.9	60.0	117.9	
	Rapid Applied Research Translation	10.0	17.6	16.6	20.6	22.0	22.0	22.0	23.0	23.0	176.9	138.0	314.9	
	Medical Research Commercialisation	10.0	15.4	15.3	60.3	35.3	45.0	45.0	45.0	45.0	316.3	270.0	586.3	
	National Critical Research Infrastructure			7.7	12.6	119.2	75.0	75.0	75.0	75.0	439.5	350.0	789.5	
	Research Data Infrastructure				12.9	12.3	10.0	10.0	10.0	10.0	65.2	60.0	125.2	
Total MRFF profile		18.0	30.1	206.4	375.5	597.9	627.4*	650.0	650.0	642.8	629.5	4,427.6	3,732.3	8,159.9
MRFF budget balance 2022-23 over forward estimates										7.2	20.5	27.7	167.7	195.4
Revised MRFF profile due to low RBA cash rate**								-52.0				-52.0		-52.0
MRFF supplementation^								52.0				52.0		52.0
MRFF total		18.0	30.1	206.4	375.5	597.9	627.4	650.0	650.0	650.0	650.0	4,455.3	3,900.0	8,355.3

* The Actuals for 2021-2022 includes expenditure from the MRFF Health Special Account (MHSA) and \$172.5 million MRFF supplementation (announced at the Mid-Year Economic and Fiscal Outlook 2020–2021 which was administered separately to the MSHA).

**The historic low Reserve Bank of Australia cash rate prior to 2022-23 reduced the amount available from the MRFF in 2022-23 from \$650.0 million to \$598.0 million.

^ To maintain the Australian Government's commitment to the investments under the MRFF 10-year investment plan, an additional \$52.0 million was provided to the MRFF in 2022-23, which is administered separately to the MHSA.

Notes: The table includes all funding since MRFF's inception and is not reflective of the current reporting period. Figures may not add up exactly due to rounding.


Funding

MRFF initiatives (see Appendix A) have continued to invest in a broad range of research areas.

There were fewer grant opportunities during the period the 2020-2022 Priorities were in force, compared with the 2018-2020 Priorities³. The number of projects funded, and the quantum of grant funds disbursed was significantly higher in the 2020-2022 Priorities period, compared with the 2016-2018 and 2018-2020 Priorities.

50% of all MRFF grants since inception were awarded in 2020-2022.

Priorities in force



Data represents grant opportunities that were opened and grants with payments commencing during the periods when Australian Medical Research and Innovation Priorities were in force: 9 November 2016 to 8 November 2018, 8 November 2018 to 6 November 2020 and 7 November 2020 to 5 November 2022. Analysis at 30 November 2022.

³ Australian Medical Research and Innovation Priorities 2016-2018 were in force from 9 November 2016 to 8 November 2018 and Australian Medical Research and Innovation Priorities 2018-2020 were in force from 8 November 2018 to 6 November 2020.

Highlights from the MRFF initiatives

MRFF funding has:

- increased support for medical research commercialisation
- enabled clinical trials research
- supported research in rural health
- prioritised leadership of Aboriginal and/or Torres Strait Islander researchers and communities in research on First Nations health.

Increasing support for medical research commercialisation


Australia has clear strengths across a range of health and medical research areas, where the nation performs well above world standard and has very strong capabilities. The successes of many organisations now growing and thriving in Australia signals the potential benefits of commercialisation, and there are opportunities for leveraging Australia's research strengths, capabilities, and successes to support the commercialisation and translation of new drugs, devices, and digital technologies into practice.

MRFF funding has been disbursed to a range of grant opportunities seeking to support projects with commercial potential (particularly from Small and Medium Enterprises (SMEs)), with a focus on supporting research discoveries, as they progress from proof of concept through to clinical implementation.

Medical research commercialisation

4 grant opportunities


7 number of grants


\$146,300,000 value of grants


Data note: The number of grant opportunities are those completed, where outcomes were awarded and announced up to 5 November 2022. Number of grants are grants where payments commenced up to 5 November 2022.

The medical research commercialisation initiative featured the following grant opportunities.

BioMedTech Horizons

\$45 million


49 projects supported


Funded projects and investments focused on supporting proof-of-concept to commercial development of biomedical and medical technologies.



Biomedical Translation Bridge

\$22.3 million


21 projects supported


Nurtured the translation of innovation through to the proof-of-concept stage with expert industry support and mentoring, addressing unmet needs, priority indications or rare diseases, including a specific funding round targeting COVID-19 related projects supporting diagnostics research, vaccines and therapeutic approaches.

Included matched funding requirements to promote translation into practice



Early Stage Translation and Commercialisation Support

\$79 million


33 projects supported


Supports early-stage Australian medical research and medical innovation projects with commercial potential.

Australian SMEs provided with specialist support and expertise with the aim of de-risking project outputs and progressing towards commercialisation.



BioMedTech Incubator

\$50 million


project funding to commence 2023

Support Australian SMEs undertaking early-stage medical research and innovation projects with commercial potential.



Enabling clinical trials research

Clinical trials are an essential component of health and medical research, playing an important role in validating new treatments and approaches for the prevention, management, detection, and diagnosis of health conditions.

Through a range of its initiatives, the MRFF has funded Australian clinical trials across many different health conditions. MRFF-funded projects bring researchers, medical specialists, and patients together to promote clinical innovation, improve patient outcomes and support jobs and economic growth of the health and medical research sector.



Data note: The number of grant opportunities are those completed, where outcomes were awarded and announced up to 5 November 2022. Number of grants are grants where payments commenced up to 5 November 2022.

The MRFF Clinical Trials Activity initiative dedicates funding for clinical trials including:

grant opportunities which have funded Australian clinical trials in rare cancers, rare diseases, and areas of unmet need – targeted funding has been provided in areas such as childhood brain cancers, neurodegenerative diseases, low survival cancers and diseases, reproductive cancers, and COVID-19



International Clinical Trial Collaboration grant opportunities which allow Australian researchers to participate in and/or lead an international clinical trial



the 2021 Innovative Therapies in Mental Therapies grant opportunity which supported trials assessing the safety and efficacy of new therapies for treatment resistant mental illness.



Clinical trials research is also supported through several other MRFF initiatives including:



- Research Missions
- Clinician Researchers
- Early to Mid-Career Researchers
- Emerging Priorities and Consumer-Driven Research
- Frontier Health and Medical Research

- Global Health
- Indigenous Health Research Fund
- National Critical Research Infrastructure
- Preventative and Public Health
- Primary Health Care Research

Examples include:

Mission grant opportunities have funded new clinical trials in cardiovascular health, dementia, ageing and aged care, genomics, mental health, stem cells therapies, traumatic brain injury, Indigenous health research and brain cancer

the 2019 Rural, Regional and Remote Clinical Trial Enabling Infrastructure grant opportunity invested \$124.4 million so that patients can access clinical trials where they live

Emerging Priorities and Consumer-Driven Research grant opportunities have supported clinical trials in a range of areas including endometriosis, medicinal cannabis, and lung cancer genomics.

Investing in rural research

Almost a third of Australians live in rural, regional, and remote areas, and rural and remote communities have significantly worse health outcomes and shorter life expectancies.

To support better rural health outcomes, a rural focus has been embedded in a range of MRFF open and competitive grant opportunities.

Rural research – conducted in rural, regional, or remote areas ^a

23 grant opportunities



37 number of grants



 **\$80,062,347.28** funding

Rural research – a focus on regional, rural, or remote health research

26 grant opportunities



52 number of grants



 **\$269,774,301.80** funding

Data note: a: Location of the grantee/organisation is deemed to be rural, regional, or remote, per the Modified Monash (MM) model with MM 2 - MM 7 categories. 18 grants are included in both categories, that is grants with a focus on rural health and the grantee is located in a rural, regional, or remote area.

The number of grant opportunities are those completed, where outcomes were awarded and announced up to 5 November 2022. Number of grants are grants where payments commenced up to 5 November 2022.

Significant investment includes in:

clinical trials including establishing infrastructure to promote access to clinical trials in rural and regional areas



rural health services for rural people as a group (population health) and individuals (e.g., primary health care)



evaluating rural health generally as well as models of care in practice-including access to care.




Funded projects that are focused on specific diseases and health conditions cover:



- chronic illnesses
- dental health
- elderly care (including wound care) and end of life
- emergency and acute care
- infectious diseases (including 2 COVID-19 related grants)
- mental health
- obstetrics, contraception, gynaecology, and perinatal care
- prevention and behavioural interventions to promote health.

Prioritised leadership of Aboriginal and/or Torres Strait Islander researchers and communities in research on First Nations health

The Indigenous Health Research Fund (IHRF) supports First Nations-led research to tackle health issues that are of importance to Aboriginal and Torres Strait Islander people. It aims to improve health outcomes and contribute to closing the gap on health mortality and morbidity of Aboriginal and Torres Strait Islander people. Grant opportunities in other MRFF initiatives also support projects that align with the objectives of the IHRF.



Data note: The number of grant opportunities are those completed, where outcomes were awarded and announced up to 5 November 2022. Number of grants are grants where payments commenced up to 5 November 2022.

The MRFF has supported research to improve First Nations health outcomes through:




- chronic and infectious disease
- cultural safety in health care
- exercise and nutrition
- genomics
- maternal and infant health
- mental health
- primary health care
- preventive health
- vaccine development.

MRFF First Nations health research grants acknowledge, prioritise and promote First Nations leadership in research practice, governance, and knowledge translation. The grants recognise that First Nations leadership, including through research, is best placed to generate evidence based structural change in Aboriginal and Torres Strait Islander health practice and outcomes.

The MRFF has increased First Nations leadership in MRFF grants through refinements to the application assessment process. The percentage of grants led by an Aboriginal and/or Torres Strait Islander Chief Investigator increased over time following progressive modification to the assessment process for IHRF grant opportunities. Modification to the assessment process included:

- 2020 Indigenous Health Research Grant Opportunity: demonstration of Aboriginal and/or Torres Strait Islander leadership and community involvement in an applicant's project included in the assessment criteria
- 2021 Indigenous Health Research Grant Opportunity: scoring matrices covering the assessment criteria used by Grant Assessment Committees (GAC) included guidance on assessing Aboriginal and/or Torres Strait Islander leadership and community involvement and efforts were made to ensure the majority of the GAC members were Aboriginal and/or Torres Strait Islander.

Grant Opportunity



Data note: Percentage was determined by the total number of grants awarded and the number of grants led by an Aboriginal and/or Torres Strait Islander Chief Investigator.

Research to improve the health and wellbeing of Aboriginal and Torres Strait Islander mothers and babies

Aboriginal and Torres Strait Islander women currently have limited access to maternity and midwifery care that meets their cultural, spiritual, social, emotional, and physical needs.

Research has highlighted the importance of culturally safe models of care for birthing mothers, which help give babies the best possible start in life.

The 2021 Improving the Health and Wellbeing of Aboriginal and Torres Strait Islander Mothers and Babies grant opportunity aimed to support research that will improve access to culturally safe care during pregnancy, birthing and the post-natal period, for example on-country birthing and continuity of family and midwifery care. In addition to the IHRF, First Nations leadership was prioritised in this grant opportunity. Five projects, totalling \$18.4 million, have been supported to undertake research in this important area of health.

More information on MRFF Indigenous Health Research Grants is on the Department's [website](#).


A snapshot of publications of research funded by MRFF

Research outputs, such as scientific articles, give healthcare systems, clinicians, researchers, consumers, and other end-users access to the latest information on topics that may be relevant to advancing continued research and health care. Sharing of research outcomes also reduces research waste, minimising unnecessary research duplication and maximising the benefits and value arising from research funding.

Bibliometrics is a way of measuring research volume and impact by analysing the publication of scientific articles. An impact of a scientific article is measured by citations. This is how many times other researchers, anywhere in the world, reference the scientific article.


Sharing of scientific knowledge is enabled by combining research outcomes from projects supported by different funders

The majority of papers that attribute MRFF funding have also been co-funded by other agencies. For example, over 50% of papers that attribute MRFF funding have also been co-funded by the National Health and Medical Research Council (NHMRC) and almost 60% of MRFF-attributed papers have been co-funded by Australian Research Council (ARC) or NHMRC. Different research projects are funded by MRFF, NHMRC and ARC, but each project outcome contributes to a scientific article and the sharing of knowledge.



Scientific articles of research supported by MRFF have higher impact than the global average

Publications that attribute MRFF funding have a higher percentage of papers that rank in the top 1% based on citation and a higher citation impact. Together, these data illustrate the high impact, relative to respective field, year, and document type, of publications which attribute MRFF funding, with impact one of many indicators of research excellence.



All Australian publications indexed in Clarivate Web of Science from 1 January 2018-11 January 2023 were identified. Data was then filtered to the 121 Web of Science topics that publications funded by MRFF have been categorized to, prior to being categorized by Australian attributed funder. Other funders include funders from Australia, excluding MRFF, NHMRC and ARC. The percentage of attributed funders do not add up to 100%, as there is overlap between categories. The proportion of publications which are in the top 1% of all publications is based on citations by category, year, and document type. Category Normalized Citation Impact (CNCI) is an indicator of the impact of a publication which has been normalised against the expected citation rate for documents with the same document type, year of publication and subject area. The CNCI of a set of documents, for example works attributed to a funder, is the average of the CNCI values for all the documents in the set. The global average is presented as a benchmark. A CNCI of two is considered twice the global average.

Medical Research Future Fund 2020-2022

From 7 November 2020 to 5 November 2022, the Priorities provided a wide-ranging platform that allowed the MRFF to respond to health challenges, while continuing to fund projects aimed at stimulating health and medical research across the entire research pipeline and achieve the MRFF's strategic objectives. An adaptive approach has allowed research investment to remain flexible and meet the needs of the changing health and medical research landscape. Innovative MRFF-funded projects are featured at the [MRFF website](#).

Funding

MRFF funding has continued to support and promote developments in current and future health and medical research projects. In 2020–2022:

- 61 grant opportunities opened across 21 MRFF initiatives
- 454 grants — with a combined value of \$1,177.3 million — were awarded, representing half of all MRFF grants awarded since the inception of the MRFF.

Missions

Missions are programs of work with ambitious objectives that are only possible through major funding, leadership and collaboration.

Missions are initiatives with specific, ambitious goals; in some instances, missions are designed with the objective to seek significant co-investments.

The missions are:

- Australian Brain Cancer Mission
- Cardiovascular Health Mission
- Dementia, Ageing and Aged Care Mission
- Genomics Health Futures Mission
- Indigenous Health Research Fund
- Million Minds Mental Health Research Mission
- Stem Cell Therapies Mission
- Traumatic Brain Injury Mission.

The MRFF missions have provided in 183 grants — with a combined value of \$326.6 million — awarded in 2020–2022. This is about 28% of the total MRFF investment.

Analysis of MRFF funding

Analysis⁴ of the financial assistance provided from the MRFF during 2020–2022 shows:

- funding was provided across MRFF themes and initiatives
- funding was spread across all states and territories
- projects were predominately led through universities and medical research institutes
- funding was provided to support a broad range of research areas and fields of research
- support for innovative research approaches using different grant models
- diversity of ages for funded applicants
- thousands of researchers have been funded for carry out projects
- similar overall funded rates by gender
- a broad range of research areas was supported however the relative number of women or men leading projects differs by research area
- diversity in the expertise of MRFF grant assessment committee membership, including international experts.

⁴ Note about data in analysis of MRFF 2020-2022 activities: This section includes grant opportunities that opened for applications between 7 November 2020 and 5 November 2022. Not all grant opportunities had closed or undergone the assessment phase by 5 November 2022. The awarded grant numbers and funding figures are based on MRFF-funded grants with payment commencing between 7 November 2020 and 5 November 2022. These figures include grants from opportunities that were opened before 7 November 2020. Information such as Broad Research Area and Field of Research data is only collected for NHMRC-administered grants. These terms are self-nominated by applicants and there may be a difference to descriptions of MRFF initiatives. Therefore, the total number of grant opportunities, grants and funding for NHMRC-administered grants will be less than figures in Table 3 for all MRFF grants for the same period. More information on the methodology is at Appendix H.

Table 3 shows that grants, grant opportunities and funding were distributed across the 4 MRFF themes.

Table 3
MRFF themes: grants, grant opportunities and funding between 7 November 2020 and 5 November 2022

MRFF theme	Number of grant opportunities opened	Number of grants with payments commenced	Funding amount
Patients	21	132	\$274,825,416.33
Research Missions	17	183	\$326,629,028.07
Research Translation	14	73	\$363,365,534.39
Researchers	9	66	\$212,487,986.98
Total	61	454	\$1,177,307,965.77

Data represents all grant opportunities that had opened for applications between 7 November 2020 and 5 November 2022. The grant numbers and funding figures are based on each MRFF-funded grant with payment commencing between 7 November 2020 and 5 November 2022.

Table 4 presents grants, grant opportunities and funding for MRFF initiatives. Grant opportunities were open under 19 of the 21 initiatives between 7 November 2020 and 5 November 2022. MRFF grants with payments commencing between 7 November 2020 and 5 November 2022 were distributed across the 19 initiatives. The Early to Mid-Career Researchers initiative was announced as part of the 2nd 10-year investment plan. One grant opportunity was open under this initiative however outcomes were not finalised during the time period of this report.

Table 4
MRFF initiatives: grants, grant opportunities and funding between 7 November 2020 and 5 November 2022

MRFF initiative	Number of grant opportunities opened	Number of grants with payments commenced	Funding amount
Australian Brain Cancer Mission	3	4	\$8,077,924.70
Cardiovascular Health Mission	3	57	\$53,712,471.41
Clinical Trials Activity	9	68	\$140,935,111.71
Clinician Researchers	3	31	\$48,697,612.40
Dementia, Ageing and Aged Care Mission	3	29	\$42,051,843.06
Early to Mid-Career Researchers	1	0	\$0.00
Emerging Priorities and Consumer-Driven Research	8	64	\$133,890,304.62
Frontier Health and Medical Research	2	35	\$163,790,374.58
Genomics Health Futures Mission	3	41	\$130,170,721.91
Global Health	0	0	\$0.00
Indigenous Health Research Fund	3	17	\$18,256,577.05
Medical Research Commercialisation	2	4	\$79,000,000.00
Million Minds Mental Health Research Mission	0	2	\$23,929,033.76
National Critical Research Infrastructure	2	7	\$130,761,257.40
Preventive and Public Health Research	8	31	\$51,925,712.23
Primary Health Care Research	2	10	\$14,514,402.76
Rapid Applied Research Translation	1	9	\$61,984,858.00
Research Data Infrastructure	3	12	\$25,179,304.00
Researcher Exchange and Development Within Industry	0	0	\$0.00
Stem Cell Therapies Mission	3	24	\$43,213,415.78
Traumatic Brain Injury Mission	2	9	\$7,217,040.40
Total	61	454	\$1,177,307,965.77

If a grant opportunity was funded across more than one MRFF initiative, it has been assigned to a single MRFF initiative for calculation purposes. Data represents all grant opportunities that had opened for applications between 7 November 2020 and 5 November 2022. The grant numbers and funding figures are based on each MRFF-funded grant with payment commencing between 7 November 2020 and 5 November 2022.

Table 5 shows the number of grants and the total funding by location of the lead researcher in the period 7 November 2020 and 5 November 2022. All states and territories received support from the MRFF.

Table 5

Location of lead researcher for grants with payments commencing between 7 November 2020 and 5 November 2022

Location	Number of grants with payments commenced	Percentage of grants	Funding amount	Percentage of funding
ACT	8	1.8%	\$15,695,830.58	1.3%
NSW	119	26.2%	\$275,466,058.08	23.4%
NT	9	2.0%	\$28,251,553.19	2.4%
QLD	58	12.8%	\$175,357,768.16	14.9%
SA	47	10.4%	\$76,715,927.68	6.5%
TAS	5	1.1%	\$5,800,132.54	0.5%
VIC	182	40.1%	\$555,229,417.74	47.2%
WA	26	5.7%	\$44,791,277.80	3.8%
Total	454	100.0%	\$1,177,307,965.77	100.0%

The grant numbers and funding figures are based on the lead organisation (also known as administering institution, eligible organisation or primary organisation) of each MRFF-funded grant with payment commencing between 7 November 2020 and 5 November 2022.

Table 6 shows the type of organisations receiving MRFF funding between 7 November 2020 and 5 November 2022. The predominant organisations receiving MRFF funding were universities and medical research institutes (95.1% of grants). In practice, many MRFF-funded grants are collaborative research efforts across multiple Australian locations and organisations.

Table 6

Organisation of lead researcher for grants with payments commencing between 7 November 2020 and 5 November 2022

Organisation	Number of grants with payments commenced	Percentage of grants	Funding amount	Percentage of funding
Corporate Commonwealth entity	2	0.4%	\$3,984,410.33	0.3%
Corporation	18	4.0%	\$152,216,654.70	12.9%
Medical Research Institute	46	10.1%	\$117,680,591.43	10.0%
State government entity/local health district	2	0.4%	\$105,788,350.00	9.0%
University	386	85.0%	\$797,637,959.31	67.8%
Total	454	100.0%	\$1,177,307,965.77	100.0%

The grant numbers and funding figures are based on the lead organisation (also known as administering institution or primary organisation) of each MRFF-funded grant with payment commencing between 7 November 2020 and 5 November 2022.

The following analysis of MRFF funding is based on the available information on applications to grant opportunities completed during the period of the report and the outcome (Funded grants) was known. More information on the methodology is at Appendix H.

Table 7 shows the broad research area of grants, grant opportunities and funding. For this subset of grant opportunities that were administered by the NHMRC, there were similar distribution across the 4 broad research areas. However, most grants and the associated funding was for projects focusing on Clinical Medicine and Science. Table 8 presents the range of fields of research support by the MRFF during 7 November 2020 and 5 November 2022.

Table 7
Broad research area of grants, grant opportunities and funding between 7 November 2020 and 5 November 2022

Broad research area	Number of grant opportunities completed	Funded grants	Funding
Basic Science	18	40	\$64,716,158.04
Clinical Medicine and Science	23	136	\$277,096,247.86
Health Services Research	18	64	\$92,819,599.82
Public Health	17	35	\$53,516,135.56

Broad research area is nominated by applicants in the application form. Applicants can assign more than one broad research area to an application. Data represents competitive grant opportunities that (1) were administered by the NHMRC, (2) the applicant nominated a research area in the application, (3) opened for applications between 7 November 2020 and 31 June 2022 and (4) had a known outcome. The grant numbers and funding figures are based on each MRFF-funded grant with payment commencing between 7 November 2020 and 5 November 2022 and had a known outcome.

Table 8
Top 20 Field of research of grants, grant opportunities and funding between 7 November 2020 and 5 November 2022

Field of research	Number of grant opportunities completed	Funded grants	Funding amount
Aboriginal and Torres Strait Islander health	3	6	\$6,662,742.65
Aged health care	1	4	\$5,948,452.60
Cancer diagnosis	3	3	\$7,864,256.80
Cardiology (incl. cardiovascular diseases)	4	9	\$16,215,042.84
Cardiorespiratory medicine and haematology	5	31	\$34,966,383.63
Central nervous system	7	8	\$13,054,884.91
Clinical sciences	10	25	\$42,893,663.28
Genetics	4	13	\$42,946,021.37
Genomics	2	3	\$8,119,751.01
Geriatrics and gerontology	4	3	\$3,211,008.50
Health sciences	1	6	\$16,070,703.83
Infectious diseases	2	3	\$12,292,525.34
Neurology and neuromuscular diseases	4	1	\$499,705.00
Neurosciences	7	5	\$7,192,463.60
Oncology and carcinogenesis	3	1	\$582,686.40
Paediatrics and reproductive medicine	5	7	\$14,300,441.43
Psychiatry (incl. Psychotherapy)	2	7	\$17,451,272.70
Public health and health services	8	41	\$47,525,358.72
Regenerative medicine (incl. Stem cells and tissue engineering)	1	2	\$1,566,475.60
Rehabilitation and therapy (excl. Physiotherapy)	3	5	\$3,234,768.66

Field of research is nominated by applicants in the application form. Applicants can assign more than one field of research to an application. The top 20 terms assigned to applications are reported. Self-reported terms may not directly align with description of MRFF initiatives. Data represents competitive grant opportunities that (1) were administered by the NHMRC, (2) the applicant nominated a field of research in the application, (3) opened for applications between 7 November 2020 and 31 June 2022 and (4) had a known outcome. The grant numbers and funding figures are based on each MRFF-funded grant with payment commencing between 7 November 2020 and 5 November 2022 and had a known outcome.

Grant models to fund research projects

Different grant models have been included in grant opportunities during 2020-2022 to support innovative research approaches and to help find solutions to significant health challenges and to turn knowledge into practice

Incubator Grants

51
grants
awarded



- support early stage, small scale research projects
- assess the potential and feasibility of novel strategies
- address critical/intractable health issues
- small scale (up to \$1 million) and short-term (6-24 months) funding
- examples:
 - 2020 Traumatic Brain Injury Mission Grant Opportunity
 - 2020 Cardiovascular Health Grant Opportunity

Accelerator Grants

16
grants
awarded



- support large-scale interdisciplinary research
- drive implementation of substantial improvements to health care and/or health system effectiveness
- large scale (up to \$5 million) and long-term (up to 5 years) funding
- examples
 - 2021 Stem Cell Therapies Grant Opportunity
 - 2021 Indigenous Health Research Grant Opportunity

Innovation Grants

5
grants
awarded



- support smaller scope research projects
- allow grantees to build evidence of the feasibility of their projects to be competitive in future funding
- small scale and short-term (6-12 months) funding
- aimed at a specific groups of researchers
- examples
 - First Nations researchers: 2021 Improving the Health and Wellbeing of Aboriginal and Torres Strait Islander Mothers and Babies Grant Opportunity
 - Early to Mid-Career Researchers: 2021 Dementia, Ageing and Aged Care Grant Opportunity

Targeted Calls for Research

- support larger-scale interdisciplinary research
- larger-scale and longer-term (generally three to 5 years)
- main model used in MRFF

382
grants
awarded




Number of grants are grants with payments commencing between 7 November 2020 and 5 November 2022 inclusive.

Transition of Clinician Researchers from funding individual researchers to teams of clinicians with a focus on their patient populations

The Clinician Researchers initiative aims to support

- the next generation of talented Australian health professionals drive medical research, make new discoveries and ensure implementation of best practice care for their patients
- health care professionals to undertake research that will improve clinical care and practice, including through engagement with patients
- clinicians to focus on developing and refining their research skills and to build research capacity.



Data is grant opportunities that were opened and grants with payments commencing during the periods when Australian Medical Research and Innovation Priorities were in force: 9 November 2016 to 8 November 2018, 8 November 2018 to 6 November 2020 and 7 November 2020 to 5 November 2022.

* The number of grants reported is the outcome of one of two grant opportunities open between 7 November 2020 to 5 November 2022 and with payments commencing up to 5 November 2022.

The Clinician Researchers initiative is designed to support the full breadth of clinicians/health care professionals to undertake research that will improve clinical care and practice, including through engagement with patients. Early grants from this initiative were Fellowships or Investigator Grants that allowed individual clinician researchers to pursue their research interests and build their individual capability.

To align the initiative more closely with its policy and program intent, the initiative moved away from individual fellowships to supporting applied health research teams predominantly comprising clinician researchers led by:

- medical specialists, nurses, midwives, and allied health professionals including nurses (in the 2020 grant opportunity)
- nurses, midwives, and allied health workers (in the 2022 grant opportunity).

Prior to the 2020-2022 Priorities, grant sizes averaged around half a million dollars; this average grew to \$2.3 million when the new grant opportunities were introduced, as the grants supported teams. To build the evidence base on the factors that support or hinder the translation of evidence into practice, the 2022 grant opportunity also introduced an additional stream to fund an organisation to evaluate the outcomes and impact of the funded projects.

Table 9 shows the funded rate (the percentage of applications funded) of grant opportunities within the 4 MRFF themes. The lowest funded rate was observed in the Researchers theme. Approximately one third of applications under the Patients and Research Missions themes were funded.

Table 9
Funded rate by MRFF theme

MRFF theme	Number of applications	Funded grants	Funded rate
Patients	279	90	32.3%
Research Missions	525	170	32.4%
Research Translation	323	52	16.1%
Researchers	207	19	9.2%

Data represents the funded rates of applications to competitive grant opportunities. Included grant opportunities that (1) were administered by the NHMRC and BGH, (2) opened for applications between 7 November 2020 and 31 June 2022 and (3) had a known outcome. A grant opportunity across more than one MRFF theme, applications or funded grants was assigned to a single MRFF theme, with the larger number of applications.

Table 10 displays the funded rates by MRFF initiatives. Of the 17 initiatives presented in this report, the funded rate varied across initiatives. The highest funded rate was observed with the Genomics Health Futures Mission.

Table 10
Funded rate by MRFF initiative

Initiative	Number of applications	Funded grants	Funded rate
Australian Brain Cancer Mission	15	3	20.0%
Cardiovascular Health Mission	175	57	32.6%
Clinical Trials Activity	161	43	26.7%
Clinician Researchers	181	14	7.7%
Dementia, Ageing and Aged Care Mission	115	29	25.2%
Emerging Priorities and Consumer-Driven Research	118	47	39.8%
Frontier Health and Medical Research	26	5	19.2%
Genomics Health Futures Mission	82	37	45.1%
Indigenous Health Research Fund	42	17	40.5%
Medical Research Commercialisation	12	4	33.3%
Preventive and Public Health Research	88	23	26.1%
Primary Health Care Research	25	4	16.0%
Rapid Applied Research Translation	72	9	12.5%
Research Data Infrastructure	126	12	9.5%
Stem Cell Therapies Mission	59	17	28.8%
Traumatic Brain Injury Mission	37	10	27.0%

Data represents the funded rates of applications to competitive grant opportunities. Included grant opportunities that (1) were administered by the NHMRC and BGH (2) opened for applications between 7 November 2020 and 31 June 2022 and (3) had a known outcome. A grant opportunity across more than one MRFF initiative, applications or funded grants was assigned to a single MRFF initiative, with the larger number of applications.

Table 11 shows that for the broad research area, the funded rates are similar across 4 categories. While a range of funded rates are observed by the field of research (Table 12).

Table 11
Funded rate by broad research area

Broad research area	Number of applications	Funded grants	Funded rate
Basic Science	124	40	32.2%
Clinical Medicine and Science	424	136	32.1%
Health Services Research	179	64	35.8%
Public Health	95	35	36.8%

Broad research area is nominated by applicants in the application form. Applicants can assign more than one broad research area to an application. Data represents the funded rates of applications to competitive grant opportunities that (1) were administered by the NHMRC, (2) the applicant nominated a research area in the application, (3) opened for applications between 7 November 2020 and 31 June 2022 and (4) had a known outcome.

Table 12
Funded rate by the top 20 field of research

Field of research	Number of applications	Funded grants	Funded rate
Aboriginal and Torres Strait Islander health	19	6	31.58%
Aged health care	17	4	23.53%
Cancer diagnosis	11	3	27.27%
Cardiology (incl. cardiovascular diseases)	42	9	21.43%
Cardiorespiratory medicine and haematology	74	32	43.24%
Central nervous system	21	8	38.10%
Clinical sciences	115	30	26.09%
Genetics	26	13	50.00%
Genomics	12	3	25.00%
Geriatrics and gerontology	13	3	23.08%
Health sciences	18	6	33.33%
Infectious diseases	14	3	21.43%
Neurology and neuromuscular diseases	17	1	5.88%
Neurosciences	25	5	20.00%
Oncology and carcinogenesis	26	1	3.85%
Paediatrics and reproductive medicine	18	8	44.44%
Psychiatry (incl. Psychotherapy)	17	7	41.18%
Public health and health services	106	41	38.68%
Regenerative medicine (incl. Stem cells and tissue engineering)	12	2	16.67%
Rehabilitation and therapy (excl. Physiotherapy)	13	5	38.46%

Field of research is nominated by applicants in the application form. Applicants can assign more than one field of research to an application. The top 20 terms assigned to applications are reported. Data represents the funded rates of applications to competitive grant opportunities that (1) were administered by the NHMRC, (2) the applicant nominated a research area in the application, (3) opened for applications between 7 November 2020 and 31 June 2022 and (4) had a known outcome.

Project applications for MRFF grant opportunities can include multidisciplinary teams of researchers called Chief Investigators (CIs). The lead applicant is referred to as Chief Investigator A (CIA). The age of CIs and the CIA was obtained for completed grant opportunities in 2020–2022. Table 13 shows the funded rates of all CIs in applications by their age. The funded rate is calculated as the percentage of CIs in funded grants compared to CIs in all applications. CIs at all ages were supported by MRFF grants. The lowest funded rate was observed in the 20–29 age group and the highest rate in the 40–49 age group. The 40–49 age group included the largest number of CIs in funded grants.

Table 13
Funded rate by age of Chief Investigators

Age band	Number of CIs in applications	Number of CIs in funded grants	Funded rate
20 – 29	69	19	27.5%
30 – 39	1271	455	35.8%
40 – 49	2598	1006	38.7%
50 – 59	2425	869	35.8%
60 – 69	1231	438	35.6%
70+	191	58	30.4%

Data represents the funded rates of all Chief Investigators (CIs) in applications to competitive grant opportunities, where the age information is available. Included grant opportunities that (1) were administered by the NHMRC, (2) opened for applications between 7 November 2020 and 31 June 2022 and (3) had a known outcome.

Table 14 shows the funded rates of CIA (lead applicant) in applications by their age. The highest number of CIAs in funded grants and the highest funded rate were observed in the 40-49 age group.

Table 14
Funded rate by age of Chief Investigator A (lead applicant)

Age band	Number of CIAs in applications	Number of CIAs in funded grants	Funded rate
20 – 29	0	0	-
30 – 39	102	27	26.5%
40 – 49	331	114	34.4%
50 – 59	312	100	32.1%
60 - 69	126	39	31.0%
70+	18	3	16.7%

Data represents the funded rates of Chief Investigators A (CIA, lead applicant) in applications to competitive grant opportunities, where the age information is available. Included grant opportunities that (1) were administered by the NHMRC, (2) opened for applications between 7 November 2020 and 31 June 2022 and (3) had a known outcome.

Gender analysis

The gender information of CIs and the lead applicant (CIA) was obtained for completed grant opportunities in 2020-2022. Table 15 shows the number of CIs that have received funding via MRFF grants. Over 3,200 CIs were funded over the analysis period with men accounting for 49.2% of the CIs.

Table 15
Chief investigators applying for MRFF grant opportunities

Gender (all CIs)	Number of CIs in funded grants across all MRFF themes	Percentage of CIs in funded grants
Women	1517	46.9%
Men	1591	49.2%
Not stated	129	4.0%
Total	3237	100.0%

Data represents the funded rates of Chief Investigators (CIs) in an application or CIA (lead applicant), who self-identified as a woman or man, to a competitive grant opportunity. The competitive grant opportunities included (1) were administered by the NHMRC and BGH, (2) opened for applications between 7 November 2020 and 31 June 2022 and (3) had a known outcome. CIs self-identified as Intersex or Indeterminate have not been included for privacy reasons.

Table 16 presents the funded rate by gender of all CIs and for the CIA (lead applicant). Overall, during 2020-2022, over 1,500 women CIs were funded, a lower number than men CIs. However funded rates for women CIs were higher than for men. Men were the CIA in a higher number of applications than women, however had a lower overall funded rate compared with women CIAs.

Table 16
Funded rates by Chief Investigators and by lead applicant (Chief Investigator A).

	Gender	Number of CIs in applications	Number of CIs in funded grants	Funded rate (%)
All CIs	Women	4415	1517	34.4%
All CIs	Men	5116	1591	31.1%
CIA	Women	457	143	31.3%
CIA	Men	564	156	27.7%

Data represents the funded rates of Chief Investigators (CIs) in an application or CIA (lead applicant), who self-identified as a woman or man, to a competitive grant opportunity. The competitive grant opportunities included (1) were administered by the NHMRC and BGH (2) opened for applications between 7 November 2020 and 31 June 2022 and (3) had a known outcome.

The funded rate analysis by gender below focusses on all CIs. Table 17 shows the funded rate by women and men CIs across each of the MRFF themes. While there was variation across the 4 MRFF themes, women CIs had a higher funded rate than men CIs in each MRFF theme.

Table 17
Funded rates by Chief Investigators by MRFF theme

MRFF theme	Gender	Number of CIs in applications	Number of CIs in funded grants	Funded rate
Patients	Women	1127	455	40.4%
Patients	Men	1311	458	34.9%
Research Missions	Women	2125	832	39.2%
Research Missions	Men	2365	884	37.4%
Research Translation	Women	1063	209	19.7%
Research Translation	Men	1320	229	17.3%
Researchers	Women	100	21	21.0%
Researchers	Men	120	20	16.7%

Data represents the funded rates of Chief Investigators (CIs) in an application, who self-identified as a woman or man, to a competitive grant opportunity. The competitive grant opportunities included (1) were administered by the NHMRC and BGH (2) opened for applications between 7 November 2020 and 31 June 2022 and (3) had a known outcome. A grant opportunity across more than one MRFF theme, applications or funded grants was assigned to a single MRFF theme, with the larger number of applications.

Table 18 shows the number of grants and funding value when women and men lead applications (i.e., are the CIA) across the 4 MRFF themes. A greater or equal number of grants with men CIAs was awarded in Patients, Research Missions and Researchers compared to grants with women CIAs.

Table 18
Chief investigators A applying for MRFF grant opportunities by MRFF theme

Themes	Gender	Number of funded grants with a CIA of this gender	Percentage of grants by gender in a theme	Value of funded grants led by a CIA of this gender	Percentage of funding by gender in a theme
Patients	Women	36	40.9%	\$83,577,663.64	41.6%
Patients	Men	52	59.1%	\$117,568,131.29	58.4%
Research Missions	Women	84	50.0%	\$108,055,731.23	43.8%
Research Missions	Men	84	50.0%	\$138,681,769.04	56.2%
Research Translation	Women	21	55.3%	\$46,917,077.11	57.0%
Research Translation	Men	17	44.7%	\$35,409,366.01	43.0%
Researchers	Women	2	40.0%	\$4,529,210.63	30.2%
Researchers	Men	3	60.0%	\$10,464,824.74	69.8%

Data represents Chief Investigators A (CIA) of an application, who self-identified as a woman or man, to a competitive grant opportunity. The competitive grant opportunities included (1) were administered by the NHMRC and BGH, (2) opened for applications between 7 November 2020 and 31 June 2022 and (3) had a known outcome. A grant opportunity across more than one MRFF theme, applications or funded grants was assigned to a single MRFF theme, with the larger number of applications.

Table 19 shows the funded rate by women and men CIs across each of the MRFF initiatives. The funded rate for women CIs was higher across all initiatives, except Preventive and Public Health Research and Stem Cell Therapies Mission.

Table 19
Funded rates by Chief Investigators by MRFF initiative

Initiative	Gender	Number of CIs in applications	Number of CIs in funded grants	Funded rate
Australian Brain Cancer Mission	Women	48	14	29.2%
Australian Brain Cancer Mission	Men	89	17	19.1%
Cardiovascular Health Mission	Women	581	221	38.0%
Cardiovascular Health Mission	Men	833	282	33.9%
Clinical Trials Activity	Women	505	150	29.7%
Clinical Trials Activity	Men	784	217	27.7%
Dementia, Ageing and Aged Care Mission	Women	618	188	30.4%
Dementia, Ageing and Aged Care Mission	Men	419	123	29.4%
Emerging Priorities and Consumer-Driven Research	Women	622	305	49.0%
Emerging Priorities and Consumer-Driven Research	Men	527	241	45.7%
Frontier Health and Medical Research	Women	100	21	21.0%
Frontier Health and Medical Research	Men	120	20	16.7%
Genomics Health Futures Mission	Women	372	204	54.8%
Genomics Health Futures Mission	Men	497	259	52.1%
Indigenous Health Research Fund	Women	219	101	46.1%
Indigenous Health Research Fund	Men	133	60	45.1%
Preventive and Public Health Research	Women	373	105	28.2%
Preventive and Public Health Research	Men	394	136	34.5%
Primary Health Care Research	Women	141	29	20.6%
Primary Health Care Research	Men	138	23	16.7%
Research Data Infrastructure	Women	549	75	13.7%
Research Data Infrastructure	Men	788	70	8.9%
Stem Cell Therapies Mission	Women	134	43	32.1%
Stem Cell Therapies Mission	Men	204	80	39.2%
Traumatic Brain Injury Mission	Women	153	61	39.9%
Traumatic Brain Injury Mission	Men	190	63	33.2%

Data represents the funded rates of Chief Investigators (CIs) in an application, who self-identified as a woman or man, to a competitive grant opportunity. The competitive grant opportunities included (1) were administered by the NHMRC and BGH, (2) opened for applications between 7 November 2020 and 31 June 2022 and (3) had a known outcome. A grant opportunity across more than one MRFF initiative, applications or funded grants was assigned to a single MRFF initiative, with the larger number of applications. The Rapid Applied Research Translation initiative is not included as gender was not stated in applications.

Table 20 shows the number of grants and funding value when women and men lead applications (i.e., are the CIA) across the initiatives. Grants lead by women were awarded in all initiatives except the Australian Brain Cancer Mission at the time of writing this report. A higher proportion of women leading projects was observed in the following initiatives: Dementia, Ageing and Aged Care Mission, Emerging Priorities and Consumer-Driven Research, Indigenous Health Research Fund, Primary Health Care Research, Research Data Infrastructure and Traumatic Brain Injury Mission.

Table 20
Chief investigators A applying for MRFF grant opportunities by MRFF initiative

Initiative	Gender	Number of funded grants with a CIA of this gender	Percentage of grants by gender in an initiative	Value of funded grants with a CIA of this gender	Percentage of funding by gender in an initiative
Australian Brain Cancer Mission	Women	0	0.0%	\$0.00	0.0%
Australian Brain Cancer Mission	Men	3	100.0%	\$5,462,646.70	100.0%
Cardiovascular Health Mission	Women	25	44.6%	\$22,069,119.47	41.6%
Cardiovascular Health Mission	Men	31	55.4%	\$30,937,110.34	58.4%
Clinical Trials Activity	Women	13	30.2%	\$36,060,231.27	36.9%
Clinical Trials Activity	Men	30	69.8%	\$61,540,429.87	63.1%
Dementia, Ageing and Aged Care Mission	Women	23	79.3%	\$32,725,955.24	77.8%
Dementia, Ageing and Aged Care Mission	Men	6	20.7%	\$9,325,887.82	22.2%
Emerging Priorities and Consumer-Driven Research	Women	23	51.1%	\$47,517,432.37	45.9%
Emerging Priorities and Consumer-Driven Research	Men	22	48.9%	\$56,027,701.42	54.1%
Frontier Health and Medical Research	Women	2	40.0%	\$4,529,210.63	30.2%
Frontier Health and Medical Research	Men	3	60.0%	\$10,464,824.74	69.8%
Genomics Health Futures Mission	Women	10	27.8%	\$26,041,109.52	25.8%
Genomics Health Futures Mission	Men	26	72.2%	\$74,990,518.29	74.2%
Indigenous Health Research Fund	Women	14	82.4%	\$16,302,995.25	89.3%

Indigenous Health Research Fund	Men	3	17.6%	\$1,953,581.80	10.7%
Preventive and Public Health Research	Women	10	43.5%	\$21,949,724.80	41.7%
Preventive and Public Health Research	Men	13	56.5%	\$30,632,859.01	58.3%
Primary Health Care Research	Women	3	75.0%	\$6,470,707.31	85.5%
Primary Health Care Research	Men	1	25.0%	\$1,093,405.00	14.5%
Research Data Infrastructure	Women	8	72.7%	\$18,496,645.00	83.4%
Research Data Infrastructure	Men	3	27.3%	\$3,683,102.00	16.6%
Stem Cell Therapies Mission	Women	6	35.3%	\$5,064,689.05	27.1%
Stem Cell Therapies Mission	Men	11	64.7%	\$13,650,558.19	72.9%
Traumatic Brain Injury Mission	Women	6	60.0%	\$5,851,862.70	71.2%
Traumatic Brain Injury Mission	Men	4	40.0%	\$2,361,465.90	28.8%

Data represents Chief Investigators (CIA) in an application, who self-identified as a woman or man, to a competitive grant opportunity. The competitive grant opportunities included (1) were administered by the NHMRC and BGH, (2) opened for applications between 7 November 2020 and 31 June 2022 and (3) had a known outcome. A grant opportunity across more than one MRFF initiative, applications or funded grants was assigned to a single MRFF initiative with the larger number of applications. MRFF initiatives, with grant opportunities where gender was not stated in applications, are not included.

Table 21 shows the funded rate by women and men CIs based on the broad research area. The funded rate for women CIs is better or equal to men CIs in 3 broad research areas, but men CIs had higher funded rates in 'Basic science' projects.

Table 21
Funded rates by Chief Investigators by broad research area

Broad research area	Gender	Number of CIs in applications	Number of CIs in funded grants	Funded rates
Basic Science	Women	310	112	36.1%
Basic Science	Men	548	221	40.3%
Clinical Medicine and Science	Women	1410	539	38.2%
Clinical Medicine and Science	Men	2139	765	35.8%
Health Services Research	Women	940	391	41.6%
Health Services Research	Men	733	307	41.9%
Public Health	Women	600	251	41.8%
Public Health	Men	369	140	37.9%

Data represents the funded rates of Chief Investigators (CIs) in an application, who self-identified as a woman or man, to a competitive grant opportunity. Broad research area is nominated by applicants in the application form. Applicants can assign more than one broad research area to an application. The competitive grant opportunities included (1) were administered by the NHMRC, (2) opened for applications between 7 November 2020 and 31 June 2022 and (3) had a known outcome.

Table 22 shows the number of grants and funding value for CIAs by gender across each of the broad research areas. A higher proportion of grants led by women were awarded under 'Health Services Research' and 'Public Health'.

Table 22
Chief Investigator A applying for MRFF grant opportunities by broad research area

Broad research area	Gender	Number of funded grants with a CIA of this gender	Percentage of grants by gender in a research area	Value of funded grants with a CIA of this gender	Percentage of funding by gender in a research area
Basic Science	Women	9	23.1%	\$12,026,499.70	19.2%
Basic Science	Men	30	76.9%	\$50,567,357.24	80.8%
Clinical Medicine and Science	Women	48	35.3%	\$93,234,489.22	33.6%
Clinical Medicine and Science	Men	88	64.7%	\$183,861,758.60	66.4%
Health Services Research	Women	41	65.1%	\$56,914,399.69	63.3%
Health Services Research	Men	22	34.9%	\$32,987,735.94	36.7%
Public Health	Women	29	85.3%	\$40,037,736.00	75.8%
	Men	5	14.7%	\$12,772,157.96	24.2%
Data represents Chief Investigators (CIA) in an application, who self-identified as a woman or man, to a competitive grant opportunity. Broad research area is nominated by applicants in the application form. Applicants can assign more than one broad research area to an application. The competitive grant opportunities included (1) were administered by the NHMRC, (2) opened for applications between 7 November 2020 and 31 June 2022 and (3) had a known outcome.					

Funded rates were analysed by field of research (table 23) and the location of the Chief Investigator. The relative funded rates by gender varied across the fields of research. The funded rate between the fields ranged from 3.7% (women CI, Neurology and neuromuscular diseases) to 65.5% (men CI, Genetics).

Table 23
Funded rates by Chief Investigator by top 20 fields of research

Field of research	Gender	Number of CIs in applications	Number of CIs in funded grants	Funded rate
Aboriginal and Torres Strait Islander health	Women	102	38	37.25%
Aboriginal and Torres Strait Islander health	Men	50	20	40.00%
Aged health care	Women	94	19	20.21%
Aged health care	Men	46	14	30.43%
Cancer diagnosis	Women	29	12	41.38%
Cancer diagnosis	Men	60	17	28.33%
Cardiology (incl. cardiovascular diseases)	Women	107	22	20.56%
Cardiology (incl. cardiovascular diseases)	Men	206	59	28.64%
Cardiorespiratory medicine and haematology	Women	249	114	45.78%
Cardiorespiratory medicine and haematology	Men	433	193	44.57%
Central nervous system	Women	62	23	37.10%
Central nervous system	Men	96	42	43.75%
Clinical sciences	Women	461	169	36.66%
Clinical sciences	Men	583	191	32.76%
Gastroenterology and hepatology	Women	28	15	53.57%
Gastroenterology and hepatology	Men	54	28	51.85%
Genetics	Women	156	93	59.62%
Genetics	Men	198	130	65.66%
Genomics	Women	40	10	25.00%
Genomics	Men	53	10	18.87%
Geriatrics and gerontology	Women	52	18	34.62%
Geriatrics and gerontology	Men	49	12	24.49%
Health sciences	Women	99	36	36.36%
Health sciences	Men	96	45	46.88%
Infectious diseases	Women	55	NR	NR
Infectious diseases	Men	71	17	23.94%

Neurology and neuromuscular diseases	Women	54	NR	NR
Neurology and neuromuscular diseases	Men	71	NR	NR
Neurosciences	Women	142	37	26.06%
Neurosciences	Men	175	53	30.29%
Oncology and carcinogenesis	Women	80	NR	NR
Oncology and carcinogenesis	Men	145	NR	NR
Paediatrics and reproductive medicine	Women	119	77	64.71%
Paediatrics and reproductive medicine	Men	68	27	39.71%
Psychiatry (incl. Psychotherapy)	Women	48	19	39.58%
Psychiatry (incl. Psychotherapy)	Men	76	34	44.74%
Public health and health services	Women	579	253	43.70%
Public health and health services	Men	452	166	36.73%
Rehabilitation and therapy (excl. Physiotherapy)	Women	69	29	42.03%
Rehabilitation and therapy (excl. Physiotherapy)	Men	38	15	39.47%
Other	Women	970	349	35.98%
Other	Men	1303	423	32.46%

NR is not reported for privacy reasons, when less than 10 people were identified. Data represents the funded rates of Chief Investigators (CIs) in an application, who self-identified as a woman or man, to a competitive grant opportunity. Field of research is nominated by applicants in the application form. Applicants can assign more than one field of research to an application. The top 20 categories were derived by the number of CIs whose application was assigned to a category. The term 'Other' relates to fields not in the top 20. The competitive grant opportunities included (1) were administered by the NHMRC, (2) opened for applications between 7 November 2020 and 31 June 2022 and (3) had a known outcome.

Table 24 shows that funded rates of women CIs were equal or better than those for men CIs in applications where the lead organisation is based in New South Wales, the Northern Territory, Queensland, South Australia, Tasmania, and Western Australia. As many MRFF-funded grants are collaborative research efforts, CIs on an application may be in multiple Australian locations.

Table 24
Funded rates by Chief Investigators by location

Location of lead applicant	Gender	Number of CIs in applications	Number of CIs in funded grants	Funded rate
ACT	Women	96	37	38.5%
ACT	Men	112	50	44.6%
NSW	Women	1306	430	32.9%
NSW	Men	1548	436	28.2%
NT	Women	57	49	86.0%
NT	Men	41	25	61.0%
QLD	Women	720	205	28.5%
QLD	Men	789	196	24.8%
SA	Women	443	148	33.4%
SA	Men	541	176	32.5%
TAS	Women	64	23	35.9%
TAS	Men	48	15	31.3%
VIC	Women	1445	514	35.6%
VIC	Men	1681	571	34.0%
WA	Women	303	111	36.6%
WA	Men	389	122	31.4%

Data represents the funded rates of Chief Investigators (CIs) in an application, who self-identified as a woman or man, to a competitive grant opportunity. The location is based on the lead organisation (also known as the administering institution or primary organisation), but CIs involved in the application may be located in other states and territories. The competitive grant opportunities included (1) were administered by the NHMRC and BGH, (2) opened for applications between 7 November 2020 and 31 June 2022 and (3) had a known outcome.

Consistency of financial assistance with the 2020–2022 Priorities

The Australian Government considered the 2020–2022 Priorities when the MRFF initiatives were established under the 10-year investment plan for the MRFF. A list of the 2020–2022 Priorities is provided at Table 1.

Table 25 presents how MRFF initiatives and grant opportunities (as at 5 November 2022) relate to the 2020–2022 Priorities.

Table 25
MRFF initiatives and open grant opportunities during 2020–2022 Priorities
(7 November 2020 and 5 November 2022)

MRFF initiative	Grant opportunity	2020 2022 Priorities
Australian Brain Cancer Mission	2021 Brain Cancer Research	<ul style="list-style-type: none"> • Consumer-Driven Research • Clinical Researcher Capacity • Translational Research Infrastructure
	2021 GBM AGILE	<ul style="list-style-type: none"> • Comparative Effectiveness Research • Consumer-Driven Research
	2022 Australian Brain Cancer Research Infrastructure	<ul style="list-style-type: none"> • Consumer-Driven Research • Digital Health Intelligence
Cardiovascular Health Mission	2020 Cardiovascular Health	<ul style="list-style-type: none"> • Primary Care Research • Consumer-Driven Research
	2021 Cardiovascular Health	<ul style="list-style-type: none"> • Aboriginal and Torres Strait Islander Health • Primary Care Research • Consumer-Driven Research • Public Health Interventions
	2022 Cardiovascular Health	<ul style="list-style-type: none"> • Primary Care Research • Consumer-Driven Research • Public Health Interventions
Clinical Trials Activity	2021 Clinical Trials Activity	<ul style="list-style-type: none"> • Comparative Effectiveness Research • Primary Care Research • Clinical Researcher Capacity • Drug Repurposing • Public Health Interventions
	2021 Innovative Therapies for Mental Illness	<ul style="list-style-type: none"> • Comparative Effectiveness Research • Drug Repurposing
	2021 International Clinical Trial Collaborations (Round 21.1)	<ul style="list-style-type: none"> • Comparative Effectiveness Research • Drug Repurposing
	2021 International Clinical Trial Collaborations (Round 21.2)	<ul style="list-style-type: none"> • Comparative Effectiveness Research • Clinical Researcher Capacity
	2021 Rare Cancers, Rare Diseases and Unmet Need	<ul style="list-style-type: none"> • Clinician Researcher Capability • Comparative Effectiveness Research • Ageing and Aged Care • One Health – Antimicrobial Resistance • Digital Health Intelligence
	2022 International Clinical Trial Collaborations (Round 22.1)	<ul style="list-style-type: none"> • Clinical Researcher Capacity

	2022 International Clinical Trial Collaborations (Round 22.2)	<ul style="list-style-type: none"> • Clinical Researcher Capacity
Clinical Trials Activity and Emerging Priorities and Consumer-Driven Research	2022 Multiple Sclerosis Research	<ul style="list-style-type: none"> • Consumer-Driven Research • Clinical Researcher Capacity
	2022 Pancreatic Cancer Research	<ul style="list-style-type: none"> • Consumer-Driven Research • Clinical Researcher Capacity
Clinician Researchers	2020 Clinician Researchers: Applied Research in Health	<ul style="list-style-type: none"> • Clinical Researcher Fellowships
	2022 Clinician Researchers: Nurses, Midwives and Allied Health	<ul style="list-style-type: none"> • Comparative Effectiveness Research • Primary Care Research • Clinical Researcher Capacity
Coronavirus Research Response	2021 COVID-19 Vaccine-Associated Thrombosis with Thrombocytopenia Syndrome	<ul style="list-style-type: none"> • Global Health and Health Security • Consumer-Driven Research • Public Health Interventions
	2021 COVID-19 Health Impacts and Vaccination Schedules	<ul style="list-style-type: none"> • Global Health and Health Security • Comparative Effectiveness Research
	2021 COVID-19 Treatment Access and Public Health Activities	<ul style="list-style-type: none"> • Global Health and Health Security • Comparative Effectiveness Research
		<ul style="list-style-type: none"> • Digital Health Intelligence • Primary Care Research • Translational Research Infrastructure • Public Health Interventions
Dementia, Ageing and Aged Care Mission	2020 Dementia, Ageing and Aged Care	<ul style="list-style-type: none"> • Ageing and Aged Care • Digital Health Intelligence • Primary Care Research • Public Health Interventions • Consumer-Driven Research
	2021 Dementia, Ageing and Aged Care	<ul style="list-style-type: none"> • Ageing and Aged care • Digital Health Intelligence • Primary Care Research • Public Health Interventions
	2022 Dementia, Ageing and Aged Care	<ul style="list-style-type: none"> • Ageing and Aged Care • Digital Health Intelligence • Primary Care Research • Public Health Interventions
Early to Mid-Career Researchers	2021 Early to Mid-Career Researchers	<ul style="list-style-type: none"> • Consumer-Driven Research • Translational Research Infrastructure
Emerging Priorities and Consumer-Driven Research	2020 Improving Diagnosis in Cancers With Low Survival Rates	<ul style="list-style-type: none"> • Consumer-Driven Research
	2020 Neurofibromatosis Research	<ul style="list-style-type: none"> • Consumer-Driven Research
	2020 Paediatric Cancer	<ul style="list-style-type: none"> • Consumer-Driven Research • Clinician Researcher Capacity • Digital Health Intelligence
	2021 Chronic Musculoskeletal Conditions in Children and Adolescents	<ul style="list-style-type: none"> • Primary Care Research • Consumer-Driven Research
	2021 Chronic Neurological Conditions	<ul style="list-style-type: none"> • Primary Care Research • Consumer-Driven Research

	2021 Improving the Health and Wellbeing of Aboriginal and Torres Strait Islander Mothers and Babies	<ul style="list-style-type: none"> • Aboriginal and Torres Strait Islander Health • Primary Care Research • Consumer-Driven Research • Public Health Interventions
	2022 Mitochondrial Donation Pilot Program	<ul style="list-style-type: none"> • Consumer-Driven Research
	2022 Models of Care to Improve the Efficiency and Effectiveness of Acute Care	<ul style="list-style-type: none"> • Consumer-Driven Research • Comparative Effectiveness Research
Genomics Health Futures Mission	2020 Genomics Health Futures Mission	<ul style="list-style-type: none"> • Consumer-Driven Research • Public Health Interventions
	2021 Genomics Health Futures Mission	<ul style="list-style-type: none"> • Digital Health Intelligence • Aboriginal and Torres Strait Islander Health • Consumer-Driven Research • Public Health Interventions
	2022 Genomics Health Futures	<ul style="list-style-type: none"> • Aboriginal and Torres Strait Islander Health • Comparative Effectiveness Research • Primary Care Research • Public Health Interventions
Indigenous Health Research Fund	2020 Indigenous Health Research	<ul style="list-style-type: none"> • Aboriginal and Torres Strait Islander Health • Primary Care Research • Consumer-Driven Research
	2021 Indigenous Health Research	<ul style="list-style-type: none"> • Aboriginal and Torres Strait Islander Health • Public Health Interventions
	2022 Indigenous Health Research	<ul style="list-style-type: none"> • Aboriginal and Torres Strait Islander Health
Medical Research Commercialisation	2020 Early Stage Translation and Commercialisation Support	<ul style="list-style-type: none"> • Translational Research Infrastructure • Drug Repurposing • Digital Health Intelligence • Comparative Effectiveness Research
	2021 BioMedTech Incubator	<ul style="list-style-type: none"> • Translational Research Infrastructure
National Critical Research Infrastructure	2021 mRNA Clinical Trials Enabling Infrastructure	<ul style="list-style-type: none"> • Global Health and Health Security • Translational Research Infrastructure
	2022 National Critical Research Infrastructure	<ul style="list-style-type: none"> • Digital Health Intelligence • Translational Research Infrastructure
Preventive and Public Health Research	2020 Quality, Safety and Effectiveness of Medicine Use and Medicine Intervention by Pharmacists	<ul style="list-style-type: none"> • Aboriginal and Torres Strait Islander health • Clinical Researcher Capacity • Consumer-Driven Research • Public Health Interventions
	2021 Chronic Respiratory Conditions	<ul style="list-style-type: none"> • Public Health Interventions
	2021 Consumer-Led Research	<ul style="list-style-type: none"> • Consumer-Driven Research
	2021 Maternal Health and Healthy Lifestyles	<ul style="list-style-type: none"> • Public Health Interventions
	2021 Optimising the Clinical Use of Immunoglobulins	<ul style="list-style-type: none"> • Comparative Effectiveness Research • Primary Care Research • Public Health Interventions
	2022 Assessment of High-Cost Gene Treatments and Digital Health Interventions	<ul style="list-style-type: none"> • Digital Health Intelligence • Comparative Effectiveness Research • Primary Care Research

		<ul style="list-style-type: none"> Public Health Interventions
	2022 Quality, Safety and Effectiveness of Medicine Use and Medicine Intervention by Pharmacists	<ul style="list-style-type: none"> Ageing and Aged Care Primary Care Research Public Health Interventions
Preventive and Public Health Research, Emerging Priorities and Consumer-Driven Research	2022 Effective Treatments and Therapies	<ul style="list-style-type: none"> Ageing and Aged Care Primary Care Research Consumer-Driven Research Public Health Interventions
Primary Health Care Research	2021 Primary Health Care Digital Innovations	<ul style="list-style-type: none"> Primary Care Research Digital Health Intelligence
	2021 Primary Health Care Research	<ul style="list-style-type: none"> Primary Care Research Digital Health Intelligence Public Health Interventions
Rapid Applied Research Translation	2020 Rapid Applied Research Translation	<ul style="list-style-type: none"> Public Health Interventions Primary Health Research Consumer-Driven Research
Research Data Infrastructure	2020 Primary Health Care Research Data Infrastructure	<ul style="list-style-type: none"> Aboriginal and Torres Strait Islander Health Digital Health Intelligence Primary Care Research Ageing and Aged Care
	2021 Research Data Infrastructure	<ul style="list-style-type: none"> Digital Health Intelligence
	2022 Research Data Infrastructure	<ul style="list-style-type: none"> Digital Health Intelligence Translational Research Infrastructure
Stem Cell Therapies Mission	2020 Stem Cell Therapies Mission	<ul style="list-style-type: none"> Consumer-Driven Research Public Health Interventions
	2021 Stem Cell Therapies	<ul style="list-style-type: none"> Consumer-Driven Research Drug Repurposing
	2022 Stem Cell Therapies	<ul style="list-style-type: none"> Consumer-Driven Research Drug Repurposing
Traumatic Brain Injury Mission	2020 Traumatic Brain Injury Mission	<ul style="list-style-type: none"> Digital Health Intelligence Primary Care Research Consumer-Driven Research
Traumatic Brain Injury Mission and Emerging Priorities and Consumer-Driven Research	2021 Traumatic Brain Injury	<ul style="list-style-type: none"> Digital Health Intelligence Consumer-Driven Research

Processes for determining grants of financial assistance

All MRFF grant opportunities are consistent with the *Commonwealth Grant Rules and Guidelines 2017* and the MRFF Act.

Determination of MRFF initiatives

The Australian Medical Research Advisory Board (AMRAB) is responsible for developing the MRFF Strategy and Priorities. AMRAB determined the 2016–2021 Strategy, 2021–2026 Strategy and the 2020–2022 Priorities through extensive national consultation with consumers, researchers, health care providers and managers.

The Health Minister took into account the 2020–2022 Priorities when the MRFF initiatives were extended under the second 10-year investment plan for the MRFF. This occurred in the context of the 2022–2023 Budget.

Determination of grants of financial assistance

Grant opportunities under MRFF initiatives are supported by grant opportunity guidelines and processes that outline the:


- conduct of the application process
- assessment of applications
- determination of outcomes based on assessment
- awarding of grants to successful applicants

The Department works in partnership with BGH within the Department of Industry, Science and Resources, and the NHMRC to administer grant opportunities under the MRFF. In this relationship, the Department retains responsibility for policy and program oversight to ensure that grants align with the aims and objectives of specific grant opportunities. The grants hub (BGH or NHMRC) is responsible for conducting the grant opportunity, inclusive of the assessment of applications by expert reviewers (such as scientific experts, consumers, industry experts, and health service providers) and reporting the outcomes of the assessment process to the program delegate as determined by the Health Minister.

Grant opportunities can be ‘open competitive’ and ‘targeted or restricted competitive’, depending on the aims and objectives of the specific grant opportunities. These categorisations allow all organisations, identified in the MRFF Act as eligible to receive MRFF funding, to be able to apply for funding (i.e., these grant opportunities are not restricted to an application from a single organisation). During 2020–2022, 60 of 61 grant opportunities (in Table 25) were ‘open competitive’ or ‘targeted or restricted competitive’. All applications to MRFF grant opportunities were assessed by independent experts against criteria set out in the grant opportunity guidelines.

The list of MRFF grants with payments commencing during the period when the 2020–2022 Priorities were in force (7 November 2020 to 5 November 2022), is provided at Appendices E and F. The funded rates of grant opportunities are provided at Appendix G.

What happens after a grant opportunity closes?



* The Health Minister delegates powers under the MRFF Act to the Department's senior executives.

MRFF Grant Assessment Committees

MRFF funding is primarily disbursed through peer-reviewed contestable processes to ensure the integrity of the research design, quality and safety for patients, and best return on government investment.

Independent Grant Assessment Committees (GACs) are assembled and managed by one of the grants hubs (NHMRC or BGH), comprised of qualified and experienced national and international experts who assess applications and provide recommendations regarding funding.


GAC members come from different backgrounds and bring different perspectives. They include expert reviewers such as scientific experts, consumers, industry experts and health service providers. Members are selected on the basis that they will bring experience and expertise in a range of areas including:

- transdisciplinary
- academia
- clinical
- health services delivery
- translation research
- consumers and patients
- Aboriginal and/or Torres Strait Islander health
- industry and commercialisation expertise.


People who would like to participate in MRFF grant assessments are able to register their interest on this MRFF [website](#). Potential members of GACs may be contacted directly by the Department or one of the grants hubs.

A snapshot of Grant Assessment Committees


During 2020-2022, 905 experts were engaged in Grant Assessment Committees across 40 panels.



GAC members came from all states and territories. International experts participated in GACs.



GAC members came from 119 Australian and 41 international organisations.



Diversity of experience in GAC membership is important.



The data represents the composition of 40 GAC panels held to consider the subset of competitive grant opportunities that were assessed while the Priorities were in force between 7 November 2020 and 5 November 2022. Gender and terms describing expertise were self-assigned by the GAC members. Australian organisations identified by GAC members as their employer or organisation they were representing.

Other financial assistance provided by the Australian Government for medical research and innovation

Other financial assistance provided by the Australian Government for medical research and innovation includes funding from:

- the NHMRC, for research grants
- the Biomedical Translation Fund (BTF) to private sector fund managers to develop and commercialise biomedical discoveries in Australia
- other funding opportunities.

Table 26 outlines the financial assistance provided in 2020–21 and 2021–22; these periods represent financial years and are not identical to the period during which the 2020–2022 Priorities were in force.

Table 26
Australian Government financial support for medical research and innovation, 2020–21 and 2021–22

Funding opportunity	2020–21 (\$ million)	2021–22 (\$ million)
NHMRC research grants ^a	850.4	830.2
BTF investments ^b	38.3	28.1
Other initiatives ^c	99.0	113.8

- a. The actual amounts paid as per the 2020–2021 NHMRC Annual Report (p. 136) and the 2021–22 NHMRC Annual Report (p. 131).
- b. Reporting by the Translation and Commercialisation Section managing the BTF within the Department of Industry, Science and Resources.
- c. The amounts for other initiatives were derived from the Australian Government's Science, Research and Innovation Budget Tables 2021–22 — research and development investment by program/activity under the Health Portfolio, excluding the MRFF, the NHMRC and the BTF. At the time of writing this report, estimated actual figures are available for 2020–21 and budget estimates for 2021–22.

Other financial assistance provided by the Australian Government for research and development


The Australian Government provides support for research and development across the whole of government. Table 27 outlines the financial assistance for key research and development initiatives in 2020–21 and 2021–22; these are the financial years — that is, the period is not identical to the period during which the 2020–2022 Priorities were in force.

Table 27
Australian Government financial support for key research and development initiatives, 2020–21 and 2021–22

Funding opportunity ^a	2020 21 (\$ million)	2021 22 (\$ million)
Australian Research Council – National Competitive Grants Program	806.4	814.6
Research Block Grants ^b	2,973.3	1,999.8
Cooperative Research Centres	234.2	189.0

- a. The amounts were derived for the stated initiative from the Australian Government's Science, Research and Innovation Budget Tables 2021–22 — research and development investment by program/activity. At the time of writing this report, estimated actual figures are available for 2020–21 and budget estimates for 2021–22.
- b. Comprises the Research Support Program and the Research Training Program.

Overall, the MRFF accounted for 12% of Australian Government financial support in key research and development initiatives during 2020–21 and 2021–22.



The data represents combinations of the amounts from 2020–21 and 2021–22 financial years in Tables 2, 26 and 27.

Appendix A Initiatives under the 2020–2022 Priorities

Table A MRFF initiatives under the 2020–2022 Priorities

Theme	Initiative	Objective
Patients	Clinical Trials Activity	The objective of this initiative is to increase clinical trial activity in Australia to: <ul style="list-style-type: none"> • improve the evidence base supporting clinical care • help patients access trials relevant to their health circumstances • enable researchers to bring international trials to Australian patients.
	Emerging Priorities and Consumer-Driven Research	The objectives of this initiative are to support research that improves patient care and translation of new discoveries, and encourage collaboration between consumers and researchers.
	Global Health	The objectives of this initiative are to develop knowledge and tools for addressing threats to Australia's national health security from the regional and global challenges of antimicrobial resistance and drug-resistant tuberculosis.
Researchers	Clinician Researchers	The objective of this initiative is to help the next generation of talented Australian health professionals drive medical research, make new discoveries and ensure implementation of best practice care for their patients.
	Early to Mid-Career Researchers	The objective of this new initiative is to build and grow research capacity and capability in Australia by supporting Early to Mid-Career Researchers to continue their health and medical research careers.
	Frontier Health and Medical Research	The objective of this initiative is to create opportunities to explore bold and innovative ideas, make discoveries of great potential, and to support the translation and commercialisation of these discoveries to achieve global health impact.
	Researcher Exchange and Development Within Industry	The objective of this initiative is to foster partnerships between industry, universities, registered training organisations and governments, and strengthen Australia's success in research translation and commercialisation.
Research missions	Australian Brain Cancer Mission	The objectives of this Mission are to: <ul style="list-style-type: none"> • double the survival rate of Australians living with brain cancer over 10 years • improve quality of life for people with brain cancer • give every patient (adult and child) with brain cancer a chance to join a clinical trial • boost Australian research and build research capacity.
	Cardiovascular Health Mission	The objective of this Mission is to make transformative improvements in cardiovascular health and stroke management for all Australians.
	Dementia, Ageing and Aged Care Mission	The objective of this Mission is to improve quality of life for Australians as they age.
	Genomics Health Futures Mission	The objective of this Mission is to save or transform the lives of more than 200,000 Australians through genomic research to deliver better testing, diagnosis and treatment.

Research translation	Indigenous Health Research Fund	<p>The objectives of the Indigenous Health Research Fund are to improve the health of Aboriginal and Torres Strait Islander people through:</p> <ul style="list-style-type: none"> • Indigenous-led research practice and governance • knowledge translation • evidence-based structural change in Aboriginal and Torres Strait Islander health practice • building on the unique knowledge, strengths and endurance of our communities, with particular reference to Country, culture and spirituality.
	Million Minds Mental Health Research Mission	This mission aims to support a million Australians with mental health issues to access new approaches to prevention, diagnosis, treatment and recovery.
	Stem Cell Therapies Mission	The objective of this Mission is to support world-leading translational stem cell research that develops and delivers innovative, safe and effective stem cell medicines to improve health outcomes, in partnership with patients and carers.
	Traumatic Brain Injury Mission	<p>The objectives of this Mission are to:</p> <ul style="list-style-type: none"> • better predict recovery outcomes after a traumatic brain injury • identify the most effective care and treatments • reduce barriers to support people to live their best life after a traumatic brain injury.
	Medical Research Commercialisation	The objective of this initiative is to support early-stage health and medical research and innovation in Australia through to proof-of-concept and beyond, providing opportunities for commercialisation.
	National Critical Research Infrastructure	The objective of this initiative is to establish and extend infrastructure (facilities, equipment, systems and services) of critical importance that will be used to conduct world-class health and medical research.
	Preventative and Public Health Research	The objective of this initiative is to support research into new ways to address risk factors for chronic and complex diseases in Australia.
	Primary Health Care Research	The objective of this initiative is to increase Australia's evidence base in primary health care through research to improve service delivery and patient outcomes, and translate this knowledge into action.
	Rapid Applied Research Translation	The objective of this initiative is to support transformative translational research, so that patients can benefit from better quality of care.
	Research Data Infrastructure	The objective of this initiative is to support strategic investments that establish and extend national research data infrastructure to support world-class health and medical research.

Description of MRFF initiatives from the [MRFF website](#) (accessed 30 November 2022).

Appendix B MRFF Disbursements since inception by theme and initiative.

Table B MRFF Disbursements since inception by theme and initiative

Theme	MRFF initiative	Financial year (\$ million)							Total
		16 17	17 18	18 19	19 20	20 21	21 22	22 23	
Patients	Emerging Priorities and Consumer-Driven Research	7.0		63.4	54.0	84.5	84.4	19.1	312.4
	Clinical Trials Activity	1.0	4.8	47.4	68.1	63.7	59.3		244.3
	Global Health		2.5	1.8	3.4	2.7	3.0		13.3
Researchers	Frontier Health and Medical Research				20.1	53.6	61.5	23.7	158.9
	Researcher Exchange and Development within Industry				8.0	10.0	10.0	4.0	32.0
	Clinician Researchers		1.8	4.9	19.8	20.4	22.2	1.4	70.4
	Early to Mid-Career Researchers								
Research Missions	Australian Brain Cancer Mission		1.0	4.7	7.4	5.0	3.6	2.5	24.3
	Million Minds Mental Health Research Mission			6.2	7.0	12.0	15.0	2.9	43.0
	Genomics Health Futures Mission			8.8	37.5	87.4	69.9		203.7
	Dementia, Ageing and Aged Care Mission			10.0	13.1	17.0	17.2		57.3
	Indigenous Health Research Fund			15.0	22.5	18.8	11.4		67.7
	Stem Cell Therapies Mission				6.0	17.6	18.0		41.6
	Cardiovascular Health Mission				22.1	23.8	23.6		69.6
	Traumatic Brain Injury Mission				5.0	4.0	3.9		12.9
Research Translation	Preventive and Public Health Research	10.0		11.2	35.2	63.9	31.5	10.0	161.7
	Primary Health Care Research				6.7	7.1	4.1		17.9
	Rapid Applied Research Translation		10.0	17.6	16.6	20.6	22.0		86.9
	Medical Research Commercialisation		10.0	15.4	15.3	60.3	35.3		136.3
	National Critical Research Infrastructure				7.7	12.6	119.2	3.7	143.3
	Research Data Infrastructure					12.9	12.3		25.2
Total		18.0	30.1	206.4	375.5	597.9	627.4	67.4	1,922.6

Data represents payments made to all active grants in the relevant financial year (FY) (i.e., new grants as well as grants contracted in previous FYs). Figures for 2022-2023 are partial. Data as at 31 December 2022.

Appendix C MRFF grants since inception by theme and initiative.

Table C MRFF grants since inception by theme and initiative

Theme	MRFF initiative	Number in Financial Year							Total
		16 17	17 18	18 19	19 20	20 21	21 22	22 23	
Patients	Emerging Priorities and Consumer-Driven Research	2		23	38	28	36		127
	Clinical Trials Activity	1	18	32	43	25	43		162
	Global Health		5		4				9
Researchers	Frontier Health and Medical Research				16	22	18		56
	Researcher Exchange and Development within Industry				1				1
	Clinician Researchers		37	28	15	17	14		111
	Early to Mid-Career Researchers								
Research Missions	Australian Brain Cancer Mission		1	4	2	1		3	11
	Million Minds Mental Health Research Mission			7	3	8			18
	Genomics Health Futures Mission			2	20	21	20		63
	Dementia, Ageing and Aged Care Mission			1	15	11	18		45
	Indigenous Health Research Fund			1	9	6	11		27
	Stem Cell Therapies Mission				10	17	7		34
	Cardiovascular Health Mission				14	16	41		71
	Traumatic Brain Injury Mission				3	6	3		12
Research Translation	Preventive and Public Health Research	1		13	32	25	6		77
	Primary Health Care Research				4	7	4		15
	Rapid Applied Research Translation		9	9	8	1	9		36
	Medical Research Commercialisation		1	2		4			7
	National Critical Research Infrastructure				5	5	3		13
	Research Data Infrastructure					7	5		12
Total		4	71	122	242	227	238	3	907

Data represents newly awarded and announced grants in the relevant financial year. Figures for 2022-2023 are partial. Data as at 31 December 2022.

Appendix D MRFF grant opportunities since inception by theme and initiative.

Table D MRFF Grant opportunities opened since inception by theme and initiative

Theme	Initiative	Number in financial year							Total
		16 17	17 18	18 19	19 20	20 21	21 22	22 23	
Patients	Emerging Priorities and Consumer-Driven Research	2	8	15	16	6	6	1	54
	Clinical Trials Activity	1	3	3	5	7	3	2	24
	Global Health	-	2	-	1	-	-	-	3
Researchers	Frontier Health and Medical Research	-	-	1	5	5	-	-	11
	Researcher Exchange and Development within Industry	-	-	-	1	-	-	-	1
	Clinician Researchers	1	1	-	1	1	1	-	5
	Early to Mid-Career Researchers	-	-	-	-	-	1	-	1
Research Missions	Australian Brain Cancer Mission	-	3	1	1	1	3	-	9
	Million Minds Mental Health Research Mission	-	-	1	2	1	-	1	5
	Genomics Health Futures Mission	-	-	4	1	1	1	1	8
	Dementia, Ageing and Aged Care Mission	-	-	1	3	1	2	-	7
	Indigenous Health Research Fund	-	-	1	1	1	1	1	5
	Stem Cell Therapies Mission	-	-	-	2	1	2	-	5
	Cardiovascular Health Mission	-	-	-	4	1	2	-	7
	Traumatic Brain Injury Mission	-	-	-	1	1	-	-	2
Research Translation	Preventive and Public Health Research	1	-	5	3	4	5	1	19
	Primary Health Care Research	-	-	-	1	1	2	-	4
	Rapid Applied Research Translation	1	-	1	1	1	-	-	4
	Medical Research Commercialisation	-	1	2	-	1	1	-	5
	National Critical Research Infrastructure	-	-	-	3	1	2	-	6
	Research Data Infrastructure	-	-	-	-	1	1	1	3
Various	Various ^a	-	-	-	1	-	5	-	6
TOTAL		6	18	35	53	36	38	8	194

a: Includes grant opportunities that were funded across more than one MRFF initiative.

Data represents all grant opportunities that had opened for applications as at 31 December 2022. Figures for 2022-2023 are partial.

Appendix E MRFF grants with payments commencing between 7 November 2020 and 5 November 2022

Table E - MRFF grant recipients with payments commencing between 7 November 2020 and 5 November 2022 inclusive

MRFF initiative	Grant opportunity	Institution	Project name or description	Amount (\$ excl GST)	
Australian Brain Cancer Mission	2020 Brain Cancer Survivorship	University of Melbourne	Responding to need: technology-enhanced brain cancer survivorship	2,615,278.00	a
Australian Brain Cancer Mission	2021 Brain Cancer Research	The Walter and Eliza Hall Institute of Medical Research	"GLIMMER" - Glioma Liquid biopsy and Multiomic-Monitoring Enabled Research platform	4,550,471.30	
Australian Brain Cancer Mission	2021 Brain Cancer Research	The Council of the Queensland Institute of Medical Research	"Off-the-shelf" CAR-T cell immunotherapy for brain cancer	329,489.00	
Australian Brain Cancer Mission	2021 Brain Cancer Research	University of New South Wales	A new targeted combination therapy with matched biomarker to treat intractable glioblastoma	582,686.40	
Cardiovascular Health Mission	2020 Cardiovascular Health	University of New South Wales	CardiacAI: Deep learning to predict and prevent secondary cardiovascular events	544,978.65	
Cardiovascular Health Mission	2020 Cardiovascular Health	The University of Queensland	Development of drugs to prevent ischemic injuries of the heart and brain	1,499,560.20	
Cardiovascular Health Mission	2020 Cardiovascular Health	University of New South Wales	Development of novel, clinically viable strategies for reducing cardiac damage and preventing future events in myocardial infarction (MI) survivors by targeting inflammation	2,849,891.71	
Cardiovascular Health Mission	2020 Cardiovascular Health	University of Sydney	Digital solutions for heart failure best practice care	936,836.88	
Cardiovascular Health Mission	2020 Cardiovascular Health	Monash University	ECMO-Rehab: A Randomised Controlled Trial of Early Cardiac Rehabilitation to Improve Survival and Recovery in Critically-ill Patients on ECMO	662,648.57	
Cardiovascular Health Mission	2020 Cardiovascular Health	University of Sydney	Guardian Angel: Implementation of a peer support program for people with heart disease	655,522.17	
Cardiovascular Health Mission	2020 Cardiovascular Health	University of Melbourne	Improving life after stroke with tailored support: Innovation in use of national registry data	505,704.36	
Cardiovascular Health Mission	2020 Cardiovascular Health	University of Sydney	LesioLogic	1,102,873.15	

Cardiovascular Health Mission	2020 Cardiovascular Health	The University of Queensland	Measuring, Monitoring, and Motivating Adherence to Self-Managed Aphasia Treatment	388,521.10
Cardiovascular Health Mission	2020 Cardiovascular Health	Monash University	New models of rehabilitation to improve work and health outcomes after stroke	999,056.20
Cardiovascular Health Mission	2020 Cardiovascular Health	University of Melbourne	REACHING FOR YOUR WORDS: A Phase IIa umbrella trial of integrated UPper limb & Language Impairment and Functional Training (UPLIFT) after stroke	992,634.36
Cardiovascular Health Mission	2020 Cardiovascular Health	University of Sydney	Safety and Tolerability of AZD6482 in Reperfusion for Stroke (STARS)	2,706,533.13
Cardiovascular Health Mission	2020 Cardiovascular Health	Monash University	Statins and Progression of Coronary Atherosclerosis in Melanoma Patients Treated with Immune Checkpoint Inhibitors	1,669,300.28
Cardiovascular Health Mission	2020 Cardiovascular Health	The University of Newcastle	Stroke in patients with large Ischaemic Core: Assessment of Reperfusion therapy Impact on Outcome (SICARIO)	1,515,113.87
Cardiovascular Health Mission	2020 Cardiovascular Health	The University of Adelaide	The SPRINTS Project: Stroke - Prevention of Reperfusion Injury and Neuroinflammation - a Therapeutic Strategy	2,563,915.78
Cardiovascular Health Mission	2020 Cardiovascular Health	The University of Newcastle	Yarning up After Stroke	485,061.66
Cardiovascular Health Mission	2021 Cardiovascular Health	University of Canberra	A very brief intervention for physical activity behaviour change in cardiac rehabilitation: the 'Measure It!' trial	510,069.60
Cardiovascular Health Mission	2021 Cardiovascular Health	Monash University	Addressing the poor medication adherence in prevention of cardiovascular mortality and morbidity in Australia: development of a clinical decision support tool	706,241.60
Cardiovascular Health Mission	2021 Cardiovascular Health	University of Western Australia	Alloantibody in kidney transplant recipients: is this the missing link to reduce the risk of heart disease? (AN-INSPIRE STUDY)	996,354.00
Cardiovascular Health Mission	2021 Cardiovascular Health	Monash University	Atheroma Progression in Clonal Haematopoiesis Investigation with Imaging, Biomarkers and Genomic Sequencing (ARCHIMEDES)	996,384.68
Cardiovascular Health Mission	2021 Cardiovascular Health	University of Sydney	Beyond Country of Birth: Transforming approaches to quantifying ethnic inequalities in access to best care for CVD	782,008.00
Cardiovascular Health Mission	2021 Cardiovascular Health	The University of Newcastle	Cardiovascular disease and cancer: identifying shared disease pathways and pharmacological management	999,998.00
Cardiovascular Health Mission	2021 Cardiovascular Health	Monash University	Combining Novel Imaging Biomarkers with AI-Accelerated Diagnosis for Equitable Patient Selection To Proactive Treatment With Middle Meningeal Artery Embolisation To Improve Outcomes in cSDH	999,865.70

Cardiovascular Health Mission	2021 Cardiovascular Health	Queensland University of Technology	CTCA-POC: CT Coronary Angiography Inspired Point-of-Care Technology for Enhanced Diagnosis and Monitoring of Coronary Artery Disease	999,995.90
Cardiovascular Health Mission	2021 Cardiovascular Health	University of New South Wales	Developing a holistic machine learning based rapid response system and end of life care system in preventing cardiac arrests and preventable deaths and improving end of life care in acute hospitals	700,583.20
Cardiovascular Health Mission	2021 Cardiovascular Health	Monash University	Discovery of new molecular targets for stroke-Associated pneumonia to improve recovery	663,217.60
Cardiovascular Health Mission	2021 Cardiovascular Health	University of Sydney	Discovery of new platelet targets to improve the management of coronary artery disease	659,293.00
Cardiovascular Health Mission	2021 Cardiovascular Health	Macquarie University	Early Atrial fibrillation Screening for Indigenous people (EASI)	574,883.90
Cardiovascular Health Mission	2021 Cardiovascular Health	University of Sydney	Enhancing engagement with eHealth approaches to prevent cardiovascular disease among adolescents: The Triple E Project	993,682.00
Cardiovascular Health Mission	2021 Cardiovascular Health	University of Sydney	Identifying and addressing barriers and enablers to implementing best-practice cardiac rehabilitation: the Quality Improvement in Cardiac Rehabilitation (QUICR) Cluster-Randomised Controlled Trial	894,507.20
Cardiovascular Health Mission	2021 Cardiovascular Health	Flinders University	Impact of non-invasive coronary angiography on suspected acute coronary syndromes with low concentration troponin elevation	999,542.50
Cardiovascular Health Mission	2021 Cardiovascular Health	University of Tasmania	Improving cardiovascular health through increased transport-related physical activity: A co-designed randomised controlled trial	767,132.85
Cardiovascular Health Mission	2021 Cardiovascular Health	Monash University	Improving short- and long-term outcomes in cardiac bypass surgery by preventing acute kidney injury	511,208.00
Cardiovascular Health Mission	2021 Cardiovascular Health	University of New South Wales	Investigating Mechanisms of Alcohol-Induced Heart Disease	999,995.60
Cardiovascular Health Mission	2021 Cardiovascular Health	Monash University	Love Your Brain: A stroke prevention digital platform	944,787.90
Cardiovascular Health Mission	2021 Cardiovascular Health	The University of Adelaide	Next Generation Precision Health Platform to support Atrial Fibrillation Management	791,555.40
Cardiovascular Health Mission	2021 Cardiovascular Health	Menzies School of Health Research	Non Expert Acquisition and Remote Expert Review of Screening echocardiography images from Child health and AnteNatal clinics (NEARER SCAN)	999,764.40
Cardiovascular Health Mission	2021 Cardiovascular Health	University of Sydney	Non-invasive imaging of atherosclerotic plaque: quantification of disease activity for improved identification of patients with residual cardiovascular risk	999,631.42

Cardiovascular Health Mission	2021 Cardiovascular Health	University of Melbourne	Novel targeted anti-inflammatory and anti-thrombotic mRNA therapies: Establishing innovative technologies to combat cardiovascular diseases	689,854.82
Cardiovascular Health Mission	2021 Cardiovascular Health	University of New South Wales	Outcome PredicTion in IntraCerebral haemorrhage Study (OPTICS) with machine learning	404,190.00
Cardiovascular Health Mission	2021 Cardiovascular Health	Monash University	PRrecision Ecmo in Cardlogenic Shock Evaluation: PRECISE Study	999,779.40
Cardiovascular Health Mission	2021 Cardiovascular Health	Flinders University	Real-time measurement of renewal rate constants in pulsed field ablation of atrial fibrillation	604,305.60
Cardiovascular Health Mission	2021 Cardiovascular Health	University of Sydney	REnAl FactORs Modify HEART disease Study - REFORM HEARTS	865,396.80
Cardiovascular Health Mission	2021 Cardiovascular Health	James Cook University	Supervised Home Exercise for Peripheral Artery Disease	999,999.71
Cardiovascular Health Mission	2021 Cardiovascular Health	St Vincent's Institute of Medical Research	Sustained delivery of stem cell secretome for cardiac repair	958,504.12
Cardiovascular Health Mission	2021 Cardiovascular Health	University of Melbourne	Targeting no-reflow to augment tissue salvage in stroke	999,978.19
Cardiovascular Health Mission	2021 Cardiovascular Health	The University of Adelaide	The Asialoglycoprotein Receptor 1 (ASGR1): a novel target for atherosclerosis	999,989.20
Cardiovascular Health Mission	2021 Cardiovascular Health	University of South Australia	The feasibility and potential of a novel robotic gait bioprosthesis for people with severe gait impairment post-stroke	513,102.80
Cardiovascular Health Mission	2021 Cardiovascular Health	The University of Queensland	The Right Treatment for the Right Person at the Right Time. Driving High-Value Aphasia Care through Meaningful Health System Monitoring	451,221.00
Cardiovascular Health Mission	2021 Cardiovascular Health	University of Western Australia	Towards Remote Patient Monitoring of Heart Failure Using Event-Driven AI Systems	583,551.20
Cardiovascular Health Mission	2021 Cardiovascular Health	James Cook University	Transforming clinical pathways for abdominal aortic aneurysm through use of blood and imaging biomarkers	999,999.60
Cardiovascular Health Mission	2021 Cardiovascular Health	University of Melbourne	Translating novel mechanism-guided therapeutics to improve functional recovery of the brain and kidneys after open-heart surgery	998,224.25
Cardiovascular Health Mission	2021 Cardiovascular Health	University of Melbourne	Treating the impact of seizures on cardiac function to reduce death	847,479.70
Cardiovascular Health Mission	2021 Cardiovascular Health	University of Melbourne	Use of Artificial Intelligence-Guided Echocardiography to Guide Cardiovascular Management in Rural and Remote Australia	999,996.60

Cardiovascular Health Mission	2021 Cardiovascular Health	Monash University	Using co-design to improve accessibility and acceptability of cardiac services for vulnerable populations: The Equal Hearts Study	597,104.30	
Cardiovascular Health Mission	2021 Cardiovascular Health	The University of Newcastle	Using existing digital infrastructure for the national scale-up of an effective school nutrition program to reduce population CVD risk	997,350.60	
Cardiovascular Health Mission	2021 Cardiovascular Health	Flinders University	Yolngu Heart Health for Life: Person-centred, co-designed and student-assisted cardiac rehabilitation in East Arnhem Land	633,589.00	
Clinical Trials Activity	2020 International Clinical Trial Collaborations (Round 20.1)	University of Sydney	AGITG and Scandinavian Sarcoma Group International Trial Collaboration. SSG XXII: International randomised phase III multicenter study of 3 v 5 years of adjuvant imatinib as treatment of patients with operable GIST with high risk for recurrence	1,036,125.09	a
Clinical Trials Activity	2020 International Clinical Trial Collaborations (Round 20.1)	University of Melbourne	AMEND-CRT trial	991,197.80	a
Clinical Trials Activity	2020 International Clinical Trial Collaborations (Round 20.1)	Curtin University	Nasal high-flow Oxygen Therapy After Cardiac Surgery: NOTACS	1,460,861.70	a
Clinical Trials Activity	2020 International Clinical Trial Collaborations (Round 20.1)	Queensland University of Technology	Oral bacterial lysate to prevent persistent wheeze in infants after severe bronchiolitis; a randomised placebo controlled trial (BLIPA; Bacterial Lysate in Preventing Asthma)	1,598,380.42	a
Clinical Trials Activity	2020 International Clinical Trial Collaborations (Round 20.1)	University of Sydney	SAFER (AUS) Trial: Screening for Atrial Fibrillation with ECG to Reduce stroke - a randomised controlled trial	1,782,949.60	a
Clinical Trials Activity	2020 International Clinical Trial Collaborations (Round 20.2)	Macquarie University	Determining the impact of a new primary care model for low back pain: A cluster randomised trial	2,107,805.90	a
Clinical Trials Activity	2020 International Clinical Trial Collaborations (Round 20.2)	University of Sydney	RADAR: A randomised PET-adapted study of bleomycin-free treatment of early stage Hodgkin Lymphoma	1,395,463.00	a
Clinical Trials Activity	2020 International Clinical Trial Collaborations (Round 20.2)	University of Melbourne	The C*STEROID Trial: An international, randomised placebo-controlled trial to determine the effect of antenatal corticosteroids on newborn health when given prior to planned caesarean section birth from 35+0 to 39+6 weeks of pregnancy	2,151,495.00	a

Clinical Trials Activity	2020 Rare Cancers, Rare Diseases and Unmet Need - General	University of Melbourne	A randomized phase III study of neoadjuvant chemotherapy followed by surgery versus surgery alone for patients with High Risk RetroPeritoneal Sarcoma (STRASS 2)	901,695.00	a
Clinical Trials Activity	2020 Rare Cancers, Rare Diseases and Unmet Need - General	University of Sydney	An adaptive, randomised controlled trial to treat polyomavirus infections (BKPyV) in kidney and kidney pancreas transplant recipients (BEAT-BK) trial	2,894,369.05	a
Clinical Trials Activity	2020 Rare Cancers, Rare Diseases and Unmet Need - General	La Trobe University	Employing rational novel agent combination therapy to improve transplant cure rates for relapsed/refractory Hodgkin Lymphoma	1,225,487.40	a
Clinical Trials Activity	2020 Rare Cancers, Rare Diseases and Unmet Need - General	La Trobe University	I-124 PET Directed Redifferentiation Therapy for Radioiodine Refractory Thyroid Cancer: the I-FIRST Study	2,708,660.70	a
Clinical Trials Activity	2020 Rare Cancers, Rare Diseases and Unmet Need - General	The Council of the Queensland Institute of Medical Research	MoST-LLy (Molecular Screening and Therapeutics in Leukaemia and Lymphoma)	2,688,736.40	a
Clinical Trials Activity	2020 Rare Cancers, Rare Diseases and Unmet Need - General	University of Melbourne	POST ETERNAL Extending the time window for Tenecteplase by Effective Recanalization of bAsiLar artery thrombus in patients with POSTerior circulation stroke	2,860,248.50	a
Clinical Trials Activity	2020 Rare Cancers, Rare Diseases and Unmet Need - General	Monash University	Preventing bones loss and restoring sexual function in women with premature ovarian insufficiency: a randomised, double-blind, placebo-controlled clinical trial	912,513.66	a
Clinical Trials Activity	2020 Rare Cancers, Rare Diseases and Unmet Need - General	University of New South Wales	StoPain: A randomised placebo-controlled trial to investigate the efficacy of an advanced interactive brain-computer interface neuromodulation treatment for spinal cord injury neuropathic pain	1,780,269.60	a
Clinical Trials Activity	2020 Rare Cancers, Rare Diseases and Unmet Need - General	University of Melbourne	Targeted therapies for vascular malformations	1,699,253.60	a
Clinical Trials Activity	2020 Rare Cancers, Rare Diseases and	The University of Queensland	Testing a sinonasal microbiome transplant as a therapy for Chronic Rhinosinusitis by randomised controlled trial	707,954.00	a

	Unmet Need - General				
Clinical Trials Activity	2020 Rare Cancers, Rare Diseases and Unmet Need - General	Monash University	Third Degree Burn Wound Closure using Engineered Skin - Phase I Clinical Trial	2,363,239.15	a
Clinical Trials Activity	2021 Innovative Therapies for Mental Illness	University of Melbourne	A Randomised Controlled Trial of MDMA-Assisted Psychotherapy for Treatment-Resistant Social Anxiety in Young Adults with Autism Spectrum Disorder	3,762,327.90	
Clinical Trials Activity	2021 Innovative Therapies for Mental Illness	University of Sydney	A randomised, double-blind, controlled trial of MDMA-assisted exposure therapy for comorbid alcohol use disorder and post-traumatic stress disorder	1,951,246.45	
Clinical Trials Activity	2021 Innovative Therapies for Mental Illness	University of Melbourne	Clinical Trial of Cannabidiol for Treatment Resistant Anxiety Disorders in Youth	1,745,708.55	
Clinical Trials Activity	2021 Innovative Therapies for Mental Illness	University of Melbourne	Dimethyltryptamine (DMT)-Assisted Psychological Therapy for Treatment-Resistant Major Depression, Alcohol Use Disorder, and Dual Diagnosis	1,977,354.90	
Clinical Trials Activity	2021 Innovative Therapies for Mental Illness	Australian National University	Evaluating the efficacy of psilocybin-assisted psychotherapy in treatment resistant depression	2,727,173.50	
Clinical Trials Activity	2021 Innovative Therapies for Mental Illness	University of Sydney	PANOREXIA: A clinical trial of psilocybin-assisted psychotherapy in anorexia nervosa	1,175,522.20	
Clinical Trials Activity	2021 Innovative Therapies for Mental Illness	University of Melbourne	Psilocybin-assisted therapy for refractory Functional Neurological Disorder	1,448,343.80	
Clinical Trials Activity	2021 International Clinical Trial Collaborations (Round 21.1)	University of Sydney	Anticoagulation for Stroke Prevention In patients with Recent Episodes of perioperative Atrial Fibrillation after noncardiac surgery - The ASPIRE-AF trial	1,816,175.10	
Clinical Trials Activity	2021 International Clinical Trial Collaborations (Round 21.1)	University of New South Wales	Dapagliflozin in advanced chronic kidney disease and kidney failure: The RENAL LIFECYCLE trial	2,229,409.70	
Clinical Trials Activity	2021 International Clinical Trial	University of New South Wales	Enhanced Control of Hypertension and Thrombectomy Stroke Study (ENCHANTED-MT)	2,029,360.80	

	Collaborations (Round 21.1)			
Clinical Trials Activity	2021 International Clinical Trial Collaborations (Round 21.1)	The University of Adelaide	The single dose of antenatal corticosteroids (SNACS) randomised trial for women at risk for preterm birth	3,025,898.90
Clinical Trials Activity	2021 International Clinical Trial Collaborations (Round 21.2)	Monash University	Adaptive platform trial for severe community acquired pneumonia: new interventions for severe CAP and influenza	2,824,703.40
Clinical Trials Activity	2021 International Clinical Trial Collaborations (Round 21.2)	University of Melbourne	PET/CT for Staphylococcus aureus bloodstream infections: an international, multicentre, randomised controlled trial	998,222.40
Clinical Trials Activity	2021 International Clinical Trial Collaborations (Round 21.2)	University of New South Wales	Sedation, TEmpérature and Pressure after Cardiac Arrest and REsuscitation (STEP CARE) trial	844,764.00
Clinical Trials Activity	2021 Rare Cancers, Rare Diseases and Unmet Need	University of New South Wales	4CAST: A phase I/II study evaluating the safety and efficacy of VT-464 in combination with chemotherapy in patients with metastatic breast cancer	668,444.00
Clinical Trials Activity	2021 Rare Cancers, Rare Diseases and Unmet Need	Edith Cowan University	A Multicomponent Exercise Medicine Programme in Patients with Pancreatic Cancer Undergoing Neoadjuvant Therapy (the EXPAN trial): A Two-armed Phase I Randomised Controlled Trial	561,910.00
Clinical Trials Activity	2021 Rare Cancers, Rare Diseases and Unmet Need	University of New South Wales	A Platform trial of combination precision guided therapies for high risk childhood cancer	1,515,180.00
Clinical Trials Activity	2021 Rare Cancers, Rare Diseases and Unmet Need	The University of Newcastle	A precision medicine clinical trial platform to BEAT CF	2,107,804.40
Clinical Trials Activity	2021 Rare Cancers, Rare Diseases and Unmet Need	Flinders University	A randomised controlled trial of Standard Of Care versus RadioAblation in Early Stage HCC (The SOCRATES HCC Study)	2,352,010.80
Clinical Trials Activity	2021 Rare Cancers, Rare Diseases and Unmet Need	University of Melbourne	Accelerating clot lysis in ischemic stroke with dornase alfa in an Umbrella Bayesian Optimised Phase 2 trial	1,453,336.70

Clinical Trials Activity	2021 Rare Cancers, Rare Diseases and Unmet Need	University of Melbourne	Addressing the poor outcomes of young women with hormone receptor-positive, HER2-negative (HR+HER2-) early breast cancer	4,909,215.00
Clinical Trials Activity	2021 Rare Cancers, Rare Diseases and Unmet Need	The University of Queensland	An early phase, open label, multi-centre trial of front-line TheRapy for EBv-associated Lymphomas – 2: TREBL-2	2,844,744.60
Clinical Trials Activity	2021 Rare Cancers, Rare Diseases and Unmet Need	University of Melbourne	Augmenting dietary protein during critical illness: A cluster randomised cross-sectional double cross-over clinical trial	1,992,218.00
Clinical Trials Activity	2021 Rare Cancers, Rare Diseases and Unmet Need	University of Melbourne	Driving functional recovery after spinal cord injury using transcutaneous electrical spinal cord neuromodulation (TESCoN)	2,038,621.80
Clinical Trials Activity	2021 Rare Cancers, Rare Diseases and Unmet Need	Monash University	Duration of Cardiac Antimicrobial Prophylaxis Outcomes Study (CALIPSO): multicentre, adaptive, double-blind, three-arm, placebo-controlled, non-inferiority trial examining antimicrobial prophylaxis duration in cardiac surgery	7,979,999.10
Clinical Trials Activity	2021 Rare Cancers, Rare Diseases and Unmet Need	University of Melbourne	Eliminating HIV that persists on antiretroviral therapy through treatment with the BCL-2 antagonist, venetoclax	1,400,752.00
Clinical Trials Activity	2021 Rare Cancers, Rare Diseases and Unmet Need	Monash University	Fibrinogen Early In Severe Trauma Study II (FEISTY II)	3,162,379.40
Clinical Trials Activity	2021 Rare Cancers, Rare Diseases and Unmet Need	The University of Adelaide	HEPATA: Hereditary Pancreatitis and Autologous Transplant Trials in Australia	2,014,561.20
Clinical Trials Activity	2021 Rare Cancers, Rare Diseases and Unmet Need	Flinders University	Implementing a Nurse-Enabled, Shared-Care Model to Address Unmet Needs of People with Neuroendocrine Tumours: the AUS-NET Trial	2,374,220.10
Clinical Trials Activity	2021 Rare Cancers, Rare Diseases and Unmet Need	Queensland University of Technology	Improving clinical outcomes for children and adults with bronchiectasis: a multi-centre randomised controlled trial using a novel mucolytic with a discovery biomarker	2,069,492.72
Clinical Trials Activity	2021 Rare Cancers, Rare Diseases and Unmet Need	University of New South Wales	Improving the lives of people with Phantom Limb Pain - the TITAN trial (graded motor Imagery for phantom Limb pain)	1,531,130.80
Clinical Trials Activity	2021 Rare Cancers, Rare Diseases and Unmet Need	Monash University	INTER-EWING -1 - International clinical research program to improve outcomes in newly diagnosed Ewing Sarcoma patients - Trial 1.	998,608.80

Clinical Trials Activity	2021 Rare Cancers, Rare Diseases and Unmet Need	Murdoch Children's Research Institute	Is oral antibiotic treatment alone non-inferior to standard care for children with bone and joint infections?	1,230,723.80	
Clinical Trials Activity	2021 Rare Cancers, Rare Diseases and Unmet Need	University of Melbourne	Look before you leap: How transthoracic ECHOCardiography before fractured Neck Of Femur saves lives in frail older people – the proposed Pragmatic ECHONOF III trial	3,686,076.20	
Clinical Trials Activity	2021 Rare Cancers, Rare Diseases and Unmet Need	University of Sydney	LUMOS: Low and Anaplastic Grade Glioma Umbrella Study of Molecular Guided Therapies	1,982,681.32	
Clinical Trials Activity	2021 Rare Cancers, Rare Diseases and Unmet Need	Monash University	More efficient delivery of high-cost standard-of-care therapies in relapsed multiple myeloma using real-time feedback of patient-reported outcome measures: the MY-PROMPT-2 trial	1,678,493.00	
Clinical Trials Activity	2021 Rare Cancers, Rare Diseases and Unmet Need	The University of Queensland	Optimising Care: Phase III Trial in women with metastatic breast cancer to improve quality of life via exercise and diet	2,044,955.10	
Clinical Trials Activity	2021 Rare Cancers, Rare Diseases and Unmet Need	Monash University	REDEEM: A Randomised Controlled Trial of ECMO to Desedate, Extubate Early and Mobilise in severe acute respiratory infection	2,534,432.00	
Clinical Trials Activity	2021 Rare Cancers, Rare Diseases and Unmet Need	The University of Adelaide	REMIT: An international, multi-centre, randomised clinical trial to compare Obinutuzumab + Calcineurin Inhibitor to Corticosteroid + Cyclophosphamide treatment regimens in Primary Membranous Nephropathy	2,904,210.20	
Clinical Trials Activity	2021 Rare Cancers, Rare Diseases and Unmet Need	Monash University	SCANPatient: Synoptic reporting of CT scans assessing cancer of the pancreas	2,970,301.10	
Clinical Trials Activity	2021 Rare Cancers, Rare Diseases and Unmet Need	The University of Queensland	SWiMS - Schizophrenia Weight, Metformin and Semaglutide: A double blind double dummy placebo controlled multi-centre RCT	3,839,117.60	
Clinical Trials Activity	2021 Rare Cancers, Rare Diseases and Unmet Need	The University of Adelaide	The AIRSPACE Trial: Anti-MRSA PhAge Cocktail treatment via Acoustic Enhanced Nebulisers	1,712,340.60	
Clinical Trials Activity	2021 Rare Cancers, Rare Diseases and Unmet Need	The University of Queensland	The SiroSkin study: A multi-centre randomised double-blind placebo-controlled trial of 1% topical sirolimus in the chemoprevention of facial squamous cell carcinomas in solid organ transplant recipients	2,486,489.20	
Clinician Researchers	2019 Investigator Grants: Medical	University of Melbourne	A Neural Systems Model to Optimize Treatment Outcomes in Binge Eating Populations	645,205.00	a

Research Future Fund Priority Round					
Clinician Researchers	2019 Investigator Grants: Medical Research Future Fund Priority Round	The Walter and Eliza Hall Institute of Medical Research	Advancing Personalised Treatment in Colorectal Cancer with Tissue and Liquid Biomarkers	1,187,350.00	a
Clinician Researchers	2019 Investigator Grants: Medical Research Future Fund Priority Round	University of Western Australia	Better penicillin, better hearts: improving secondary prevention of rheumatic heart disease	1,281,125.00	a
Clinician Researchers	2019 Investigator Grants: Medical Research Future Fund Priority Round	University of Melbourne	Closing the critical knowledge gaps in perinatal genomics	1,281,125.00	a
Clinician Researchers	2019 Investigator Grants: Medical Research Future Fund Priority Round	Murdoch Children's Research Institute	Establishing the early diagnosis of atherosclerosis and cardiovascular risk factors in adults with repaired aortic arch obstruction: The key to decreasing premature death	329,041.00	a
Clinician Researchers	2019 Investigator Grants: Medical Research Future Fund Priority Round	University of South Australia	Evidence-based digital technologies for health behaviour	1,118,593.01	a
Clinician Researchers	2019 Investigator Grants: Medical Research Future Fund Priority Round	Flinders University	Meeting psychological needs to improve the quality and safety of aged care	420,078.91	a
Clinician Researchers	2019 Investigator Grants: Medical Research Future Fund Priority Round	Menzies School of Health Research	Moving together towards the elimination of chronic Hepatitis B in the Northern Territory	1,131,125.00	a
Clinician Researchers	2019 Investigator Grants: Medical Research Future Fund Priority Round	Monash University	Optimise Primary Aldosteronism Detection For Better Health Outcomes	570,205.00	a
Clinician Researchers	2019 Investigator Grants: Medical Research Future Fund Priority Round	The University of Newcastle	Personalised biomarker-guided management of asthma during pregnancy	1,562,250.00	a

Clinician Researchers	2019 Investigator Grants: Medical Research Future Fund Priority Round	University of Sydney	Policy-driven research to improve the immunisation program for young children	1,062,555.48	a
Clinician Researchers	2019 Investigator Grants: Medical Research Future Fund Priority Round	University of Western Australia	Preventing Bronchiectasis in Indigenous People	1,131,125.00	a
Clinician Researchers	2019 Investigator Grants: Medical Research Future Fund Priority Round	University of Melbourne	Saving time, saving brain through prehospital stroke care	645,205.00	a
Clinician Researchers	2019 Investigator Grants: Medical Research Future Fund Priority Round	Macquarie University	Screening and Risk Reduction for Dementia in Primary Care	1,562,250.00	a
Clinician Researchers	2019 Investigator Grants: Medical Research Future Fund Priority Round	The University of Newcastle	Sustaining the implementation of evidence-based chronic disease prevention programs in education	1,562,250.00	a
Clinician Researchers	2019 Investigator Grants: Medical Research Future Fund Priority Round	University of New South Wales	Tackling it with Tech: Using novel Internet solutions to overcome the burden of depression in youth	620,205.00	a
Clinician Researchers	2019 Investigator Grants: Medical Research Future Fund Priority Round	Monash University	Using a purpose-built digital assessment tool to determine the mechanisms driving addictive behaviours and its utility to improve treatment engagement and outcomes	645,205.00	a
Clinician Researchers	2020 Clinician Researchers: Applied Research in Health	Queensland Rural Medical Education Limited	Assessing cultural safety in GP consultations for Indigenous Australians	120,320.00	
Clinician Researchers	2020 Clinician Researchers: Applied Research in Health	University of Melbourne	CURE-NG: A Human Challenge Model to Develop New Treatments for Gonorrhoea	2,300,321.00	
Clinician Researchers	2020 Clinician Researchers: Applied Research in Health	University of New South Wales	Enhancing prison-to-community mental healthcare for Aboriginal prisoners	1,180,613.00	

Clinician Researchers	2020 Clinician Researchers: Applied Research in Health	Monash University	Equipping Tertiary Care for the Optimal Diagnosis of Primary Aldosteronism	2,993,294.00	
Clinician Researchers	2020 Clinician Researchers: Applied Research in Health	Monash University	Intensive physiotherapy to lower hospital length of stay after hip fracture	2,930,647.00	
Clinician Researchers	2020 Clinician Researchers: Applied Research in Health	The George Institute for Global Health	Optimal Post rTPA-iv Monitoring in Ischaemic Stroke (OPTIMISTmain)	1,774,988.00	
Clinician Researchers	2020 Clinician Researchers: Applied Research in Health	Monash University	PROMOTE: a cluster-randomised implementation trial to promote evidence use	2,996,464.00	
Clinician Researchers	2020 Clinician Researchers: Applied Research in Health	The University of Queensland	RELEASE: REDressing Long-tErM Antidepressant uSE in general practice	1,912,691.00	
Clinician Researchers	2020 Clinician Researchers: Applied Research in Health	University of Melbourne	Strengthening care for rural children: stepped wedge trial in primary care	2,996,188.00	
Clinician Researchers	2020 Clinician Researchers: Applied Research in Health	University of New South Wales	The Australian Endometriosis Clinicians Collaborative (AECC)	1,937,950.00	
Clinician Researchers	2020 Clinician Researchers: Applied Research in Health	University of Melbourne	The Australian New Zealand Oncofertility Clinical Trials Network	2,999,970.00	
Clinician Researchers	2020 Clinician Researchers: Applied Research in Health	James Cook University	The Tele-Artery Trial (TEAL)	2,862,084.00	
Clinician Researchers	2020 Clinician Researchers: Applied Research in Health	University of Melbourne	Transforming Clinical Research to Improve Outcomes for Preterm Infants	2,642,199.00	
Clinician Researchers	2020 Clinician Researchers: Applied Research in Health	University of Melbourne	Validating cognitive screening for first-episode psychosis - CogScreen	2,294,990.00	
Coronavirus Research Response	2020 Rare Cancers, Rare Diseases and Unmet Need COVID-19	Flinders University	3D-Printed Facial Guards to reduce P2/N95 respirator leak and protect health care workers from COVID-19	973,119.00	a

Coronavirus Research Response	2020 Rare Cancers, Rare Diseases and Unmet Need COVID-19	University of Melbourne	Accelerated phase I trial of targeted and tunable SARS-Cov-2 spike protein receptor binding domain recombinant protein and mRNA vaccines	1,588,283.00	a
Coronavirus Research Response	2020 Rare Cancers, Rare Diseases and Unmet Need COVID-19	Flinders University	Prevention of SARS-CoV-2 transmission in aged care (PreSTAC): Effective evidence-based measures for rapid translation	1,366,094.00	a
Coronavirus Research Response	2020 Rare Cancers, Rare Diseases and Unmet Need COVID-19	University of New South Wales	Statin Treatment for COVID-19 to optimise Neurological Recovery (STRONGER) trial	2,375,779.00	a
Coronavirus Research Response	2020 Rare Cancers, Rare Diseases and Unmet Need COVID-19	University of Melbourne	The Pomerium Trial: Protecting Aged Care Residents from the Pandemic via Specialised Nutritional Supplementation	1,189,527.00	a
Coronavirus Research Response	2020 Rare Cancers, Rare Diseases and Unmet Need COVID-19	University of Melbourne	Use of Cardioprotective Therapy to Manage Persistent Cardiovascular Effects of COVID-19: A Pathway to Recognition and Treatment of Subclinical Disease	2,574,943.00	a
Coronavirus Research Response	2020 Communication Strategies and Approaches During Outbreaks	Monash University	Effectiveness of tailored COVID-19 message for vulnerable Australians	315,961.00	a
Coronavirus Research Response	2020 Communication Strategies and Approaches During Outbreaks	Macquarie University	Harnessing the health communication power of the early childhood sector	174,992.00	a
Coronavirus Research Response	2020 Communication Strategies and Approaches During Outbreaks	Deakin University	Inclusive Health Communication in Specialist Disability Accommodation	109,047.00	a
Coronavirus Research Response	2020 Rapid Response Digital Health Infrastructure	University of Sydney	Integrating remote monitoring technology into digital health infrastructure	670,406.00	a
Coronavirus Research Response	2020 Rapid Response Digital Health Infrastructure	Monash University	Real-time modelling of Australia's COVID-19 response	810,300.00	a

Coronavirus Research Response	2020 Rapid Response Digital Health Infrastructure	Monash University	Towards a national data management platform and Learning Health System	1,922,584.00	a
Coronavirus Research Response	2020 Antiviral Development for COVID-19	The Walter and Eliza Hall Institute of Medical Research	Biologics for the prophylaxis and treatment of COVID-19	5,000,000.00	a
Coronavirus Research Response	2020 COVID-19 Vaccine Candidate Research (Round 2)	University of Sydney	A single dose, globally accessible vaccine to combat emerging SARS-CoV-2 variants	1,556,560.00	a
Coronavirus Research Response	2020 COVID-19 Vaccine Candidate Research (Round 2)	University of South Australia	Accelerated clinical development of a next generation COVID-19 vaccine using the established Sementis Copenhagen Vector platform system	2,983,909.00	a
Coronavirus Research Response	2020 COVID-19 Vaccine Candidate Research (Round 3)	University of Melbourne	AdaptiVax-CoV: A novel adaptable SARS-CoV2 VLP vaccine to produce broad humoral and T cell responses to S, E and M viral proteins	2,999,862.00	a
Coronavirus Research Response	2020 COVID-19 Vaccine Candidate Research (Round 3)	University of Melbourne	Chimeric next generation COVID vaccines	3,000,000.00	a
Coronavirus Research Response	2020 Stem Cell Therapies Mission	The Commonwealth Scientific and Industrial Research Organisation	The sySTEMs initiative: systems biology-augmented, stem cell-derived, multi-tissue panel for rapid screening of approved drugs as potential COVID-19 treatments	998,355.93	
Coronavirus Research Response	2021 COVID-19 Health Impacts and Vaccination Schedules	Monash University	Bringing Optimised COVID-19 vaccine Schedules To ImmunoCompromised populations (BOOST-IC)	2,911,774.24	
Coronavirus Research Response	2021 COVID-19 Health Impacts and Vaccination Schedules	University of New South Wales	Comparing Immunisation-boosting Regimens for COVID-19 Upon Initiation of immunosuppressive Therapies (CIRCUIT Study)	2,752,966.61	
Coronavirus Research Response	2021 COVID-19 Health Impacts and Vaccination Schedules	Murdoch University	Molecular phenomic approaches to improve understanding of Post-Acute COVID-19 Syndrome – a biomarker-augmented strategy for risk based stratification and targeted intervention to improve clinical outcomes	3,395,672.56	
Coronavirus Research Response	2021 COVID-19 Health Impacts and Vaccination Schedules	University of Melbourne	Predicting the neurological impact of SARS-CoV-2 Variants of Concern-protecting Australians from long-COVID brain injury	1,776,244.02	

Coronavirus Research Response	2021 COVID-19 Health Impacts and Vaccination Schedules	University of Western Australia	The Platform trial In COVID-19 vaccine BOosting (PICOBOO)	4,157,377.94
Coronavirus Research Response	2021 COVID-19 Vaccine-Associated Thrombosis With Thrombocytopenia Syndrome	Monash University	A national, multi-centre study evaluating Thrombotic Thrombocytopenia Syndrome (TTS) associated with ChAdOx1 (AZD1222) and other SARS-CoV-2 vaccines (viral vector and m-RNA)	2,917,087.28
Coronavirus Research Response	2021 COVID-19 Treatment Access and Public Health Activities	The Walter and Eliza Hall Institute of Medical Research	A lethal and irresistible combination: Simultaneous targeting of the SARS-CoV-2 proteases Mpro and PLpro	999,687.40
Coronavirus Research Response	2021 COVID-19 Treatment Access and Public Health Activities	University of Melbourne	Aerosol Infection Research: Better mOdelS to Reduce iNdoor Exposure (AIRBORNE)	998,338.80
Coronavirus Research Response	2021 COVID-19 Treatment Access and Public Health Activities	University of New South Wales	Aerosol transmission of SARS-CoV-2 experimentally and in an intensive care setting	992,908.20
Coronavirus Research Response	2021 COVID-19 Treatment Access and Public Health Activities	Curtin University	Compound repurposing into novel therapeutics to treat SARS-COV2 infection	998,520.00
Coronavirus Research Response	2021 COVID-19 Treatment Access and Public Health Activities	University of New South Wales	Development of antiviral RNA therapeutics targeting SARS-CoV-2 infection	998,339.60
Coronavirus Research Response	2021 COVID-19 Treatment Access and Public Health Activities	Esfam Biotech Pty Ltd	Experimental Validation of the Target of ESFAM289 - a molecule with in vivo efficacy against SARS-CoV-2	1,000,000.00
Coronavirus Research Response	2021 COVID-19 Treatment Access and Public Health Activities	University of Melbourne	Immune responses to SARS-CoV-2 variants across age groups and vulnerable populations	3,001,424.40
Coronavirus Research Response	2021 COVID-19 Treatment Access	University of Melbourne	Intranasal TLR2/6 activation to prevent COVID infection in the elderly	3,883,462.60

	and Public Health Activities			
Coronavirus Research Response	2021 COVID-19 Treatment Access and Public Health Activities	University of Melbourne	mRNA-based antiviral therapeutics for SARS-CoV-2 using Cas13	1,000,000.00
Coronavirus Research Response	2021 COVID-19 Treatment Access and Public Health Activities	Monash University	Pre-clinical testing of novel inhaled RNA therapies for stability, safety and effectiveness against SARS-CoV-2 to demonstrate proof of concept	499,697.24
Coronavirus Research Response	2021 COVID-19 Treatment Access and Public Health Activities	Monash University	PROPHECY: Profiling immune RespOnse in Paediatric and High-risk populations to SARS-CoV-2	6,327,279.57
Coronavirus Research Response	2021 COVID-19 Treatment Access and Public Health Activities	University of Western Australia	The Platform Trial in COVID-19 Boosting: stage 2 (PICOBOO-2)	3,830,631.40
Coronavirus Research Response	2021 COVID-19 Treatment Access and Public Health Activities	Australian Institute of Health and Welfare	Towards an Australian COVID-19 Register and linked data set	2,986,054.40
Coronavirus Research Response	2021 COVID-19 Treatment Access and Public Health Activities	Monash University	A coordinated multiplatform randomised trial for hospitalised patients with COVID-19	3,997,914.20
Dementia, Ageing and Aged Care Mission	2020 Dementia, Ageing and Aged Care	The University of Queensland	Alignment, Harmonisation, and Results: translating Core Outcome Measures to Improve Care (COM-IC) for People Living with Dementia into Australian practice	999,286.80
Dementia, Ageing and Aged Care Mission	2020 Dementia, Ageing and Aged Care	University of Melbourne	Blood testing to predict and discriminate dementias	3,999,909.28
Dementia, Ageing and Aged Care Mission	2020 Dementia, Ageing and Aged Care	Flinders University	Creating partnership in iSupport program to optimise carers' impact on dementia care	1,406,657.60
Dementia, Ageing and Aged Care Mission	2020 Dementia, Ageing and Aged Care	University of Melbourne	Development and Implementation of the National Infection Surveillance Program for Aged Care (NISPAC)	997,734.30

Dementia, Ageing and Aged Care Mission	2020 Dementia, Ageing and Aged Care	University of New South Wales	Development, validation and implementation of a computerised tool to assess instrumental activities of daily living	1,252,778.00
Dementia, Ageing and Aged Care Mission	2020 Dementia, Ageing and Aged Care	National Ageing Research Institute	Drawing out care: Using animation and digital technologies to support Culturally and Linguistically Diverse (CALD) family carers and people living with dementia	797,773.60
Dementia, Ageing and Aged Care Mission	2020 Dementia, Ageing and Aged Care	University of Melbourne	IMpleMenting Effective infection prevention and control in ReSidential aged carE (IMMERSE)	757,520.30
Dementia, Ageing and Aged Care Mission	2020 Dementia, Ageing and Aged Care	Monash University	Knowledge brokers for evidence translation to improve quality use of medicines in residential aged care	1,952,566.00
Dementia, Ageing and Aged Care Mission	2020 Dementia, Ageing and Aged Care	University of Melbourne	Music Attuned Technology Care eHealth (MATCH): A music based mobile eHealth solution to support care of people with dementia	1,998,865.50
Dementia, Ageing and Aged Care Mission	2020 Dementia, Ageing and Aged Care	The University of Queensland	SENSEcog aged care: Hearing and vision support to improve quality of life for people living with dementia in residential aged care	1,200,710.20
Dementia, Ageing and Aged Care Mission	2020 Dementia, Ageing and Aged Care	The University of Queensland	Technology Assisted and Remotely Delivered Anxiety Psychotherapy Intervention for People living with Dementia and Their Care Partners (Tech-CBT)	1,626,883.28
Dementia, Ageing and Aged Care Mission	2021 Dementia, Ageing and Aged Care	The University of Newcastle	A Preventative Care Program to optimise mental health during transition into residential aged care	200,000.00
Dementia, Ageing and Aged Care Mission	2021 Dementia, Ageing and Aged Care	Monash University	Better Environment, Healthier Ageing	200,000.00
Dementia, Ageing and Aged Care Mission	2021 Dementia, Ageing and Aged Care	Monash University	EMBED: A stepped wedge cluster randomised trial of a tailored, integrated model of care to reduce symptoms of depression in home aged care	1,997,775.71
Dementia, Ageing and Aged Care Mission	2021 Dementia, Ageing and Aged Care	University of Sydney	Evaluation of primary care and help-seeking promotion programs to increase dementia diagnosis and early treatment	1,999,814.75
Dementia, Ageing and Aged Care Mission	2021 Dementia, Ageing and Aged Care	The University of Queensland	Frailty KIT: An Australian Frailty Network to Create Knowledge, Implement Findings and Support Training	4,993,238.54

Dementia, Ageing and Aged Care Mission	2021 Dementia, Ageing and Aged Care	Edith Cowan University	Getting to the heart of healthy ageing: a behaviour change program to promote dietary pattern changes	506,834.96
Dementia, Ageing and Aged Care Mission	2021 Dementia, Ageing and Aged Care	Torrens University Australia Ltd	IMPAACT: IMProving the PARticipation of older Australians in policy decision-making on Ageing-related CondiTions	584,430.14
Dementia, Ageing and Aged Care Mission	2021 Dementia, Ageing and Aged Care	University of Melbourne	Implementation of a co-designed exercise and fall prevention program for older people from CALD backgrounds	200,000.00
Dementia, Ageing and Aged Care Mission	2021 Dementia, Ageing and Aged Care	Deakin University	Implementing innovative technology promoting self-awareness of brain health and self-determination in obtaining a timely dementia diagnosis	1,052,176.56
Dementia, Ageing and Aged Care Mission	2021 Dementia, Ageing and Aged Care	James Cook University	METformin for treating peripheral artery disease Related walking Impairment Trial (MERIT)	1,215,182.04
Dementia, Ageing and Aged Care Mission	2021 Dementia, Ageing and Aged Care	The University of Queensland	Navigating Fitness to Drive with Patients with Dementia in Primary Care: Delivering an innovative Online Driver Safety Assessment and Management Package to Practitioners	1,316,765.43
Dementia, Ageing and Aged Care Mission	2021 Dementia, Ageing and Aged Care	University of Melbourne	No more shame: Changing health providers recognition and response to elder abuse to reduce Associated stigma	1,561,144.75
Dementia, Ageing and Aged Care Mission	2021 Dementia, Ageing and Aged Care	Monash University	Residential Aged Care - Enhanced Dementia Diagnosis	200,000.00
Dementia, Ageing and Aged Care Mission	2021 Dementia, Ageing and Aged Care	University of South Australia	The Australian Consortium for Aged Care - Quality Measurement Toolbox (ACAC-QMET): Improving Quality of Care through Better Measurement and Evaluation	2,999,445.80
Dementia, Ageing and Aged Care Mission	2021 Dementia, Ageing and Aged Care	University of Melbourne	The ENJOY Seniors Exercise Park IMP-ACT project: IMProving older people's health through physical ACTivity: a hybrid II implementation project design	2,011,748.53
Dementia, Ageing and Aged Care Mission	2021 Dementia, Ageing and Aged Care	Monash University	The right to rehabilitation for people with dementia: tackling stigma and implementing evidence-based interventions	1,015,820.66
Dementia, Ageing and Aged Care Mission	2021 Dementia, Ageing and Aged Care	Macquarie University	Transforming residential aged care through evidence-based informatics	992,386.00

Dementia, Ageing and Aged Care Mission	2021 Dementia, Ageing and Aged Care	The University of Queensland	Unspoken, Unheard, Unmet: Improving Access to Preventative Health Care through Better Conversations about Care	2,014,394.33	
Emerging Priorities and Consumer-Driven Research	2020 Childhood Cancer Research	University of South Australia	ABOLISH Neuroblastoma: Defining the Aetiology and underlying BiOLogy of neuroblastoma to Innovate and SHape new options for prevention, diagnosis and treatment	1,420,132.30	a
Emerging Priorities and Consumer-Driven Research	2020 Childhood Cancer Research	The University of Adelaide	Adolescents with Acute Lymphoblastic Leukaemia: Focussing on the gut microbiota, its role in therapeutic response and potential as an effective adjunct therapeutic in this High-Risk group	1,292,871.49	a
Emerging Priorities and Consumer-Driven Research	2020 Childhood Cancer Research	University of Sydney	Alternative Lengthening of Telomeres (ALT): Target Discovery to Treatment	1,484,000.00	a
Emerging Priorities and Consumer-Driven Research	2020 Childhood Cancer Research	University of New South Wales	Improving outcomes for children with high risk cancer	1,497,517.83	a
Emerging Priorities and Consumer-Driven Research	2020 Childhood Cancer Research	University of New South Wales	Rationalised inclusion of HDAC inhibitors with standard-of-care chemotherapy to improve outcomes for primary and relapsed neuroblastoma	614,017.00	a
Emerging Priorities and Consumer-Driven Research	2020 Childhood Cancer Research	St Vincent's Institute of Medical Research	Reducing tumour incidence in adolescents with germ-line mutations in RECQL4	957,598.55	a
Emerging Priorities and Consumer-Driven Research	2020 Childhood Cancer Research	University of Melbourne	Studying the origins, maintenance and resistance mechanisms of poor prognosis paediatric leukaemia at single cell resolution to develop novel therapeutic approaches	1,488,670.80	a
Emerging Priorities and Consumer-Driven Research	2020 Improving Diagnosis in Cancers With Low Survival Rates	The University of Queensland	Implementing a Multivariate Index Assay for the Earlier Detection of Ovarian Cancer	2,664,278.15	
Emerging Priorities and Consumer-Driven Research	2020 Improving Diagnosis in Cancers With Low Survival Rates	The University of Queensland	Lung cancer screening for early detection	2,836,143.00	
Emerging Priorities and Consumer-Driven Research	2020 Improving Diagnosis in Cancers With Low Survival Rates	University of New South Wales	Microbial based biomarkers powered by artificial intelligence for early detection of liver cancer in Australia. The Australian Liver Cancer Microbiome Consortium	3,989,421.75	

Emerging Priorities and Consumer-Driven Research	2020 Improving Diagnosis in Cancers With Low Survival Rates	University of South Australia	Predicting and Preventing Ovarian Cancer: a machine learning approach	1,260,168.70	
Emerging Priorities and Consumer-Driven Research	2020 Improving Diagnosis in Cancers With Low Survival Rates	University of Melbourne	Ready to screen. Targeting the high-risk population to improve lung cancer diagnosis	1,999,923.40	
Emerging Priorities and Consumer-Driven Research	2020 Improving Diagnosis in Cancers With Low Survival Rates	Flinders University	Shining Light into the “unknown” on Indigenous and non-Indigenous Australians with Cancer of Unknown Primary	2,401,509.40	
Emerging Priorities and Consumer-Driven Research	2020 Improving Diagnosis in Cancers With Low Survival Rates	Swinburne University of Technology	Solving Unknown Primary cancer Earlier Diagnosis (SUPER-ED): A stepped wedge cluster randomised controlled trial implementing a new model of care to support earlier diagnosis	2,366,198.20	
Emerging Priorities and Consumer-Driven Research	2020 Improving Diagnosis in Cancers With Low Survival Rates	University of Western Australia	The IC3 Trial: Identifying Cirrhosis and Liver Cancer in Primary Care	3,192,950.55	
Emerging Priorities and Consumer-Driven Research	2020 Medicinal Cannabis Clinical Trials	Queensland University of Technology	A prospective multicentre randomised blinded two arm parallel trial of medicinal cannabis products for alleviating symptom burden in children with advanced cancer	692,016.90	a
Emerging Priorities and Consumer-Driven Research	2020 Medicinal Cannabis Clinical Trials	The University of Queensland	Medicinal Cannabis randomised multicentre double blind placebo-controlled trial to assess THC/CBD to relieve symptom burden in patients with cancer	1,526,796.49	a
Emerging Priorities and Consumer-Driven Research	2020 Medicinal Cannabis Clinical Trials	The University of Adelaide	The CANNabinoids for CANcer Therapy (CANCAN) Trial	1,486,715.40	a
Emerging Priorities and Consumer-Driven Research	2020 Neurofibromatosis Research	Murdoch Children's Research Institute	A randomised control trial of remote microphone listening devices in children with neurofibromatosis type 1 and central auditory deficits	599,283.40	
Emerging Priorities and Consumer-Driven Research	2020 Neurofibromatosis Research	Monash University	Defining NF1 clinical variation at the microscale to discover new therapeutic targets	818,472.00	
Emerging Priorities and Consumer-Driven Research	2020 Neurofibromatosis Research	Murdoch Children's Research Institute	Malignant Peripheral Nerve Sheath Tumour Genomics in Neurofibromatosis 1 (MaGeN)	1,593,512.65	

Emerging Priorities and Consumer-Driven Research	2020 Neurofibromatosis Research	The University of Newcastle	The Neurofibromatosis type 1 (NF1) Cutaneous Neurofibroma Consortium: Identifying Genetic modifiers of disease burden to inform treatment pathways	1,607,737.60	
Emerging Priorities and Consumer-Driven Research	2020 Paediatric Cancer	Monash University	The Victoria Paediatric Cancer Consortium: A Multi-institutional Partnership to Catalyze Advances in Childhood Cancer Research and Clinical Implementation	9,599,999.61	
Emerging Priorities and Consumer-Driven Research	2020 Primary Care Fracture Liaison Services Pilot Project	Osteoporosis Australia	Primary Care Fracture Liaison (PCFLS) Pilot Project	2,808,000.00	a
Emerging Priorities and Consumer-Driven Research	2020 Silicosis Research	The University of Queensland	Silicosis – Harnessing new ideas to conquer the re-emergence of an ancient lung disease – The SHIELD Study	2,216,631.00	a
Emerging Priorities and Consumer-Driven Research	2020 Silicosis Research	Monash University	The NLRP3 inflammasome as a potential biomarker and therapeutic target for silicosis	645,763.70	a
Emerging Priorities and Consumer-Driven Research	2020 Silicosis Research	University of Tasmania	The role of particle size in the pathogenesis of engineered stone-associated accelerated silicosis	665,842.70	a
Emerging Priorities and Consumer-Driven Research	2020 Silicosis Research	University of Sydney	Transforming diagnosis of silicosis: a novel AI approach	1,481,686.00	a
Emerging Priorities and Consumer-Driven Research	2021 Chronic Musculoskeletal Conditions in Children and Adolescents	Monash University	A national functional diagnostic program for therapy development in congenital muscle disease	2,498,200.00	
Emerging Priorities and Consumer-Driven Research	2021 Chronic Musculoskeletal Conditions in Children and Adolescents	University of Sydney	A3BC for Kids	2,496,875.50	
Emerging Priorities and Consumer-Driven Research	2021 Chronic Musculoskeletal Conditions in Children and Adolescents	The University of Queensland	ACTIVE KNEECAPs! tArgeted effeCTIVE treatments for adolescent KNEECAP pain	2,043,046.84	
Emerging Priorities and Consumer-Driven Research	2021 Chronic Musculoskeletal Conditions in	University of New South Wales	Advancing congenital and childhood-onset muscle disease diagnosis and treatment - a cross-disciplinary Australian collaboration	2,499,988.00	

	Children and Adolescents			
Emerging Priorities and Consumer-Driven Research	2021 Chronic Musculoskeletal Conditions in Children and Adolescents	The University of Queensland	Australian Cerebral Palsy Musculoskeletal Health Network	2,498,384.20
Emerging Priorities and Consumer-Driven Research	2021 Chronic Musculoskeletal Conditions in Children and Adolescents	Murdoch Children's Research Institute	Bridging Evidence Gaps - Developmental Dysplasia of the Hip (DDH)	2,499,714.14
Emerging Priorities and Consumer-Driven Research	2021 Chronic Musculoskeletal Conditions in Children and Adolescents	Monash University	Children with Lower Limb Pain (CLLiP): Working with families, community and health care provider's to improve outcomes	1,809,204.97
Emerging Priorities and Consumer-Driven Research	2021 Chronic Musculoskeletal Conditions in Children and Adolescents	University of Melbourne	Force-reducing minimalist footwear for adolescents with chronic knee pain: a randomised clinical trial	994,740.80
Emerging Priorities and Consumer-Driven Research	2021 Chronic Musculoskeletal Conditions in Children and Adolescents	University of Sydney	JIA KidsLink: Joint Venture to improve surveillance, clinical pathways and health outcomes of children with juvenile idiopathic arthritis	1,597,811.40
Emerging Priorities and Consumer-Driven Research	2021 Chronic Musculoskeletal Conditions in Children and Adolescents	Curtin University	myPainhealTH (myPATH): a digitally-enabled adaptive learning system to support quality care of young Australians living with chronic musculoskeletal (MSK) pain	1,474,044.60
Emerging Priorities and Consumer-Driven Research	2021 Chronic Musculoskeletal Conditions in Children and Adolescents	University of Sydney	Pain Smart: Integrating education and clinical care for adolescents with pain	1,242,434.80

Emerging Priorities and Consumer-Driven Research	2021 Chronic Neurological Conditions	Curtin University	Developmental Delay: Enabling early and accurate detection of speech impairment through a web-based assessment application	312,583.90
Emerging Priorities and Consumer-Driven Research	2021 Chronic Neurological Conditions	The Bionics Institute of Australia	Earlier intervention for infants with auditory neuropathy for lifelong benefit	392,940.00
Emerging Priorities and Consumer-Driven Research	2021 Chronic Neurological Conditions	The University of Queensland	Early Sleep Interventions to Improve Outcomes in Children with Neurodisability	1,614,882.40
Emerging Priorities and Consumer-Driven Research	2021 Chronic Neurological Conditions	Monash University	Early, novel and accessible intervention for children with developmental regression	1,995,974.54
Emerging Priorities and Consumer-Driven Research	2021 Chronic Neurological Conditions	Griffith University	Enhancing Quality of Life through an early InTervention co-developed with the autistic communitY (E-QoL-ITY)	579,747.48
Emerging Priorities and Consumer-Driven Research	2021 Chronic Neurological Conditions	Monash University	Targeted Surveillance of Developmental Delay and Impairments for Young Children Born Very Preterm	1,829,994.60
Emerging Priorities and Consumer-Driven Research	2021 Chronic Neurological Conditions	University of New South Wales	Using technological innovations to provide equitable access to early identification of child developmental needs and integrated health and social care using a blended service delivery framework	1,964,142.00
Emerging Priorities and Consumer-Driven Research	2021 Chronic Neurological Conditions	University of Sydney	We hear your voice! A consumer-codesigned program to customize, evaluate and implement speech recognition technology, for people with chronic degenerative neurologic diseases	1,990,688.40
Emerging Priorities and Consumer-Driven Research	2021 Improving the Health and Wellbeing of Aboriginal and Torres Strait Islander Mothers and Babies	Children's Ground Limited	Arelhe ante areyele arntarnte-arelhetyeke ampe akweke arle atnyenetyenheke (Arrente). Women guiding women who are going to have babies (English)	200,000.00
Emerging Priorities and Consumer-Driven Research	2021 Improving the Health and Wellbeing of Aboriginal and Torres Strait Islander Mothers and Babies	Institute for Urban Indigenous Health Ltd	Birthing in Our Community: gold standard Indigenous maternal infant health	4,999,156.00
Emerging Priorities and Consumer-Driven Research	2021 Improving the Health and Wellbeing of Aboriginal and	Charles Darwin University	Birthing on Country: RISE SAFELY in rural, remote and very remote Australia	4,998,540.00

	Torres Strait Islander Mothers and Babies			
Emerging Priorities and Consumer-Driven Research	2021 Improving the Health and Wellbeing of Aboriginal and Torres Strait Islander Mothers and Babies	University of Western Australia (Kimberley Aboriginal Medical Services Limited)	Optimisation of screening and management of hyperglycaemia in pregnancy	3,236,071.00
Emerging Priorities and Consumer-Driven Research	2021 Improving the Health and Wellbeing of Aboriginal and Torres Strait Islander Mothers and Babies	University of Melbourne	Replanting the Birthing Trees to Support First Nations Parents and Babies	4,999,905.00
Emerging Priorities and Consumer-Driven Research	2021 Traumatic Brain Injury	Monash University	INFORMED: Integrative approaches For Optimizing Recognition, Management and Education of concussion at the community sports level	996,288.20
Emerging Priorities and Consumer-Driven Research	2022 Models of Care to Improve the Efficiency and Effectiveness of Acute Care	Flinders University	"There must be a better way": partnering with consumers to implement a digitally enabled geriatric urgent care unit to improve hospital flow	1,116,756.25
Emerging Priorities and Consumer-Driven Research	2022 Models of Care to Improve the Efficiency and Effectiveness of Acute Care	University of Sydney	Giving patients an EPIC-START: An evidence based, data driven model of care to improve patient care and efficiency in emergency departments	2,847,592.24
Emerging Priorities and Consumer-Driven Research	2022 Models of Care to Improve the Efficiency and Effectiveness of Acute Care	University of Tasmania	Implementing clinical Pathways for Acute Care in Tasmania (IMPACT)	2,919,107.99
Emerging Priorities and Consumer-Driven Research	2022 Models of Care to Improve the Efficiency and Effectiveness of Acute Care	Griffith University	Improved Respiratory Support in Remote Settings for Children: A Paediatric Acute Respiratory Intervention Study (PARIS), PARIS on Country	1,630,153.35
Emerging Priorities and Consumer-Driven Research	2022 Models of Care to Improve the Efficiency and	The University of Adelaide	Improving Acute Atrial Fibrillation Management for better patient outcomes	1,075,421.05

	Effectiveness of Acute Care				
Emerging Priorities and Consumer-Driven Research	2022 Models of Care to Improve the Efficiency and Effectiveness of Acute Care	University of Western Australia	OPERATE: Older Persons Early Recognition Access and Treatment in Emergencies	2,918,995.31	
Emerging Priorities and Consumer-Driven Research	2022 Models of Care to Improve the Efficiency and Effectiveness of Acute Care	University of Sydney	Reshaping the management of low back pain in emergency departments	2,818,123.56	
Emerging Priorities and Consumer-Driven Research	2022 Models of Care to Improve the Efficiency and Effectiveness of Acute Care	Menzies School of Health Research	StreamlinED – improving the effectiveness and efficiency of Northern Territory (NT) Emergency Departments	2,917,464.19	
Emerging Priorities and Consumer-Driven Research	2022 Models of Care to Improve the Efficiency and Effectiveness of Acute Care	South Australian Health and Medical Research Institute Limited	Using a State-wide Learning Health System for the Rapid Deployment, Evaluation and Translation of New Models of Care in South Australia to Reduce Pressure on Emergency Departments and Acute Care	2,919,835.56	
Emerging Priorities and Consumer-Driven Research	2022 Models of Care to Improve the Efficiency and Effectiveness of Acute Care	Macquarie University	Working together: innovation to improve Emergency Department (ED) performance, and patient outcomes and experience for five complex consumer cohorts	2,836,550.50	
Frontier Health and Medical Research	2020 Frontier Health and Medical Research (Cohort 1, Stage Two)	Australian Lung Health initiative Pty Ltd	4D Functional diagnosis: a new frontier in lung health for children	28,867,540.00	a
Frontier Health and Medical Research	2020 Frontier Health and Medical Research (Cohort 1, Stage Two)	University of Melbourne	The Australian Epilepsy Project	30,080,129.00	a
Frontier Health and Medical Research	2020 Frontier Health and Medical Research (Cohort 1, Stage Two)	University of Melbourne	The Stroke Golden Hour: delivering urgent stroke care to all Australians	40,167,052.00	a

Frontier Health and Medical Research	2021 Frontier Health and Medical Research	The Walter and Eliza Hall Institute of Medical Research	Australian Centre for E3 Therapeutics (ACE3T)	999,999.00	a
Frontier Health and Medical Research	2021 Frontier Health and Medical Research	University of Sydney	Australian Corneal Bioengineering: Novel Therapies to Fight Blindness	999,224.00	a
Frontier Health and Medical Research	2021 Frontier Health and Medical Research	University of Western Australia	Disruptive Technologies for Precision Medicine in Coronary Artery Disease	896,606.00	a
Frontier Health and Medical Research	2021 Frontier Health and Medical Research	The University of Queensland	Earlier Diagnosis and Personalised Treatments for Endometriosis (EndoAIMM)	927,741.00	a
Frontier Health and Medical Research	2021 Frontier Health and Medical Research	University of New South Wales	EpiWatch – Artificial Intelligence Early-Warning System for Epidemics	799,788.00	a
Frontier Health and Medical Research	2021 Frontier Health and Medical Research	University of Sydney	New Frontiers in Personalised Prevention of Coronary Artery Disease	997,562.00	a
Frontier Health and Medical Research	2021 Frontier Health and Medical Research	Snoretex Pty Ltd	Novel, Innovative Modified Tetanus Toxin Drugs for Weak Muscle Conditions	994,509.00	a
Frontier Health and Medical Research	2021 Frontier Health and Medical Research	University of Sydney	Phage Australia	999,999.00	a
Frontier Health and Medical Research	2021 Frontier Health and Medical Research	Monash University	The Artificial Heart Frontiers Program	999,570.00	a
Frontier Health and Medical Research	2021 Frontier Health and Medical Research	Synchron Australia Pty Ltd	The Brain-Machine Interface Frontier: Pioneering Endovascular Bionics	996,000.00	a
Genomics Health Futures Mission	2019 Pathogen Genomics	Monash University	Genomics, Digital Health and Machine Learning: the SuperbugAi Flagship	3,403,772.00	a
Genomics Health Futures Mission	2019 Pathogen Genomics	University of New South Wales	H2Seq: Viral genomics for public health interventions in HIV and HCV	6,629,162.00	a
Genomics Health Futures Mission	2019 Pathogen Genomics	University of Melbourne	META-GP: Delivering a Clinical Metagenomics Platform for Australia	6,984,360.00	a

Genomics Health Futures Mission	2019 Pathogen Genomics	University of Melbourne	Precision Public Health in Australia through Integrated Pathogen Genomics	9,999,499.00	a
Genomics Health Futures Mission	2020 Genomics Health Futures Mission	Flinders University	A liquid biopsy DNA methylation blood test for personalised treatment of patients with gastrointestinal cancers	1,980,810.10	
Genomics Health Futures Mission	2020 Genomics Health Futures Mission	Murdoch Children's Research Institute	A national large scale automated reanalysis program to increase rare disease diagnosis	2,999,982.60	
Genomics Health Futures Mission	2020 Genomics Health Futures Mission	University of Western Australia	Closing the gap in diagnosis of neurological disorders including ataxias and neuropathies – a trans-Australia collaboration	2,996,253.50	
Genomics Health Futures Mission	2020 Genomics Health Futures Mission	University of Melbourne	Diagnosis, discovery and novel phenotype characterisation using multimodal genomics in patients with inherited bone marrow failure and related disorders	2,997,450.25	
Genomics Health Futures Mission	2020 Genomics Health Futures Mission	University of Melbourne	Evaluating clinically relevant biomarkers to improve early detection and treatment of head and neck cancer	2,231,954.50	
Genomics Health Futures Mission	2020 Genomics Health Futures Mission	University of Melbourne	Genetic mosaicism as a stable and robust blood DNA biomarker for precision risk assessment for cancer	2,122,301.10	
Genomics Health Futures Mission	2020 Genomics Health Futures Mission	University of Sydney	Genomic risk prediction and risk-tailored screening and early detection for common cancers	2,999,860.35	
Genomics Health Futures Mission	2020 Genomics Health Futures Mission	The University of Queensland	Improving genomic testing rates for inoperable lung cancer patients	2,492,446.30	
Genomics Health Futures Mission	2020 Genomics Health Futures Mission	Macquarie University	Integrated Multimodal Precision Liquid biopsy to Enhance MELanoma and NSCLC Treatment (IMPLEMENT)	2,031,178.80	
Genomics Health Futures Mission	2020 Genomics Health Futures Mission	Murdoch Children's Research Institute	Mitochondrial Diagnostic Network for Genomics and Omics	2,999,999.66	
Genomics Health Futures Mission	2020 Genomics Health Futures Mission	Murdoch Children's Research Institute	New technologies for improved diagnosis of ataxia and the repeat expansion disorders	653,299.00	
Genomics Health Futures Mission	2020 Genomics Health Futures Mission	University of Melbourne	Novel predictive disease modelling using liquid biopsies to improve outcomes in melanoma	2,049,125.70	

Genomics Health Futures Mission	2020 Genomics Health Futures Mission	Monash University	Population genomic screening of young adults to prevent cancer in Australia	2,968,057.20
Genomics Health Futures Mission	2020 Genomics Health Futures Mission	University of Melbourne	Precision Diagnosis for the Remaining 50% of Unsolved Developmental and Epileptic Encephalopathies	2,992,144.21
Genomics Health Futures Mission	2020 Genomics Health Futures Mission	Murdoch Children's Research Institute	The Australian Functional Genomics Network	5,999,547.00
Genomics Health Futures Mission	2020 Genomics Health Futures Mission	Murdoch Children's Research Institute	The Australian Undiagnosed Diseases Network (UDN-Aus): An internationally networked national approach for transforming diagnosis for individuals living with rare diseases	2,974,134.60
Genomics Health Futures Mission	2020 Genomics Health Futures Mission	James Cook University	The KidGen National Kidney Genomics Program – improving genomic outcomes for Australian families with genetic kidney disease	2,999,537.40
Genomics Health Futures Mission	2021 Genomics Health Futures Mission	The Walter and Eliza Hall Institute of Medical Research	Advancing genetic diagnosis and health by leveraging high-throughput functional assay data into existing disease-agnostic variant platforms	2,573,362.20
Genomics Health Futures Mission	2021 Genomics Health Futures Mission	Murdoch Children's Research Institute	Assessing benefits of extended genomic newborn screening trialled on 100,000 infants from Generation Victoria	2,999,919.80
Genomics Health Futures Mission	2021 Genomics Health Futures Mission	University of New South Wales	Developing a long-read nanopore sequencing platform for Indigenous genomics	986,060.00
Genomics Health Futures Mission	2021 Genomics Health Futures Mission	The Council of the Queensland Institute of Medical Research	Ensuring genetics based prediction of glaucoma can benefit all Australians	997,796.80
Genomics Health Futures Mission	2021 Genomics Health Futures Mission	Australian National University	Establishing epigenetic biomarkers in Indigenous Australians for precision health	991,506.00
Genomics Health Futures Mission	2021 Genomics Health Futures Mission	University of Sydney	Ethical governance for clinical and genomic data	4,999,986.85
Genomics Health Futures Mission	2021 Genomics Health Futures Mission	Murdoch Children's Research Institute	Genomic Newborn Screening for personalised lifelong healthcare in Australian babies	2,998,078.35

Genomics Health Futures Mission	2021 Genomics Health Futures Mission	University of Sydney	gEnomics4newborns: integrating Ethics and Equity with Effectiveness and Economics for genomic newborn screening	2,117,960.40
Genomics Health Futures Mission	2021 Genomics Health Futures Mission	University of New South Wales	High throughput functional genomics assays for ion channelopathies	2,877,650.40
Genomics Health Futures Mission	2021 Genomics Health Futures Mission	Australian National University	High throughput validation of genomic variants in Indigenous Australians and their contribution to kidney and immune disease	975,502.80
Genomics Health Futures Mission	2021 Genomics Health Futures Mission	University of Sydney	Newborn GEN SEQ TRAIL: Newborn GENomicSEQuencing in screening: TherapyReadyAndInformation for Life	2,954,189.32
Genomics Health Futures Mission	2021 Genomics Health Futures Mission	The University of Adelaide	Newborn screening model using Integrated multi-omics in South Australia (NewbornsInSA)	2,941,351.00
Genomics Health Futures Mission	2021 Genomics Health Futures Mission	Australian National University	Pathways to benefit for Indigenous Australians in Genomic Medicine	4,986,948.70
Genomics Health Futures Mission	2021 Genomics Health Futures Mission	University of Melbourne	Perioperative Pharmacogenomic Testing (PPGx): A Feasibility and Randomised Controlled Pilot Study	355,255.20
Genomics Health Futures Mission	2021 Genomics Health Futures Mission	The University of Adelaide	PERSYST: Pathogenic Evaluation of Recalcitrant Variants by Systematic Transactivation	2,996,428.00
Genomics Health Futures Mission	2021 Genomics Health Futures Mission	The University of Queensland	Preparing Australia for use of genomics in prevention of heart-disease: Focus on South Asian Australians	928,898.92
Genomics Health Futures Mission	2021 Genomics Health Futures Mission	University of Melbourne	RDMassSpec: Mass-Spectrometry based Functional Genomics Platform for solving Rare Genetic Disorders	2,998,604.40
Genomics Health Futures Mission	2021 Genomics Health Futures Mission	University of Sydney	RNA-4RD: Disease-agnostic, nationally-accessible pipelines of clinical RNA Diagnostics	2,991,954.80
Genomics Health Futures Mission	2021 Genomics Health Futures Mission	University of New South Wales	The Australian Genetic Diversity Database: towards a more equitable future for genomic medicine in Australia	9,996,894.20

Genomics Health Futures Mission	2021 Genomics Health Futures Mission	The University of Queensland	TRIAGE: A disease agnostic computational and modelling platform to accelerate variant classification	2,997,498.50
Indigenous Health Research Fund	2020 Indigenous Health Research	University of Melbourne	Healing the Past by Nurturing the Future: Trauma-integrated perinatal care to improve health outcomes for Indigenous parents and infants in a rural setting	1,499,041.20
Indigenous Health Research Fund	2020 Indigenous Health Research	The Sax Institute	Indigenous Led Evaluation of Aboriginal Programs (ILEAP)	1,499,251.70
Indigenous Health Research Fund	2020 Indigenous Health Research	University of New South Wales	Understanding how cultural resilience impacts Aboriginal health & quality of life	560,209.30
Indigenous Health Research Fund	2020 Indigenous Health Research	University of Sydney	Understanding the contribution of Aboriginal and Torres Strait Islander culture and wellbeing to health: Implementation of the What Matters 2 Adults wellbeing measure	998,036.60
Indigenous Health Research Fund	2020 Indigenous Health Research	University of Sydney	VOICE - Validating Outcomes by Including Consumer Experience. Developing a Patient Reported Experience Measure for Aboriginal and Torres Strait Islander people accessing primary health care	1,430,917.85
Indigenous Health Research Fund	2020 Indigenous Health Research	The University of Adelaide	Working with Aboriginal families and health and social service providers to assess the feasibility of a novel care package to reduce cannabis and alcohol use and social stress in pregnancy	675,286.00
Indigenous Health Research Fund	2021 Indigenous Health Research	The University of Adelaide	A silver fluoride intervention to improve the life trajectories of Indigenous young people and reduce dental disease across the life course	3,208,372.40
Indigenous Health Research Fund	2021 Indigenous Health Research	University of Western Australia	Building a Culturally Safe Mental Health System for Aboriginal and Torres Strait Islander Young People	713,520.00
Indigenous Health Research Fund	2021 Indigenous Health Research	Flinders University	Child Protection Services in Health: Fostering community led solutions to minimise trauma and change trajectories of pregnant Aboriginal women, their children and their families	2,297,754.60
Indigenous Health Research Fund	2021 Indigenous Health Research	South Australian Health and Medical Research Institute Limited	Co-Designing a Coordinated, Sustainable and Supportive Patient Navigator Program to Improve Kidney Health Outcomes	986,773.80
Indigenous Health Research Fund	2021 Indigenous Health Research	Menzies School of Health Research	Examining the impact of extreme temperature on primary healthcare services utilisation in remote Central Australia to inform adaptation strategies	480,027.60
Indigenous Health Research Fund	2021 Indigenous Health Research	Curtin University	Improving coverage, confidence and knowledge about COVID-19 vaccination among Aboriginal Women of child-bearing age in Western Australia	805,458.80

Indigenous Health Research Fund	2021 Indigenous Health Research	Flinders University	Knowledge interface co-design of a diabetes and metabolic syndrome intervention with and for Aboriginal and Torres Strait Islander peoples living on Ngarrindjeri country	756,623.00	
Indigenous Health Research Fund	2021 Indigenous Health Research	The University of Queensland	Multidisciplinary co-design of innovative, client-centred models for Indigenous mental health services in South East Queensland	999,912.20	
Indigenous Health Research Fund	2021 Indigenous Health Research	University of New South Wales	Our Wisdom, Our Ways supporting Aboriginal Women carers using a strengths based approach to the development of carer and clinician resources that support the carer to continue to care	479,465.00	
Indigenous Health Research Fund	2021 Indigenous Health Research	James Cook University	Strong Community, Strong Health: Exploring opportunities for chronic disease prevention in the Torres Strait	473,642.00	
Indigenous Health Research Fund	2021 Indigenous Health Research	The University of Queensland	Type 2 diabetes prevalence and management in patients attending an Aboriginal and Torres Strait Islander Health Service in Southeast Queensland over a twelve-year period: factors Associated with good management and low risk of hospitalisation	392,285.00	
Medical Research Commercialisation	2020 Early Stage Translation and Commercialisation Support	ANDHealth Limited	Delivering Research, Impact and Health Outcomes in Digital Health (DROID)	19,750,000.00	
Medical Research Commercialisation	2020 Early Stage Translation and Commercialisation Support	MTPConnect	MedVentures - Medical Devices Research Commercialisation Program	19,750,000.00	
Medical Research Commercialisation	2020 Early Stage Translation and Commercialisation Support	MRCF Pty Ltd	The MRCF's Commercialisation Incubator (#1)	19,750,000.00	
Medical Research Commercialisation	2020 Early Stage Translation and Commercialisation Support	MRCF Pty Ltd	The MRCF's Commercialisation Incubator (#2)	19,750,000.00	
Million Minds Mental Health Research Mission	2020 Mental Health Research	University of Sydney	Growing Minds Australia: A National Trials Strategy to Transform Child and Youth Mental Health Services	11,930,126.00	a
Million Minds Mental Health Research Mission	2020 Mental Health Research	Deakin University	Mental Health Australia General Clinical Trial Network (MAGNET)	11,998,907.76	a

National Critical Research Infrastructure	2019 Rural, Regional and Remote Clinical Trial Enabling Infrastructure	Ministry of Health, NSW	Improving access to innovative healthcare in RRR NSW and ACT	30,548,184.00	a
National Critical Research Infrastructure	2019 Rural, Regional and Remote Clinical Trial Enabling Infrastructure	Border Medical Oncology Research Unit	ReViTALISE Project Bridging the metro - regional trials gap by 2025	18,583,563.00	a
National Critical Research Infrastructure	2019 Rural, Regional and Remote Clinical Trial Enabling Infrastructure	Department of Health, Queensland	The Australian Teletrial Program - access to clinical trials closer to home	75,240,166.00	a
Preventive and Public Health Research	2020 Efficient Use of Existing Medicines	The University of Queensland	A novel use of sterile water for injection to relieve pain in labour	302,942.48	a
Preventive and Public Health Research	2020 Efficient Use of Existing Medicines	University of New South Wales	A Phase III randomised placebo-controlled trial of mirtazapine as a pharmacotherapy for methamphetamine ("Ice") dependence	4,899,579.86	a
Preventive and Public Health Research	2020 Efficient Use of Existing Medicines	University of New South Wales	A Prospective Randomised Controlled Trial of Adults with Perianal Fistulising Crohn's Disease and Optimised Therapeutic Infliximab Levels: PROACTIVE Trial	834,374.30	a
Preventive and Public Health Research	2020 Efficient Use of Existing Medicines	University of Sydney	Cost-Utility Comparison of Down-Titration Strategies for Safer and More Efficient Use of Biologics in Adults with Rheumatoid Arthritis and Psoriatic Arthritis	2,720,942.80	a
Preventive and Public Health Research	2020 Efficient Use of Existing Medicines	University of Sydney	MOTIVATE C: The Methodical evaluation and Optimisation of Targeted Incentives for Accessing Treatment of Early stage hepatitis C	2,126,775.89	a
Preventive and Public Health Research	2020 Efficient Use of Existing Medicines	Melanoma Institute Australia	NADINA Phase 3 trial comparing response driven neo-adjuvant combination of ipilimumab + nivolumab versus adjuvant nivolumab	2,023,376.40	a
Preventive and Public Health Research	2020 Efficient Use of Existing Medicines	University of Melbourne	Repurposing BCL-2 inhibitors for immune manipulation to improve outcomes in allogeneic stem cell transplantation	599,595.60	a
Preventive and Public Health Research	2020 Efficient Use of Existing Medicines	La Trobe University	Repurposing valproate for the treatment of colorectal cancer	751,884.70	a

Preventive and Public Health Research	2020 Maternal Health and First 2000 Days, Exercise and Nutrition and Early Childhood	University of South Australia	A multi-site guideline implementation randomised controlled trial to improve physical activity and screen time in Out of School Hours Care	1,451,734.59	a
Preventive and Public Health Research	2020 Maternal Health and First 2000 Days, Exercise and Nutrition and Early Childhood	Monash University	Benchmarking for healthy stores in remote Aboriginal and Torres Strait Islander communities	1,450,376.89	a
Preventive and Public Health Research	2020 Maternal Health and First 2000 Days, Exercise and Nutrition and Early Childhood	The University of Newcastle	Effectiveness and cost effectiveness of a time-efficient school-based physical activity intervention for adolescents living with disability	712,779.71	a
Preventive and Public Health Research	2020 Maternal Health and First 2000 Days, Exercise and Nutrition and Early Childhood	La Trobe University	Exploring the impact of midwife-led group antenatal care on caesarean section rates and infant health: a multi-site randomised controlled trial	1,284,106.01	a
Preventive and Public Health Research	2020 Maternal Health and First 2000 Days, Exercise and Nutrition and Early Childhood	University of Melbourne	HipHealth: an exercise and weight loss telehealth program to improve outcomes for Australians living with hip osteoarthritis	1,124,557.63	a
Preventive and Public Health Research	2020 Maternal Health and First 2000 Days, Exercise and Nutrition and Early Childhood	Murdoch Children's Research Institute	Infant2Child: Optimising nutrition in early life to reduce childhood dental caries	1,267,826.21	a
Preventive and Public Health Research	2020 Maternal Health and First 2000 Days, Exercise and Nutrition and Early Childhood	The University of Queensland	Mothers and their Children's Healthcare Experience Study (MatCHES)	659,448.80	a
Preventive and Public Health Research	2020 Maternal Health and First 2000 Days, Exercise and Nutrition and Early Childhood	Monash University	Optimising the delivery of antenatal interventions in public healthcare: Improving equity, access and engagement for better maternal and neonatal health outcomes	1,450,942.83	a

Preventive and Public Health Research	2020 Maternal Health and First 2000 Days, Exercise and Nutrition and Early Childhood	The University of Queensland	School Readiness child outcomes of early neuroprotection/early neurorehabilitation for infants at high risk of Cerebral Palsy in the first 2,000 days	1,451,738.18	a
Preventive and Public Health Research	2020 Maternal Health and First 2000 Days, Exercise and Nutrition and Early Childhood	Monash University	The protective effect of maternal immunisation on obstetric outcomes: characterising the underlying mechanisms and impact on newborn immune function	1,146,489.15	a
Preventive and Public Health Research	2020 Quality, Safety and Effectiveness of Medicine Use and Medicine Intervention by Pharmacists	University of Sydney	A Systems approach to enhancing community-based medication review	2,432,288.00	
Preventive and Public Health Research	2020 Quality, Safety and Effectiveness of Medicine Use and Medicine Intervention by Pharmacists	The University of Queensland	Activating pharmacists to reduce medication related problems: ACTMed	2,498,824.00	
Preventive and Public Health Research	2020 Quality, Safety and Effectiveness of Medicine Use and Medicine Intervention by Pharmacists	University of Sydney	Pharmacy-based screening and quality use of medicines in kidney disease	1,894,075.00	
Preventive and Public Health Research	2020 Quality, Safety and Effectiveness of Medicine Use and Medicine Intervention by Pharmacists	University of Sydney	Safer medicines To reduce falls and fractures for Osteoporosis (#STOP)	2,337,170.00	
Preventive and Public Health Research	2020 Quality, Safety and Effectiveness of Medicine Use and Medicine Intervention by Pharmacists	Monash University	The ALLIANCE Trial	2,493,400.00	
Preventive and Public Health Research	2021 Optimising the Clinical Use of Immunoglobulins	University of Sydney	antiCD20 treatment to rationalise the use of IV/SC-IG in CIDP	2,891,769.00	

Preventive and Public Health Research	2021 Optimising the Clinical Use of Immunoglobulins	University of Sydney	Australian CIDP National Registry: Dissecting Phenotypes and Immunoglobulin Usage Requirements	812,889.00	
Preventive and Public Health Research	2021 Optimising the Clinical Use of Immunoglobulins	Monash University	eEvidence synthesis to inform the optimAL Use of Immunoglobulin (The VALUE-Ig Study)	1,723,772.00	
Preventive and Public Health Research	2021 Optimising the Clinical Use of Immunoglobulins	Monash University	Generating evidence to improve use of immunoglobulin replacement to reduce infections in blood cancers: the RATIONAL Platform Trial	3,984,139.00	
Primary Health Care Research	2020 Primary Health Care Research	Flinders University	A hybrid, implementation-effectiveness trial of a nurse-enabled, shared-care MOdel between primary and acute care for proStatE cancer Survivors (The MOSES Trial)	1,625,286.65	a
Primary Health Care Research	2020 Primary Health Care Research	Bond University Limited	Activating primary care COPD patients with Multi-morbidity (APCOM) study	977,628.15	a
Primary Health Care Research	2020 Primary Health Care Research	University of Sydney	Health4Me: Improving adolescent physical activity and nutrition behaviours via primary care	511,750.50	a
Primary Health Care Research	2020 Primary Health Care Research	Curtin University	Improving diet quality of patients living with obesity: A randomised controlled trial to build effective dietetic service delivery in a primary health care setting	1,060,354.10	a
Primary Health Care Research	2020 Primary Health Care Research	Flinders University	Improving the social and emotional wellbeing of Aboriginal and Torres Strait Islander men in South Australia	1,255,051.40	a
Primary Health Care Research	2020 Primary Health Care Research	Australian National University	Optimising primary health care in Australia: multi-method whole-of-population investigation of the impact of telehealth on uptake and quality of care	1,520,219.65	a
Primary Health Care Research	2021 Primary Health Care Research	Curtin University	CP Movetime	1,538,149.96	
Primary Health Care Research	2021 Primary Health Care Research	Flinders University	Equitable access to full blood evaluation testing at the point-of-care in remote primary health	2,996,294.25	
Primary Health Care Research	2021 Primary Health Care Research	University of New South Wales	Transforming blood pressure control in primary care using the next generation of wearable blood pressure devices: The NEXTGEN-BP randomised trial	1,936,263.10	
Primary Health Care Research	2021 Primary Health Care Research	Bond University Limited	Wearables Integrated Technology to support healthy behaviours in people with Type 2 Diabetes (Wear-IT)	1,093,405.00	
Rapid Applied Research Translation	2020 Rapid Applied Research Translation	Central Australian Aboriginal Congress Aboriginal Corporation	Aboriginal prosperity through community driven translational research	9,760,245.00	

Rapid Applied Research Translation	2020 Rapid Applied Research Translation	Florey Institute of Neuroscience and Mental Health	Building Australia's First Young Stroke Service	9,932,108.00
Rapid Applied Research Translation	2020 Rapid Applied Research Translation	Western Alliance Health Research Ltd	Delivering enhanced healthcare at home for older people in rural Australia	9,067,407.00
Rapid Applied Research Translation	2020 Rapid Applied Research Translation	The George Institute for Global Health	Implementing holistic burn care through a culturally safe integrated model	2,410,958.00
Rapid Applied Research Translation	2020 Rapid Applied Research Translation	St Vincent's Institute of Medical Research	Pathway to use of immunotherapy in clinical practice for type 1 diabetes	2,676,000.00
Rapid Applied Research Translation	2020 Rapid Applied Research Translation	The Garvan Institute of Medical Research	P-OMICs-flow: Integrating precision oncology into clinical programs	5,868,917.00
Rapid Applied Research Translation	2020 Rapid Applied Research Translation	University of New South Wales	Scaling up infectious disease point-of-care testing for Indigenous people	9,967,326.00
Rapid Applied Research Translation	2020 Rapid Applied Research Translation	Menzies School of Health Research	Top End Partners: translational research to improve health outcomes (TOP R)	5,802,202.00
Rapid Applied Research Translation	2020 Rapid Applied Research Translation	COVIU Global Pty Ltd	Transforming Wound Care through Telehealth in Aged Care	6,499,695.00
Research Data Infrastructure	2020 Primary Health Care Research Data Infrastructure	The University of Adelaide	Imagendo: Diagnosing endometriosis with imaging and AI	1,990,998.00
Research Data Infrastructure	2020 Primary Health Care Research Data Infrastructure	The University of Queensland	Improving surveillance infrastructure for Indigenous primary health care	1,990,329.00
Research Data Infrastructure	2020 Primary Health Care Research Data Infrastructure	Monash University	Optimising health information exchange during aged care transfers	1,949,557.00
Research Data Infrastructure	2020 Primary Health Care Research Data Infrastructure	University of Melbourne	Platform to Enhance Prostate Cancer Shared care Integration (PEPSI)	1,995,611.00

Research Data Infrastructure	2020 Primary Health Care Research Data Infrastructure	Kimberley Aboriginal Medical Services Limited	Regional collaboration to create a Kimberley Health Evidence Data Platform	1,027,835.00
Research Data Infrastructure	2020 Primary Health Care Research Data Infrastructure	South Australian Health and Medical Research Institute Limited	Registry of Senior Australians: Improving Care and Outcomes in Aged Care	1,966,031.00
Research Data Infrastructure	2020 Primary Health Care Research Data Infrastructure	Menzies School of Health Research	Territory Integrated Care: Primary health data Linkage Using Software	1,962,185.00
Research Data Infrastructure	2021 Research Data Infrastructure	University of Melbourne	Appropriate Antimicrobial Use: Scaling Surveillance Using Digital Health	2,962,654.00
Research Data Infrastructure	2021 Research Data Infrastructure	The University of Queensland	Digital Infrastructure For improving First Nations Maternal & Child Health	2,999,587.00
Research Data Infrastructure	2021 Research Data Infrastructure	University of New South Wales	EndoLinked: Identifying fertility outcomes for women with endometriosis	689,236.00
Research Data Infrastructure	2021 Research Data Infrastructure	Monash University	National Transfusion Research Data Infrastructure initiative	2,999,557.00
Research Data Infrastructure	2021 Research Data Infrastructure	University of New South Wales	Next-gen clinical registries: common data models, AI & cloud computing	2,645,724.00
Stem Cell Therapies Mission	2020 Stem Cell Therapies Mission	The University of Adelaide	A Precision Medicine Based Approach to Treat Craniosynostosis in Children	441,370.75
Stem Cell Therapies Mission	2020 Stem Cell Therapies Mission	The University of Adelaide	Developing an Evidence-Based Model for Building Trust in Australian Stem Cell Research and Therapies	995,406.75
Stem Cell Therapies Mission	2020 Stem Cell Therapies Mission	The University of Adelaide	Engineered human stem cells for mutation-specific eradication of myelofibrosis	853,274.50
Stem Cell Therapies Mission	2020 Stem Cell Therapies Mission	Murdoch Children's Research Institute	Evaluating safety and efficacy of bioengineered heart tissue for congenital heart repair	998,838.15
Stem Cell Therapies Mission	2020 Stem Cell Therapies Mission	University of South Australia	Identification and assessment of new treatment options for the childhood cancer Neuroblastoma	982,101.20
Stem Cell Therapies Mission	2020 Stem Cell Therapies Mission	Macquarie University	Improving decisions about access to stem cell interventions	799,543.40
Stem Cell Therapies Mission	2020 Stem Cell Therapies Mission	University of Sydney	Induced pluripotent stem cell derived cardiomyocytes: a new therapy for "no-option" end stage heart failure	4,978,360.66
Stem Cell Therapies Mission	2020 Stem Cell Therapies Mission	Murdoch Children's Research Institute	Insights into CDKL5 neuronal regulation: pathways to improving neurological outcomes for CDKL5 Deficiency Disorder	854,205.00

Stem Cell Therapies Mission	2020 Stem Cell Therapies Mission	University of Melbourne	iPSC clinical trials - population wide screening of patient iPSC's to reassess high value drug targets for motor neuron disease	1,000,000.00
Stem Cell Therapies Mission	2020 Stem Cell Therapies Mission	Monash University	Locally administered extracellular vesicles for perianal fistulising Crohn's disease	935,629.60
Stem Cell Therapies Mission	2020 Stem Cell Therapies Mission	Murdoch Children's Research Institute	New therapies preventing heart damage during chemotherapy	879,205.45
Stem Cell Therapies Mission	2020 Stem Cell Therapies Mission	University of Wollongong	Novel SMART AAV vectors for gene therapy for Friedreich's Ataxia	982,861.60
Stem Cell Therapies Mission	2020 Stem Cell Therapies Mission	University of Sydney	Stem Cell Derived-Retinal Organoids to Test Novel Genetic Therapies	498,419.00
Stem Cell Therapies Mission	2020 Stem Cell Therapies Mission	Murdoch Children's Research Institute	Stem cell models of glomerular kidney disease for understanding disease and developing treatments	934,253.30
Stem Cell Therapies Mission	2020 Stem Cell Therapies Mission	University of Melbourne	Stem cell therapies for digestive disease	583,614.00
Stem Cell Therapies Mission	2020 Stem Cell Therapies Mission	The University of Queensland	Transforming the paradigm of epilepsy care with precision medicine	999,807.95
Stem Cell Therapies Mission	2021 Stem Cell Therapies	Cartherics Pty Ltd	Gene modified pluripotent stem cells to generate and empower innate immune cells against poor-prognosis cancers	5,376,696.00
Stem Cell Therapies Mission	2021 Stem Cell Therapies	University of Melbourne	Cartilage based stem cell therapies for joint deformity and facial disfigurement. A framework for point-of-care manufacturing and delivery (ARISTOCRAT)	6,999,671.10
Stem Cell Therapies Mission	2021 Stem Cell Therapies	University of Sydney	Development of photoreceptor cell therapy to treat blindness	2,566,652.72
Stem Cell Therapies Mission	2021 Stem Cell Therapies	Griffith University	Drug discovery for schizophrenia using patient-derived stem cells	1,425,156.50
Stem Cell Therapies Mission	2021 Stem Cell Therapies	University of Western Australia	Eyes and Ears: a human retinal and inner ear organoid platform for pre-clinical screening of novel therapeutics for Usher Syndrome	2,215,017.62
Stem Cell Therapies Mission	2021 Stem Cell Therapies	University of Melbourne	Necessary steps to advance a pluripotent stem cell-derived tissue repair therapy to the clinic for stroke	2,065,971.00
Stem Cell Therapies Mission	2021 Stem Cell Therapies	Monash University	Pre-clinical evaluation of selective adenosine A1 receptor positive allosteric modulators for the treatment of Drug-resistant epilepsy	3,849,003.60
Traumatic Brain Injury Mission	2020 Traumatic Brain Injury Mission	Curtin University	An informatics approach to predict outcomes and monitor intervention efficacy following moderate to severe traumatic brain injury	499,815.70

Traumatic Brain Injury Mission	2020 Traumatic Brain Injury Mission	The University of Queensland	Australian Clinical Practice Guidelines for the Assessment and Management of Mild Traumatic Brain Injury and Post-Concussion Symptoms	497,834.00
Traumatic Brain Injury Mission	2020 Traumatic Brain Injury Mission	University of Tasmania	Clinical practice guidelines for the management of psychosocial disorders following adult traumatic brain injury	448,051.00
Traumatic Brain Injury Mission	2020 Traumatic Brain Injury Mission	Monash University	Exercise therapy for mild traumatic brain injury (mTBI) and persistent post-concussion symptoms (PPCS) across the lifespan	499,705.00
Traumatic Brain Injury Mission	2020 Traumatic Brain Injury Mission	University of Sydney	From injury to long-term physical activity for people living with traumatic brain injury	406,506.00
Traumatic Brain Injury Mission	2020 Traumatic Brain Injury Mission	Monash University	PRECISION-TBI – Promoting evidence-based, data driven care for critically ill moderate-to-severe TBI patients	499,477.70
Traumatic Brain Injury Mission	2020 Traumatic Brain Injury Mission	Monash University	The Australian Traumatic Brain Injury National Data (ATBIND) Project	365,995.00
Traumatic Brain Injury Mission	2020 Traumatic Brain Injury Mission	University of Tasmania	Transforming Awareness, Literacy & Knowledge of Traumatic Brain Injury (TALK-TBI)	999,998.00
Traumatic Brain Injury Mission	2021 Traumatic Brain Injury	Curtin University	AUS-mTBI: designing and implementing the health informatics approaches to enhance treatment and care for people with mild TBI	2,999,658.00
Total				1,177,307,965.77

a Grants included in the 2018–2020 reporting period, but with payments commencing during the 2020–2022 reporting period.
Note: The grant recipients are listed on the [MRFF website](#). Figures may not add up exactly due to rounding.

Appendix F MRFF funding with payments commencing between 7 November 2020 and 5 November 2022

Table F Total funding by MRFF initiative, with payments commencing between 7 November 2020 and 5 November 2022

Theme	MRFF initiative	Funding amount (\$)
Patients	Emerging Priorities and Consumer-Driven Research	133,890,304.62
	Clinical Trials Activity	140,935,111.71
	Global Health	0.00
Researchers	Frontier Health and Medical Research	163,790,374.58
	Researcher Exchange and Development Within Industry	0.00
	Clinician Researchers	48,697,612.40
	Early to Mid-Career Researchers	0.00
Research missions	Australian Brain Cancer Mission	8,077,924.70
	Million Minds Mental Health Research Mission	23,929,033.76
	Genomics Health Futures Mission	130,170,721.91
	Dementia, Ageing and Aged Care Mission	42,051,843.06
	Indigenous Health Research Fund	18,256,577.05
	Stem Cell Therapies Mission	43,213,415.78
	Cardiovascular Health Mission	53,712,471.41
	Traumatic Brain Injury Mission	7,217,040.40
Research translation	Preventive and Public Health Research	51,925,712.23
	Primary Health Care Research	14,514,402.76
	Rapid Applied Research Translation	61,984,858.00
	Medical Research Commercialisation	79,000,000.00
	National Critical Research Infrastructure	130,761,257.40
	Research Data Infrastructure	25,179,304.00
Total		1,177,307,965.77

Appendix G Funded rates of MRFF grant opportunities opened between 7 November 2020 and 5 November 2022

Table G Funded rates of MRFF grant opportunities

MRFF initiative	Grant opportunity	Applications	Applications funded	Funded rate
Australian Brain Cancer Mission	2021 Brain Cancer Research	14	3	21.4%
	2021 GBM AGILE	This grant opportunity was withdrawn.		
	2022 Australian Brain Cancer Research Infrastructure	2	1	50%
Cardiovascular Health Mission	2020 Cardiovascular Health	75	16	21.3%
	2021 Cardiovascular Health	100	41	41.0%
	2022 Cardiovascular Health	51	14	27.5%
Clinical Trials Activity	2021 Clinical Trials Activity	105	31	29.5%
	2021 Innovative Therapies for Mental Illness	16	7	43.8%
	2021 International Clinical Trial Collaborations (Round 21.1)	24	4	16.7%
	2021 International Clinical Trial Collaborations (Round 21.2)	24	3	12.5%
	2021 Rare Cancers, Rare Diseases and Unmet Need	97	29	29.9%
	2022 International Clinical Trial Collaborations (Round 22.1)	20	3	15%
	2022 International Clinical Trial Collaborations (Round 22.2)	No outcome available at the time this report was written.		
Clinical Trials Activity and Emerging Priorities and Consumer-Driven Research	2022 Multiple Sclerosis Research	No outcome available at the time this report was written.		
	2022 Pancreatic Cancer Research	9	4	44.4%
Clinician Researchers	2020 Clinician Researchers: Applied Research in Health	181	14	7.7%
	2022 Clinician Researchers: Nurses, Midwives and Allied Health	124	15	12.1%
Coronavirus Research Response	2021 COVID-19 Vaccine-Associated Thrombosis with Thrombocytopenia Syndrome	1	1	100%
	2021 COVID-19 Health Impacts and Vaccination Schedules	26	5	19.2%

	2021 COVID-19 Treatment Access and Public Health Activities	31	14	45.2%
Dementia, Ageing and Aged Care Mission	2020 Dementia, Ageing and Aged Care	60	11	18.3%
	2021 Dementia, Ageing and Aged Care	55	18	32.7%
	2022 Dementia, Ageing and Aged Care	36	15	41.7%
Early to Mid-Career Researchers	2021 Early to Mid-Career Researchers	428	23	5.4%
Emerging Priorities and Consumer-Driven Research	2020 Improving Diagnosis in Cancers With Low Survival Rates	20	8	40.0%
	2020 Neurofibromatosis Research	9	4	44.4%
	2020 Paediatric Cancer	1	1	100%
	2021 Chronic Musculoskeletal Conditions in Children and Adolescents	28	11	39.3%
	2021 Chronic Neurological Conditions	16	8	50.0%
	2021 Improving the Health and Wellbeing of Aboriginal and Torres Strait Islander Mothers and Babies	19	5	26.3%
	2022 Mitochondrial Donation Pilot Program	3	1	33.3%
	2022 Models of Care to Improve the Efficiency and Effectiveness of Acute Care	25	10	40.0%
Genomics Health Futures Mission	2020 Genomics Health Futures Mission	41	17	41.5%
	2021 Genomics Health Futures Mission	41	20	48.8%
	2022 Genomics Health Futures	No outcome available at the time this report was written.		
Indigenous Health Research Fund	2020 Indigenous Health Research	20	6	30.0%
	2021 Indigenous Health Research	22	11	50.0%
	2022 Indigenous Health Research	No outcome available at the time this report was written.		
Medical Research Commercialisation	2020 Early Stage Translation and Commercialisation Support	12	4	33.3%
	2021 BioMedTech Incubator	5	1	20%
National Critical Research Infrastructure	2021 mRNA Clinical Trials Enabling Infrastructure	7	5	71.4%
	2022 National Critical Research Infrastructure	142	19	13.4%

Preventive and Public Health Research	2020 Quality, Safety and Effectiveness of Medicine Use and Medicine Intervention by Pharmacists	53	5	9.4%
	2021 Chronic Respiratory Conditions	33	10	30.3%
	2021 Consumer-Led Research	102	14	13.7%
	2021 Maternal Health and Healthy Lifestyles	29	11	37.9%
	2021 Optimising the Clinical Use of Immunoglobulins	4	4	100%
	2022 Assessment of High-Cost Gene Treatments and Digital Health Interventions	No outcome available at the time this report was written		
	2022 Quality, Safety and Effectiveness of Medicine Use and Medicine Intervention by Pharmacists	19	10	52.6%
Preventive and Public Health Research and Emerging Priorities and Consumer-Driven Research	2022 Effective Treatments and Therapies	33	16	48.5%
Primary Health Care Research	2021 Primary Health Care Digital Innovations	36	6	16.7%
	2021 Primary Health Care Research	25	4	16.0%
Rapid Applied Research Translation	2020 Rapid Applied Research Translation	72	9	12.5%
Research Data Infrastructure	2020 Primary Health Care Research Data Infrastructure	34	7	20.6%
	2021 Research Data Infrastructure	92	5	5.4%
	2022 Research Data Infrastructure	No outcome available at the time this report was written.		
Stem Cell Therapies Mission	2020 Stem Cell Therapies Mission	59	17	28.8%
	2021 Stem Cell Therapies	27	7	25.9%
	2022 Stem Cell Therapies	44	13	29.5%
Traumatic Brain Injury Mission	2020 Traumatic Brain Injury Mission	26	8	30.8%
Traumatic Brain Injury Mission and Emerging Priorities and Consumer-Driven Research	2021 Traumatic Brain Injury	11	2	18.2%

Table represents the subset of grant opportunities open and assessed between November 2020 to data available at the time this report was written. Applications funded includes projects that are not listed in Appendix E as payment commenced outside the period between 7 November 2020 and 5 November 2022. The grant recipients are listed on the [MRFF website](#).

Appendix H Methodology used in this report

Grant opportunities and grants awarded

The *Australian Medical Research and Innovation Priorities 2020–2022* were in force from 7 November 2020 to 5 November 2022. For the purpose of this report at the time it was written, the included grant opportunities are those open during the period 7 November 2020 to 5 November 2022. Grants awarded and announced refers to grants with payments commencing between 7 November 2020 and 5 November 2022. Due to the usual process of awarding grants after a grant opportunity closes, grants awarded in this report includes grants from opportunities that were opened before 7 November 2020. This methodology is consistent with the approach used in the *Financial assistance to support the Australian Medical Research and Innovation Priorities 2018-20* (2018-2020 report).

The Australian Medical Research and Innovation Priorities 2016-2018 were in force from 9 November 2016 to 8 November 2018 and Australian Medical Research and Innovation Priorities 2018-2020 were in force from 8 November 2018 to 6 November 2020.

All amounts in this report are in Australian dollars and GST exclusive. Grants awarded can include projects conducted by partner organisations that were funded from a single MRFF grant, as well as grants relinquished and/or withdrawn. The grant recipients are listed on the [MRFF website](#).

Funded rates and gender of Chief Investigators

Data for grant opportunities, that are included in this report, was obtained from MRFF applications submitted through the NHMRC and BGH. The number of applications includes those deemed ineligible during the assessment phase. The data range is 7 November 2020 to 30 June 2022 and only includes grant opportunities where a funding outcome was known. Not all grant opportunities listed in Table 3 and Table 25, and not all grants listed in Table 3, Appendix E and Appendix G are included in this analysis.

The analysis of gender was based on self-identification provided by CIs as 'Male', 'Female', 'Intersex or Indeterminate', or 'Not stated'. Updated terminology in the application form has gender self-identification options as 'Man or male', 'Women or female', 'Non-binary', 'I use a different term' or 'Prefer not to answer'. This report uses 'Man', 'Woman', 'Intersex or Indeterminate', or 'Not stated'. For privacy reasons, the published information only includes people identified as a woman or man due to the low numbers of people self-identified as Indeterminate or Intersex. Further, any subcategory analysis with less than 10 people identified is not reported for privacy reasons.

The criteria of the age of a CI, Broad Research Area and Field of Research data is only available for NHMRC-administered grants. This information is nominated by applicants in the application form. There may be a difference in terms that applicants nominate in the application compared to the description of MRFF initiatives.

Grant Assessment Committees

Information on panels of GACs was provided by the NHMRC and BGH. Gender and terms describing expertise were self-assigned by the GAC members. Australian organisations identified by GAC members as their employer or organisation they were representing. The data includes grant opportunities where the GAC met during the reporting period. Not all grant opportunities listed in Table 25 are included in this analysis.

